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ABSTRACT 
 
Older people experience skeletal muscle wasting, in part due to impaired proliferative capacity of quiescent 
skeletal muscle satellite cells and. The work presented in this thesis set out to examine the hypothesis that 
microenvironment of skeletal muscles can be influenced by immune cell secretions, which affect satellite 
cell proliferation, and that beneficial immune-muscle interactions in young people are blunted in elderly. 
The aim of this research was to investigate the role of ageing human lymphocytes on skeletal muscle cell 
behaviour. For this purpose, lymphocytes were isolated from whole blood of young (aged 18-25 years) 
and older (aged 78-85 years) healthy volunteers and older healthy volunteers. All the participants were 
healthy, with no history of muscle disease and not on immunosuppressant or corticosteroids treatment that 
affect immune function. Lymphocytes were cultured with, or without, anti-CD3/CD28 activators for 4 
days to induce release of cytokines, interleukins and growth factors into the media. The secreted proteins 
were used to prepare conditioned media that were used to culture C2C12 myoblasts. Secretomes were 
analysed and fifteen secreted Th1/Th2 cytokines and IGF-I were quantified by multiplex immunoassay. 
The gene expression and protein concentrations of amphiregulin were determined from T-lymphocytes 
lysates by real-time PCR and ELISA respectively. The levels of CD25 and FoxP3 expression in 
lymphocytes were examined using flow cytometry. The expression of muscle transcription factors, MyoD 
and Myogenin were determined by real- time PCR. Activated Mek1/Erk1/2 and Akt/mTOR were 
measured by multiplex immunoassay. Our results demonstrate for the first time that a decrease in the levels 
of amphiregulin and CD25 coincides with the increase in FoxP3 with ageing, which may be involved in 
suppression of lymphocytes. Seven cytokines were differentially secreted by the young- compared with 
the old-activated lymphocytes. The secretome from young-activated lymphocytes had 30% (P<0.005) 
higher IGF-I concentrations compared with old and control treatments. The conditioned media from young 
-activated lymphocytes increased the rate of proliferation of myoblasts by ~3-fold (P<0.005) and caused 
an approximate 4-fold (P<0.005) increase in migration compared with non-activated lymphocyte control 
media. These responses were characterised the extended proliferation of young -treated myoblasts was 
also associated with a decrease in MyoD and Myogenin and an increase in mediators of proliferation 
Mek1/Erk1/2and a decrease in the key proteins for differentiation, Akt/mTOR. In contrast, myoblasts 
treated with conditioned media from old-activated lymphocytes exhibited a high degree of differentiation.  
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INTRODUCTION 
 
1.1. OVERVIEW 
 
Skeletal muscle is a highly metabolic tissue, essential for stability and body movement, 
representing approximately 40-50% of the human body mass (Adibi, 1976). Muscle wasting is 
very common health problem, resulting from several life threatening diseases such as heart 
diseases and cancer cachexia.  Ageing is also associated with reduced muscle mass, people aged 
between 40–70 lose on average  10–25% of lean body mass and people over age of 80 can lose 
up to  40% of mass (McPhee et al., 2013). These findings indicate that there is a diminished 
capacity of skeletal muscle cells to regenerate and grow with age. The diminished   capacity of 
muscle repair and regeneration with ageing is suggested to result in part from reduction in 
skeletal muscle stem cell numbers (satellite cells) and function. Furthermore, in ageing, there is 
a marked decline in immune function. Following e.g. injury, immune cells contribute to the local 
environment that can influence the regenerative process of skeletal muscle cells. Muscle injury 
is accompanied by stimulation of precursor satellite cells by infiltration of immune cells, which 
in turn release growth factors and cytokines that affect muscle repair and regeneration (Tidball 
and Villalta, 2010). Therefore, the diminished ability of muscle regeneration in older age has 
been linked to the impaired immune response (Dumke and Lee, 2011).  
 
1.2. SKELETAL MUSCLE DEVELOPMENT AND REGENERATION 
EMBRYONIC MYOGENESIS 
 
Development of somites in a vertebrate embryo results in the formation of anatomical cellular 
groups which later give rise to skeletal muscle (myotome), vertebrae (sclerotome) and dermis 
(dermatome). As shown in Figure 1.1, the somate can be divided into two distinct regions the 
hypaxial domain which forms limb muscles and the lateral trunk and the epaxial domain which 
forms dorsal muscles (Parker et al., 2003; Charge and Rudnicki, 2004; Buckingham, 2006). The 
hypaxial domain of the somite gives rise to precursor cells which migrate to the limb bud where 
key myogenic regulatory factors (MRFs) are located. These factors include the Mrf4 (myogenic 
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regulatory factor 4) and Myf5 (myogenic factor 5)(Buckingham, 2006) and their activity in 
proliferating, migrating and differentiating myoblasts can in fact be determined by 
neighbouring, thereby establishing myogenesis (Hawke and Garry 2001;Buckingham et al., 
2003). 
 
 
Figure 1.1: A schematic representation of somite: Somite is separated into epaxial and hypaxial 
regions with its surrounding structures including the notochord, neural tube and dorsal aorta provide 
signals inducing the migration of precursor cells. Precursor cells from the epaxial region of a somite 
contribute to the back musculature, while precursor cells originating from the hypaxial region migrate to 
the newly formed limb buds. Adapted from (Hawke and Garry 2001). 
 
Once within the limb buds, precursor cells derived from the hypaxial domain begin to 
exclusively produce Pax thereby making the cells specific for myogenic lineage. Cell 
proliferation and differentiation of these embryonic precursor cells expressing Pax3+/Pax7+ ( 
described in section 1.4) occurs whereas some cells leave the cell cycle becoming satellite cells 
(Yin et al., 2013).The first muscle fibres, known as primary fibres, form between E11 and E14 
in the mouse limb. Between E 14 and E16, initially smaller in size, secondary myofibres form 
parallel to motor neural innervations are formed (Messina and Cossu, 2009; Sheard et al., 1991; 
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Gros et al., 2005). It has been proposed that these cell groups demonstrate intrinsic differences 
i.e. dissimilar genetic expression and in vitro behaviour (Biressi et al., 2007; Buckingham et al., 
2003).   
Once secondary fibres are formed and every fibre is surrounded by basal lamina, satellite cells 
attain their typical morphology of mononucleated cells present between basal lamina and plasma 
membrane of the fibre. These satellite cells undergo division at a slow rate during peri and post-
natal development. Moreover, to enable hypertrophy postnatally, they merge with the adjacent 
fibres to offer new nuclei thereby amplifying the size of muscle fibre. They assume the dormant 
state at the end of post-natal growth; however, ensuing activation of these satellite cells play a 
crucial role in regeneration and muscle repair in case of any muscle damage. 
 
POSTNATAL (ADULT) MYOGENESIS 
 
Myofibres and innervating motor neurons constitute skeletal muscles which are vascularised to 
enable e.g. the provision of nutrients required for replenishment of energy stores and repair of 
muscles. Basal lamina or basement membrane refers to the endomysium (connective tissue) 
which surrounds the individual muscle fibres. A set of myofibresis collectively covered by 
different connective tissue is termed the perimysium. Finally, the epimysium is the outermost 
layer of the connective tissue which surrounds the whole bundle of myofibres. Actin and myosin 
myofibrils make up each myofibre and these myofibrils organize to form sarcomeres, functional 
units of the skeletal muscle (Yin et al., 2013; Borg and Caulfield, 1980). 
Regeneration of skeletal muscle compromises of time-dependent and sequential phases of 
degeneration, inflammation, regeneration and remodelling-repair (Carosio et al., 2011). Muscle 
injury is followed by a degenerative phase and necrosis of the cells. Certain cytokines (e.g. IL-
1, IL-6 and TNF-α) are discharged by damaged tissues which attract inflammatory immune cells 
to the site of damage (Madaro and Bouché, 2014). Immune cells have significant roles in 
clearing debris and activating satellite cells, a requirement of regeneration (Aurora and Olson, 
2014). During the regenerative phase, the satellite cells are activated, proliferate and 
differentiate to repair the damage. Satellite cells are in the G0 phase (inactive, or dormant) of 
the cell cycle in an intact fibre, these cells become activated, leave the G0 phase to enter the G1 
phase. When the satellite cells are activated, they move towards the damaged fibres and merge 
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with the necrotic myofibres. This is followed by differentiation of satellite cells for promoting 
repair of muscle fibres(Hawke, 2011; Turner and Badylak, 2012; Charge and Rudnicki, 2004). 
The satellite cells do not necessarily remain restricted to the site of muscle damage. Reports 
indicate that these cells can travel between myofibres and may go beyond to surpass the wall of 
basal lamina and connective tissue. In this way, they make sure that the regeneration is executed 
efficiently and the more extensive damage is repaired (Yin et al., 2013). Maturation of regenerated 
myofibres occurs during the final phase, which also involves remodelling of extracellular matrix 
(ECM) and finally the damaged muscles resume their function.  
 
Even though the regenerative process requires active involvement of satellite cells, some of these 
cells undergo self-renewal and attain the inactive state so that there remains a sufficient supply 
of satellite cells to be used in any injury repair throughout the lifespan (Relaix and Zammit, 
2012). It has been reported that  muscle from aged mice was estimated to contain around 65% 
fewer functioning satellite cells than muscle from young mice (Cosgrove et al., 2014) and the 
overall number of satellite cells was also lower in aged mouse muscle compared to young mice 
muscle (Chakkalakal et al., 2012).  
1.3. SATELLITE CELLS RENEWAL AND ACTIVATION 
Following activation, satellite cells undergo asymmetric division, generating two daughter cells, 
one cells becoming committed myogenic precursor cell (mpc) or myoblast and the other, 
entering a quiescent state to maintain the satellite cell pool. In  the asymmetric division phase, 
satellite cells express (Pax7+/Myf5-) and give rise to one satellite cell and one  myogenic cell 
(Pax7+/Myf5+)(Halevy et al., 2004)(Figure 1.2). Thus, the self –renewing ability should in 
theory not end up with depletion of the satellite cell pool and therefore  the ability of muscle to 
regenerate is maintained.. 
The satellite cells niche is important in regulating whether satellite cells undergo symmetric or 
asymmetric divisions. For example, if there is a need for a large number of cells, satellite stem 
cells may undergo asymmetric division to replenish the satellite cells pool and expand 
population following injury. Self-renewing satellite cell population (Pax7+/Myf5-) is governed 
by intrinsic and extrinsic factors such as Wnt7a and Notch (Conboy and Rando, 2002; Le Grand 
et al., 2009).  
 6 
 
Figure 1.2: Skeletal muscle repair and regeneration. Satellite cells exist from quiescent phase 
and undergo asymmetric cell division. One of the cells that express (Pax7+/Myf5+) is activated and 
divided symmetrically to end up with myocytes formation. The other cell with high expression of (Pax 
7/Myf5) returns to a quiescent phase to replenish non-activating satellite cells. When Myocytes express 
Myo D, they become differentiated to new myofibres and migrate to fuse at the site of injury. Adapted  
from (Tedesco et al., 2010). 
 
 It has been reported that Numb, is a crucial regulatory factor generating asymmetric satellite 
cell division. An activated daughter cell that inherits Numb will undergo myogenic 
development; this cycle progression is called irreversible G0 arrest (Dhawan and Rando, 2005). 
While a daughter cell that does not inherit Numb will undergo reversible G0 arrest in which the 
cell commits to self -renewal and returns to a quiescent state (Shen et al., 2002). The transition 
from a quiescent state to a proliferative state to is regulated by MyoD expression, which is also 
a key regulatory molecule for myogenic differentiation (de la Serna et al., 2001; Weintraub et 
al., 1989; Weintraub et al., 1991).  In the presence of proliferative signals, the cells enter S phase 
and MyoD expression decreases. In contrast, in the presence of differentiation cues in G1, cells 
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exit cycle and initiate terminal differentiation that is accompanied by up regulation of MyoD 
that induces the expression of other key molecules such as p21, which are essential for 
differentiation to the myogenic lineage (Hawke et al., 2003; de la Serna et al., 2001), including 
retinoblastoma (Rb) ,cyclinD3 and myogenin (Kitzmann and Fernandez, 2001; Dhawan and 
Rando, 2005)(Figure1.3). In addition to these target genes, other genes become activated 
including; creatinine kinase, myosin heavy chain and acetyl choline receptors that assure the 
formation of functional mature myofibres (Hawke and Garry, 2001). To enable growth arrest, 
quiescence cues p27 and p130 are expressed and cells enter the quiescence state (G0), MyoD 
declines, target genes are inactive and consequently, cells return to a dormant arrest rather than 
develop to myogenic  differentiation ( Figure 1.3)(Dhawan and Rando, 2005). 
 
Figure 1.3: The representation of   reversible and irreversible cell cycle arrest. 
Adapted from (Dhawan and Rando, 2005).  
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Replaced myofibre after damage will be functionally similar to the original myofibre in 
expression of MyoD, Myogenin and Myf4. These MRFs have key roles during fusion of 
myonuclei and generating mature myofibres (Charge and. Rudnicki, 2004). 
Minor skeletal muscle injuries, occur routinely during daily activity and may induce a limited 
number of satellite cells to proliferate and differentiate, whereas major injury require an 
extended population of satellite cells to respond. Thus, satellite cell function is essential in 
maintaining muscle repair and regeneration throughout the life (Yablonka-Reuveni, 2011).  
 
 
1.4. MOLECULAR REGULATION OF SKELETAL MUSCLE REGENERATION: the 
myogenic regulatory factors (MRFs) 
The process of skeletal muscle regeneration, from satellite cell to mature muscle fibre parallels 
embryonic myogenesis, which is highly orchestrated by a series of genetic and myogenic 
regulatory factors. During embryonic myogenesis, paired box 3&7 (Pax3& Pax7) transcriptional 
factors are expressed  by satellite cells and play key roles in myogenic specification and are able 
to compensate partially for each other during skeletal embryonic development (Buckingham et 
al., 2003; Gros et al., 2005). Pax3 is an important determinant for proliferation and migration of 
muscle precursors from the presomitic mesoderm (Sheard et al., 1991). Pax7 is essential in the 
initiation of satellite cell activation, proliferation and self-renewal to replenish the pool of 
quiescent cells (Turner and Badylak, 2012). Additionally, Pax7 triggers the sequential activation 
of the basic helix-loop-helix (bHLH) family of MRFs. Following muscle precursor cells 
commitment to the skeletal muscle lineage, the process of embryonic myogenesis parallels the 
adult myogenesis, which is regulated by series of MRFs (Figure 1.4). MRFs involved in the 
proliferative and differentiating phases of muscle regeneration include Myf5, MyoD, Myogenin, 
Myf4, and MRF4. Myf5 is expressed early after injury in the regenerative process, Myf5 alone 
is intimately involved with the early proliferation of satellite cell myoblasts. Research has also 
revealed that Myf5-/- mice present with mild deficits in the regeneration of skeletal muscle, 
manifested through the fibrosis of the endomysium and excessive accumulation of adipocytes 
at the site of injury, compared to wild-type mice (Gayraud-Morel et al., 2007). MyoD is another 
MRF responsible for the early stages of skeletal muscle regeneration and performs key functions 
of the early proliferative phase similar in nature to Myf5, in a compensatory and redundant 
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manner. As minor deficits in muscle regeneration are observed in Myf5-/- animal models, 
similar deficits are also observed in MyoD-/- models (White et al., 2000). Although myogenesis 
still progresses when one of these two factors is  deficient, it is not possible when both are devoid 
(Kassar-Duchossoy et al., 2004). Although several studies have been conducted on the MRFs 
responsible for early myogenesis and muscle regeneration (Olguin et al., 2007; Singh and 
Dilworth, 2013), the exact nature of the Myf5 MyoD molecular interaction still requires 
clarification to elucidate the synergistic action of these two MRFs. During normal muscle 
regeneration satellite cells will proliferate until a threshold is obtained, at this point the 
expression of MRFs involved with proliferation begin to decrease while differentiating MRFs 
expression increases. Myogenin is one of the MRFs identified as a requirement for the normal 
differentiation of myoblasts to myocytes and ultimately myofibres. As mentioned earlier Myf5-
/- or MyoD-/- mice displayed only minor deficits in muscle regeneration, conversely MyoG-/-
mice present with severe deficiencies, signifying myogenin is unquestionably essential for 
unflawed muscle development (Venuti et al., 1995). Additionally, myogenin does not possess 
the characteristics of redundancy or compensation during embryonic myogenesis with any of 
the other MRFs as exist between Myf5 and MyoD. Research has demonstrated that a flawed 
type of adult muscle regeneration is still possible without myogenin as MyoG-/- mice are still 
able to regenerate muscle, but are two-thirds smaller than wild-type littermates (Knapp et al., 
2006).This study suggests that mechanisms independent of myogenin can partially compensate 
for deficiency during adult regeneration. During normal skeletal muscle cell regeneration,   the 
final MRF to be expressed is muscle regulatory factor 4 (MRF4). It can be appreciated that the 
three MRFs described above each have a unique timing and magnitude of expression, which 
suggests the configuration of myogenic regulatory factor expression has significant impact on 
the regenerative process. Research has also shown MyoD expressing cells to have impacts on 
the expression of MRF4 in the late stages of regeneration. MyoD-/- mice also exhibit inhibited 
MRF4 expression compared to wild-type mice, whether this action is direct or indirect still 
remains to be explored. Ultimately, the expression of MRFs through the stages of muscular 
restoration (Figure1.4) occurs once satellite cells become activated; the expression of MRFs is 
a complex and essential process needed to ensure proper muscular regeneration. 
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Figure1.4: Molecular regulation during embryonic and postnatal myogenesis. Upon 
response to injury/damage, resident satellite cells are activated, migrate to the damaged area and 
proliferate to generate a progeny of fusion competent myoblasts. Some of the satellite cells will self-
renew and return to quiescent stage to contribute to future regeneration events. The generated progeny 
of myoblasts will fuse with each other or add new myonuclei to the damaged myofibre, thus promoting 
its repair. Figurer is adapted from (Al‐Shanti and Stewart, 2009). 
 
1.5. SIGNALLING PATHWAYS THAT REGULATE REGENERATIVE 
MYOGENESIS 
In adult vertebrate, skeletal muscle hypertrophy occurs in response to weight-bearing exercise 
and because of increased protein synthesis (Glass, 2010). Enhanced protein synthesis enables 
new contractile proteins (myosin and actin) to be added to pre-existing muscle fibres, leading to 
generation of greater  overall muscle force. 
Hypertrophy can be stimulated by insulin -like growth factors (IGF), which are potent growth 
factors that produced, by the liver (Sjögren et al., 1999; Kasprzak and Adamek, 2012). IGFs 
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bind to surface receptors which are expressed on most skeletal muscle tissues in human and 
rodents (Figure 1.5)(Kasprzak and Adamek, 2012). IGF-I is known   to induce proliferation and 
differentiation of myoblasts, increase muscle myofibre size and the number of fused myonucleus 
in differentiated myofibres (Yin et al., 2013). In addition to promoting muscle regeneration, 
IGF-1 acts as inhibitor for skeletal muscle atrophy Glass, 2010; Fuentes et al., 2011; Sukho, 
2003). These findings have been confirmed in vivo and in vitro (Musarò et al., 1999; Rommel 
et al., 2001). Activated satellite cells express insulin-like growth factor binding proteins 
(IGFBPs), which are secreted proteins that regulate the function, transport and half-life of IGF-
I. The mechanism of IGF-I effect on satellite cells proliferation and differentiation is mediated 
by IGF-1 receptors (IGF-IR). Binding IGF-I to IGF-IR recruits the insulin receptor substrate 
(IRS-1).Activation of IRS-1 triggers Raf /Ras /mitogen-activated protein 
kinases(MAPK)/extracellular signal regulated kinase (ERK) andphosphatidylinositol-3 kinase 
(PI3k)/Akt pathways (Figure1.5)(Moelling et al., 2002).The cross- talk between these  signalling 
pathways is essential for IGF-1 to induce skeletal muscle hypertrophy (Chambard et al., 2007; 
David J Glass, 2003) 
 
Figure1.5: Schematic representation of the GH-IGF in normal physiology: During postnatal 
life, liver is the main organ of IGF production and this growth factor is produced mainly upon effect of 
growth hormone (GH) secreted from pituitary gland. Binding of GH to growth hormone receptor (GHR) 
on liver cells promote IGF production which in turn bind to their receptors on skeletal muscle cells to 
initiate signalling cascade.  Adapted from (Kasprzak and Adamek, 2012). 
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1.5.1. IGF-1/MAPK-ERK1/2 
 
ERK1 and ERK2 isoforms are highly conserved serine/threonine kinases that are crucial for 
muscle cells proliferation (Jones et al., 2001). Activation of both isoforms leads to 
autophosphorylation of threonine and tyrosine, which in turn, leads to phosphorylation of several 
substrates that regulate transcription and translation of genes involved in cell cycle events 
(Sukho, 2003) (Figure 1.6). In mammals, it has been shown that inhibition of ERK1/2 leads to 
diminished cell cycle progression (Chambard et al., 2007). Blocking ERK1/2 in Raf-expressing 
myoblasts promotes myoblast fusion and differentiation (Li and Johnson, 2006). However, 
ERK1/2 is a positive regulator for skeletal muscle regeneration; it is required for terminal 
differentiation and preventing apoptosis (Li and Johnson, 2006; Fuentes et al., 2011; Saini et al., 
2008). 
 
1.5.2. IGF/Akt/mTOR 
 
The Akt/mTOR signalling pathway is important in regulating myogenesis particularly in protein 
synthesis and skeletal muscle differentiation.  Activated PI3k is essential for IGF function to 
induce hypertrophy. Activation of IRS-1 leads toPI3k phosphorylation (Fuentes et al., 2011), 
which in turn phosphorylates phosphoinositide-dependent protein kinase (PDK1) that 
translocates to the cell surface membrane (Glass, 2003) (Figure 1.6). Once activated, 
Akt1phosphorylates several substrates, including proteins that block apoptosis, promote protein 
synthesis and cell proliferation (Matsui et al., 2003; Vivanco and Sawyers, 2002). It was 
demonstrated that inhibition of PI3k prevented IGF-I-mediated hypertrophy in vitro (Rommel 
et al., 2001). The findings that Akt is also essential to promote IGF-I- induced hypertrophy have 
been reported (Rommel et al., 2001; Takahashi et al., 2002) and suggest that Akt is subsequently 
activated upon PI3k phosphorylation and both members function downstream for IGF.  
Phosphorylated Akt activates mammalian target of rapamycin (mTOR). IGF-I activation will 
stimulate downstream signalling pathways activating mTOR and p70S6k (Figure 1.6). mTOR 
also can be   activated by amino acids and efficiently initiates downstream signalling to activate 
70S6k. Thus, mTOR is vital in maintaining regular function of several factors that lead to protein 
synthesis. Both phosphorylated Akt and mTOR are elevated during skeletal muscle hypertrophy.  
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Rapamycin is a chemical that acts as an mTOR inhibitor (Pallafacchina et al., 2002). Also it was 
found to block activation of p70S6k, inhibit hypertrophy and protein synthesis. In vitro studied 
have  shown that rapamycin blocks partially IGF-1 induced skeletal muscle hypertrophy, 
suggesting activation of other alternative pathways stimulating  Akt induced hypertrophy 
(Rommel et al., 2001; Pallafacchina et al., 2002). Treatment with rapamycin blocks activation 
downstream of p70S6k but did not affect Akt and mTOR activity (Bodine et al., 2001), 
indicating that Akt subsequently activates mTOR and downstream p70S6k during hypertrophy 
(Figure1.6).   
 
Figure 1.6: IGF-1-mediated signalling pathways: The schematic representation of signalling 
pathway for IGF-1/MAPK-ERK1/2 and IGF/ Akt/ mTOR cascades. Signalling proteins that have 
negative impacts on hypertrophy are shown in red boxes, and proteins whose activation induce 
hypertrophy are shown in green boxes. Proteins that have not been assayed for their effects on 
hypertrophy were shown in blue boxes. Adapted from ( Glass, 2003). 
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1.6. MYOGENESIS AND AGEING (AGE- RELATED MUSCLE WASTING) 
Ageing is associated with a decline in muscle mass, strength and a reduced ability to regenerate 
in a condition known as sarcopenia.  Moreover, in ageing there is an increase in skeletal muscle 
fibrosis in concert with reduced quality of muscular tissue leading to impaired muscle 
regeneration, increased frailty and weakness.  
The impairment in neuromuscular function is considered to be the major contributing factor to 
age-related muscle wasting so it is important to understand the causes. Causes may include 
deficits intrinsic to old muscle cells or their satellite cells (as described above) or may also be 
due to changes in the ‘environment’ that are heavily influenced by non-muscle cell factors, such 
as inflammatory molecules, growth factors and hormones that may all change in ageing. To shed 
some light on this, a study reported that autografts of muscle from old rats (2 years) regenerate 
efficiently when transplanted into the limb of a young rat (4 months) (Carlson and Faulkner, 
1996; Gutmann and Carlson, 1976). Another cross-age transplantation study was conducted on 
young (4 months) and old (24 months) rats found that the mass and maximum force of old 
muscles grafted into young hosts were not significantly different from those of young muscles 
also transplanted into young hosts (Carlson and Faulkner, 1989).To gain further insights, a series 
of muscle transplantation experiments were conducted in which muscle was transplanted 
between geriatric (27–29 months old) and young (3 months old) mice. When young muscle was 
transplanted into the old host there was a delayed regenerative response that was related to a 
reduction of inflammatory cells in geriatric hosts (Shavlakadze et al., 2010). These results 
suggest the muscle itself is not necessarily impaired in the older rodents and therefore points 
towards the environment as a potential cause of muscle wasting in old age. However, the picture 
is more complex, because as discussed below, there are several reports of reduced satellite cell 
number and activation in older age which may or may not be related to the environment. 
 
 
 
 
AGED SATELLITE CELL POOL 
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The ageing of skeletal muscle and associated reduction in satellite cell (SC) turnover 
substantially diminish the self-renewal process of SCs and hence muscle fibre repair 
mechanisms, causing reduced ability for muscular regeneration. One experiment found that 
stimulating SC proliferation 24 hours after eccentric knee extensor exercise leads 51% increase 
in SC numbers in elderly participants, however, a significantly greater increase of 141% was 
observed in the young participants (Dreyer et al., 2006); contributing further data for the age 
related decline of SC quantity. Ageing also instigates a change in muscle fibre phenotype 
associated with type II fibre atrophy (Verdijk et al., 2014), which then influences the associated 
loss of type II muscle fibre SCs in humans. Furthermore, studies have also shown that the 
satellite cells nuclei are reduced by roughly 50% in old (aged 71 years) compared to young 
people (aged 29 years) (Sajko et al., 2004). There is evidence that the reduction of SC 
concentration precedes the deficiencies observed during myogenesis in elderly people (Shefer 
et al., 2006). 
A recent study reported that p16 depression, a master regulator for cellular senescence, impairs 
satellite cells activation, proliferation and self-renewal of old mice (Bentzinger and Rudnicki, 
2014). Furthermore, Bernet et al (2014) showed that increased P38 MAPK signalling pathway 
in response to elevated level of fibroblast growth factor -2 ( FGF-2) in the aged  niche impairs 
asymmetric self- renewal of aged satellite cells (Bernett et al., 2014). 
Even though there is valuable evidence that the deficiencies observed in old myogenesis are a 
consequence of decreased satellite cell concentrations (Day et al., 2010), a decline in aged 
extrinsic (niche) and intrinsic regulatory signals (Notch Signalling, Wnt signalling, Niche EFG2, 
p38 MAPK, JAK-STAT and TEWAK signalling) which regulate satellite cell functions also 
involved in impaired muscle regeneration. Thus, age related changes in the intrinsic 
characteristic of satellite cells, as well as the extrinsic microenvironment are associated with 
impaired muscle regeneration. 
 
 
1.7. PARABIOSIS-AN EXPERIMENTAL MODEL TO STUDY AGE -RELATED 
CHANGES IN SKELETAL MUSCLE MICROENVIROMENT 
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In the last few decades, the parabiosis model in which two animals share the same blood stream, 
re-emerged and has yielded very interesting results in endocrinology, tumour biology and 
immunology. This model enabled scientists to aim to identify the circulatory modulators 
involving growth factors, hormones and cytokines that influence tissue health and function. 
Following successful results, scientists developed the heterochronic-parabiosis (young-aged) 
model (Figure 1.7) to study whether exposure to young circulatory mediators could rejuvenate 
old tissue function. 
 
Figure 1.7: Heterochronic-parabiosis between aged and young mice. The cross connection 
between young and aged mice, allows continuous circulation of growth factors at physiological level.  
Adapted from  http://www.sciencedirect.com. 
 
This model has been applied to improve the understanding of stem cells in skeletal muscle, brain 
and spinal cord. 
Conboy and colleagues found that exposure of old microenvironment to young circulatory 
factors through heterochronic-parabiosis rejuvenated the function of stem cells in spinal cord 
(Ruckh et al., 2012) and liver in mice (Conboy et al., 2005). Similar findings were obtained in 
brain (Villeda et al., 2011) and heart (Loffredo et al., 2013) in aged mice. Moreover, 
heterochronic-parabiosis was able to restore the Notch signalling pathway and the proliferative 
capacity of senescent muscle stem when exposed to factors present in young serum in mice 
(Conboy et al., 2005). Furthermore, the experimental results of the parabiosis model in mice 
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suggested that blood factors from a young circulation can significantly affect the function of 
aging tissues, as indicated by the rejuvenation and function of endogenous, old skeletal muscle 
satellite cells after injury using dry ice (Conboy et al., 2005). In addition, exposing a young 
mouse to an old systemic environment inhibited skeletal muscle regeneration (Brack et al., 
2007). 
These studies showed that there are key regulatory molecules provided by young hosts, which 
are able to reverse age related impairment in skeletal tissues. In attempt to identify candidate 
circulatory proteins in young blood, Sinha and colleagues reported that supplementation of 
systemic GDF-11 levels, which normally reduce with age, by heterochronic-parabiosis reversed 
age –related skeletal muscle and stem cells dysfunction in mice (Sinha et al., 2014). 
However, blood contains thousands of proteins which may induce the rejuvenation process and 
therefore it is perhaps naive to think that one factor alone will underpin this process. It is also 
noteworthy that immune cells can cross between animals in parabiosis models and due to their 
role in tissue regeneration they could offer a more sophisticated regulatory mechanism for 
directing regeneration where it is needed, rather than relying on generally circulating molecules. 
Therefore, a better understanding of these cells and their secreted mediators may enhance the 
search for the candidate proteins which induce muscle rejuvenation. 
 
1.8. IMMUNE SYSTEM 
The immune system provides a defence mechanism against foreign antigens. It compromises of 
two classes: Innate and adaptive immunity (Figure1.8). Innate immunity includes chemical and 
physical barriers such as skin and mucous membranes as well as phagocytes and dendritic cells 
(DCs). Adaptive immunity is triggered by innate immunity via releasing cytokines (e.g. INF-γ) 
and cell-cell interaction between DCs and lymphocytes (Münz et al., 2005). The degree of 
specificity arises from the presence of major histocompatibility molecules (MHCI) on CD8 +T 
cells and (MHCII) on CD4+ T cells. CD4+T  and CD8+ T cells  activated after exposure to 
Antigen presenting cells (APCs ) then differentiate to effector T cells such as cytotoxic T cells 
and helper T cells (Th).  Th cells play important roles in controlling T and B-lymphocytes 
(Figure 1.8). Th cells produce IL-2 to activate CD8.  In addition, Th cells release co-stimulatory 
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cytokines to activate B-lymphocytes and differentiate them to anti-body –releasing cells 
(Murray, 1998). 
During normal physiological conditions, immune cells circulate within the blood and the 
lymphatic system, with considerable accumulations in lymphoid organs, but are also dispersed 
amongst most tissues; peripheral tissues also contain a population of resident immune cells 
primarily consisting of macrophages and DCs. However, during pathophysiological conditions 
supplementary leukocytes and lymphocytes can rapidly infiltrate tissues. These leukocytes 
become activated and release soluble cytokines that can influence the function of the 
surrounding environment.  
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Figure  1.8: The interaction between innate and adaptive immunity. Upon exposure to pathogen, or 
in response to muscle injury, the interaction between dendritic cells and T cells occurs by MHC 
molecules. Consequently, T cell become activated and differentiated to cytotoxic T cells or T-helper T 
(Th1 and Th2) cells. Th1 cells support cytotoxic T cells while Th2 support antibody releasing B- cells. 
Adapted from http://jonlieffmd.com. 
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IN VIVO AND IN VITRO ACTIVATION OF IMMUNE SYSTEM 
 
T cell activation plays an important role in the regulation of immune responses including 
initiation of multiple signalling cascades originating from cells surface receptors (TCR) engaged 
by Major histocompatibility complex (MHC) on APC.TCR is a heterodimer composed of six 
different chains which are important for ligand recognition. CD3 molecules including, CD3-
Gamma, CD3-Delta, CD3 Epsilon and CD3-Zeta, which are responsible for recognition of 
specific antigen by T lymphocytes. Engagement of TCR/CD3 by MHC leads to phosphorylation 
of tyrosine containing molecules including ERK (Extracellular signal- regulated kinase), JNK 
(c-Jun N terminal Kinase), NF-Kappa β (Nuclear factor- Kappa β) and NFAT (Nuclear factor 
of activated lymphocytes) resulting in  T cell activation and IL-2 production (Figure1.9). T cell 
activation is regulated by CD28 receptor which provides essential co-stimulatory signal 
resulting in T cell expansion (Schwartz, 1990). Under normal condition, T lymphocytes, 
engagement of TCR-CD3 complex, results in co- stimulation by CD80-CD28 and recruitment 
of LAT (Linker of  activated T-Cells) which leads to augmentation of IL-2 production and 
increase T cell proliferation (Jerome, 2008).  Partial activation of TCR and/or the absence of co-
stimulatory signals generate insufficient signals to trigger phosphorylation of ERK, JNK, 
nuclear factor kappa –Beta (NFK-β) and nuclear factor of activated T cells (NFAT)(Villarino et 
al., 2007; Sprent and Surh, 2011) (Figure 9). Therefore, IL-2 production is reduced.  Anergy, 
unresponsive state, and quiescent states also arise from the presence of inhibitory molecules. 
TOB (Transducer of erbB2) is an inhibitory regulator of T cells proliferation and IL-2 
production, it is selectively expressed in un-stimulated T lymphocytes and anergic T cells 
(Cooper et al., 2004). Inhibition of IL-2 by TOB is mediated by SMAD proteins. The latter 
mediate signals triggered by TGF-β through its receptors; TGF-B RII and TGF-BRI which in 
turn phosphorylate the downstreamSMAD2, SMAD3 and SMAD4 and translocate to the 
nucleus. The SMAD complex binds to the IL-2 promoter repressing IL-2 production (Tzachanis 
and Boussiotis, 2009)(Figure 1.9).   
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Figure  1.9: Activated and quiescence states of T cells. Activation of TCR/CD3 receptors and co-
stimulatory CD28 molecules trigger sufficient signalling pathways that lead to activation of IL_2 gene 
promoter and then IL-2 gene transcription (left panel). Partial activation of TCR/CD3 and the absence of 
CD28 a co-stimulatory signal generate weak activation signal and inhibit promoter of IL-2 gene resulting 
hindered in IL-2 transcription (right panel). Negative regulatory molecules; TOB and SMAD complex 
repress IL-2 gene promoter and suppress IL-2 transcription (right panel). Adapted 
fromhttp://www.ebioscience.com 
 
 
1.9 IMMUNE SYSTEM WITH AGEING 
 
With ageing, many biological functions become impaired, including immune system. Age 
related decline of immune cells reduces the capability to respond to a challenge (Weng, 2006). 
Innate immune response is adversely affected with senescence (Salam et al., 2013). It has been 
observed that macrophages from old individuals express lower MHC molecule and Toll like 
receptors (TLRs) compared with young, which could negatively affect on  their  antigen 
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presentations resulting in  lower cytokines productions  in  such as IL-6 and  tumour necrosis 
factor-α (TNF-α) (Renshaw et al., 2002). Other components of the innate system that are 
adversely affected with increasing age are DCs. DCs reside in all tissue types and are identified 
by their elevated phagocytic and antigens presentation capabilities. DCs prime naïve T cells by 
their excreted cytokines which determine the differentiation and development of T cells. Aged 
DCs produce fewer secreted cytokines such as IL-12, suggesting age-related changes in function 
of T lymphocytes could be a consequence of impaired DC activity with ageing. Like DCs and 
macrophages, neutrophils also are functionally affected with ageing. After an infection, 
neutrophils are the first immune cells migrate to the site of infection. While the numbers of 
infiltrating neutrophils is not impacted with age, they display biological dysfunction in aspects 
of chemotaxis and nitric oxide production (Minet-Quinard et al., 2010).  
 The aged related decline in adaptive response has been well documented. Researchers showed 
that with increasing age, the number of T cells and clonal expansion TCR signalling are 
negatively affected thus, contributing to significant alteration in immune response to infections 
and tumours. For instance, upon stimulation, the interaction between T cell receptors (TCR) and 
APC cells is decreased which subsequently leads to low proliferative rate of T CD4 and CD8 
cells and the reduction in CD4 T cells releasing cytokines. Together these events contribute to 
poor differentiation to Th1 and Th2. For example, IL-2 production from aged naïve TCD4 cells 
in mice is significantly lower compared to young counterparts. This subsequently leads to 
reduced numbers of CD4, Th1 and Th2 subsets, thus negatively influencing immune responses 
(Haynes et al., 1999; Salam et al., 2013; Buckingham, 2006). Moreover, It was observed that  
age related T CD4 dysfunction reflected on the responsiveness of CD8 TCR repertoire towards 
viral infection (Haynes and Maue, 2009) and to antibody production by B lymphocytes (Weng, 
2006). Apart from T CD4 and CD8 changes, regulatory T cells (Tregs) are also functionally 
affected with ageing. It is well documented that the number of suppressor regulatory T cells 
(Treg) increases with age(Haynes and Maue, 2009; Weng, 2006; Nishioka et al., 2006). The age 
related defects in naïve T CD4 cells result from chronological ageing of naïve cell populations 
rather that from the chronological ageing of people. In response to antigen, naïve T cells are 
activated and migrate from the pool to encounter antigen, where as some remain locally within 
secondary lymphoid organs and then die off. In aged individuals, the equilibrium is disturbed 
because of reduced thymic output, suggesting that the pool contains aged subsets of lymphocytes 
which in turn lead to reduced conversion of naïve cells to memory cells and accumulation of age 
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related defects in CD4 cells. Taking all these events together, age related changes in the 
components of the immune system could contribute to immune response impairment in aged 
people. 
 
In the last few years, there has been growing attention to the contribution of cellular and humoral 
components of the immune system in the regeneration of damaged tissues, including skeletal 
muscle, heart, and the nervous system. Recent discoveries in immune-mediated regeneration 
have been made in skeletal muscle, a well-studied model for adult mammalian regeneration that 
employs activation of satellite cells, the resident progenitors of the muscle. While the evaluation 
of macrophages in skeletal muscle regeneration has long been emphasized (Arnold et al., 2007), 
both eosinophils and regulatory T cells (Tregs) have now been shown to be necessary mediators 
of satellite cell activation and subsequently myotubes formation following muscle damage 
(Heredia et al., 2013; Wynn et al., 2013). In addition, discrete spatial and temporal regulations 
of the immune response to injury or disease determine the systemic milieu and consequently the 
future fate of the tissue.  
 
1.10. POSSIBLE INTERACTION BETWEEN SKELETAL MUSCLE CELLS AND 
IMMUNE ENVIRONMENT. 
After acute muscle injury, a sequence of events is initiated by populations of immune cells 
leading to inflammation followed by muscle regeneration (Figure 1.10). 
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Figure 1.1010: Cross-talk between immune cells and satellite cells during myogenesis 
following muscle injury. After acute muscle injury, Th1 cytokines induce neutrophils and 
subsequently macrophages during the M1 phase. During M1, cytokines are released that promote muscle 
damage. M1 undergoes a transition to M2, which inhibits M1 function and releases anti-inflammatory 
cytokines that induce muscle repair and regeneration.  T–cells release interleukins that promote muscle 
regeneration (this diagram was designed by Al-Shanti et al.). 
 
Neutrophils are the first immune cells to migrate to the site of muscle injury with, numbers 
peaking between 6 - 24 hours post- injury. Macrophages are the second responders to the muscle 
injury and their numbers peaks 48 hours post injury then begin to decrease sharply. Declining 
macrophage invasion is followed by elevated numbers of lymphocytes that remain at high level 
for approximately 10 days (Pedersen and Toft, 2000; Shephard, 1998). The inflammatory 
response following muscle injury is accompanied by macrophages and neutrophils derived free 
radicals which target cellular debris for phagocytosis and subsequently lead a clean 
microenvironment for muscle repair and regeneration (Malm et al., 2000). The persistent 
presence of lymphocytes may provoke myogenesis and repair of skeletal muscle. However, with 
ageing, the immune function becomes impaired (Haynes and Maue, 2009; Nishioka et al., 2006) 
and the ability of skeletal muscle for repair and regeneration declines, leading to decreased 
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muscle mass, quality and function.  Therefore, it could be suggested that impaired immune 
function with ageing could influence the microenvironment of skeletal muscle leading to 
inefficient muscle regeneration and repair (Dumke and Lees, 2011). 
 Cytokines and interleukins released from immune cells during inflammatory responses 
contribute to muscle adaptation during satellite cell proliferation and differentiation stages by 
affecting transcriptional activities and viability of skeletal muscle cells (Tidball and Villalta, 
2010). Therefore, a better understanding of the cross talk between immune cells and skeletal 
muscle cells could help to provide therapeutic strategies for the reduction and treatment of 
muscle wasting with old age. To date, characterisation of immune specific factors capable of 
influencing skeletal muscle cells remain elusive. 
 
1.10.1 CROSS TALK BETWEEN SKELETAL MUSCLE AND INNATE IMMUNE 
SYSTEM (MACROPHAGES). 
 
Upon muscle injury, the innate immune response is initiated and driven by Th1 cytokines 
particularly, interferon -ƴ (INF-ƴ), IL-6 and TNF-α. These cytokines recruit immune cells for 
muscle repair and regeneration. Macrophages and monocytes within peripheral tissues have 
many important functions within this microenvironment, including phagocytosis, enzyme 
secretion, as well as growth factor and cytokine/chemokine production. These modulators aid in 
the recruitment of supplementary immune cells and provide a clean microenvironment for 
muscle repair and regeneration (Malm et al., 2000). As previously stated, neutrophils are the 
first population to migrate to the damaged tissue. Infiltrating neutrophils have important 
functions involving phagocytosis and TNF-α secretion. Neutrophil-secreted TNF-α triggers 
macrophage activation to a phenotype named M1. Influx of M1 macrophages   promptly 
increases over the first 24 hours after muscle injury takes place, eventually reaching peak 
concentrations after 3 days (Saclier et al., 2013) after which numbers decline. The invading M1 
phenotypes cells are responsible for driving inflammatory responses and stimulating muscle 
damage (Aurora and Olson, 2014). After the initial infiltration and decline of M1 macrophages, 
a secondary population of M2 macrophages enters the muscle reaching peak concentrations 
between 4 and 6 days, before reducing in number over several days or weeks. M2 macrophages 
are responsible for muscle differentiation and regeneration (Tidball and Villalta, 2010). M1 
 26 
macrophages originating in the blood as monocytes are distinguishable by their expression of 
the glycoprotein lymphocyte antigen 6C (Ly6C) as well as receptors for the CX3C chemokine 
receptor1 (CX3CR1) and C-C chemokine receptor type 2 (CCR2)(Geissmann et al., 2003) 
Ly6C+ monocytes differentiate into M1 macrophages in tissue and are acknowledged as 
inflammatory cells as they ultimately produce pro-inflammatory cytokines (Jetten et al., 2014). 
CCR2 (aka MCP-1) and its ligand CCL2 are potentially involved with the recruitment of Ly6C+ 
to the site of injury supporting the pro-inflammatory response. Conversely,Ly6C- cells 
differentiate into M2 macrophages and perform anti-inflammatory tasks, such as enhancing the 
reparative process. CX3CR1 and CCR2 chemokine receptors recruit the Ly6C- cells in a similar 
way to CCR2 recruiting LyC6+ cells. The CCL2/CCR2 axis is one of the most extensively 
described and is involved   with the inflammatory response after skeletal muscle injury takes 
place. Research with CCR2-/- mice has discovered that monocyte recruitment to the site of 
injury is significantly impaired, while neutrophil and other lymphocytes remain unaffected. 
Studies with CCR2-/- mice not only display impaired muscle regeneration as a result of 
inadequate macrophage recruitment, arrested angiogenesis along with increased fibrosis and 
excess adipocyte accumulation at the injury site are also observed (Martinez et al., 2010). 
Noteworthy, another study involving CCR2-/- mice revealed that bone marrow transplants 
coming from wild-type mice result in a substantial increase in the regenerative capacity of 
skeletal muscle. This finding proposes that CCR2 released by proliferating myocytes and 
resident immune cells unmistakably recruit bone marrow derived monocytes (Sun et al., 2009). 
However, the same results are not observed in studies involving CCL2-/- mice. Minor 
deficiencies in regenerative capacity are perceived in comparison to CCR2-/- mice, which may 
indicate alternative chemokine (C-C motif) ligands can bind with the CCR2 receptor and support 
the recruitment of monocytes and ultimately improve regenerative capacity (Lu, Huang, 
Ransohoff, et al., 2011), yet CCL2 is still required for completely successful muscle 
regeneration. The cytokine IL-6 is also implicated in the initial infiltration of monocytes and 
macrophages during the inflammatory response shortly after muscle damage. Studies involving 
IL-6-/- mice have revealed a significant decrease in the early infiltration of monocytes and 
macrophage to the injury site. This results in the manifestation of diminished myofibres mass, 
along with intensified fibrosis of the muscle (Zhang et al., 2013). In wild-type mice, a large 
proportion of IL-6 production is an outcome of early monocyte and macrophage infiltration, 
which can trigger the expression of CCL2 and CCL3. Thus promoting the maximum infiltration 
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of monocyte and macrophage concentrations seen in the first 24 hours after injury. Granulocyte 
colony-stimulating factor (G-CSF) is required for typical myoblast proliferation and myofiber 
development throughout the muscle regeneration process(Hara et al., 2011). Analysis shows that 
macrophages release G-CSF when stimulated by IL-6, revealing another important role for IL-
6 function during the early stages of inflammation and regeneration. Taking these results into 
consideration it can be recognized that the release of cytokines/chemokines can alter satellite 
cell activation, proliferation and/or differentiation to mature myotubes and muscle fibres. When 
examining differentiation of M2 phenotype macrophages a considerably more complex 
development takes place (Mantovani et al., 2004). M2a macrophages emerge from the exposure 
to adaptive immune response cytokines Interleukin 4 (IL-4) and IL-13, which stimulate the 
complex phases of tissue restoration and injury healing. M2b macrophage regulates the 
activation of Toll-like receptor immune complexes, leading to the release of anti-inflammatory 
chemokines such as IL-10 and the inflammatory cytokines TNF-α, and IFN-γ. The complex 
interactions between these cytokines and the healing muscle tissue are needed to regulate the 
timing of the immune response. The release of IL-10 by M2b macrophages also supports the 
recruitment of M2c macrophages. The M2c macrophages release the cytokines that are essential 
for the cessation of M1 macrophage infiltration and activity. Additionally, M2c macrophages 
release supplementary IL-10, which stimulates the proliferation of myoblasts leading to the 
promotion of muscle growth and regeneration (Deng et al., 2012). Through increasing 
knowledge of the exact mechanisms involved with the transitions between the different 
phenotypes, an insight into the manipulation of the process may provide unique therapies to 
increase regenerative capacity of skeletal muscle. It has been illustrated that shortly after injury 
M1 macrophage infiltration to the damage site occurs rapidly. The M2 macrophages that follow 
the M1 macrophages exhibit qualities of the M2c phenotype. This is logical as they mitigate the 
activation and actions of M1 macrophages (Arnold et al., 2007). During the early repair of 
damaged muscle tissue, the M1 macrophages are responsible for phagocytosis of necrotic 
muscle fibres as well as cytokine secretion and antigen presentation. Furthermore, TNF-α 
stimulates the M1 macrophages to produce inducible nitric oxide synthase (iNOS). This leads 
to cytotoxic concentrations of nitric oxide (NO) being produced, which are needed to destroy 
intracellular pathogens but as a consequence simultaneously promotes further muscle damage 
(Villalta et al., 2009). M2a macrophages are observed at their highest concentrations in the end 
stages of muscle repair due to their functions in the repair sequence. While sub-phenotypes of 
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M2b macrophages are observed throughout the repair process as having fluctuating levels during 
the alternatively activated immune response, since their production of IL-10 is needed to 
promote anti-inflammatory actions during muscle regeneration (Bosurgi et al., 2012). IL-10-/- 
animal models have disclosed that the transition of macrophages from the M1 to M2 phenotype 
is significantly impaired in the absence of IL-10, resulting in a corresponding impairment of 
muscle regeneration. Additionally, myoblast cell cultures supplemented with IL-10 and M2 
macrophages enhance proliferation (Deng et al., 2012). Therefore, IL-10 performs important 
roles involved with mediating the conversion of M1 to M2 macrophages after muscle damage 
occurs, encouraging the proliferation of myoblasts and maturation of myofibers. Although there 
has been progress in the study of these mechanisms and persuasive evidence for the 
manifestation of diverse macrophage phenotypes in muscle repair, a robust knowledge of their 
precise roles is still elusive. Interestingly, research has presented evidence that the inflammation 
caused by macrophages and their associated pro-inflammatory cytokines have beneficial effects 
on myoblast proliferation while inhibiting differentiation (Tidball, 2005). As myoblasts switch 
from proliferation to differentiation, a shift from M1 macrophages to M2 macrophages and anti-
inflammatory cytokines occurs concurrently (Figure 1.11). 
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Figure 1.11 : Debris Clearance after skeletal muscle injury. Following muscle injury, debris clearance 
orchestrated by the immune system is a key activator of subsequent skeletal regenerative steps, including 
satellite cells activation, proliferation and differentiation.  Debris removal is orchestrated by 
macrophages M1 and fibro/adipocyte progenitors (FAPs.). FAPs function activity depends on eosinophil 
derived IL-4; the absence of on eosinophil derived IL-4, FAPs convert to fat causing muscular 
dysfunction. Phagocytic M1 (MØ) promotes satellite cells activation and proliferation shifts to M2 via 
AMP-activated protein kinase mediated signalling (AMPK) to provide an environment that stimulates 
myoblasts differentiation. Adapted from (Aurora and Olson, 2014). 
 
 The cytokine transference diminishes the pro-inflammatory response and supports the 
differentiation of muscle fibres (Deng et al., 2012). The positive effects exerted by the anti-
inflammatory cytokines produced by M2 macrophages on the differentiation of myoblasts have 
also been shown in vitro (Tidball, 2005; Arnold et al., 2007). M2 macrophages also produce 
IGF-1, a hormone known for this growth promoting skeletal muscle hypertrophy through the up 
regulation of MRFs. CCR2-/- mice not only display reductions in the adequate infiltration of 
monocytes and macrophages, a significant reduction in IGF-1 production and impaired muscle 
regeneration are correspondingly observed (Lu, Huang, Saederup, et al., 2011). This fascinating 
discovery suggests that macrophages provide growth factors that aid in the repair of muscle 
tissue damage by encouraging IGF-1 stimulated satellite cell proliferation. Overall, the 
production of  these preliminary mediators via resident immune cells recruit the infiltration of 
circulating immune cells, thus allowing for the elimination of necrotic tissue along with the 
augmentation of myoblast proliferation and differentiation.  
 
1.10.2. CROSS TALK BETWEEN SKELETAL MUSCLE AND ADAPTIVE IMMUNE 
SYSTEM (LYMPHOCYTES) 
 
In the last decade, there has been a remarkable increase in the number of descriptive studies 
concerning the interactions between innate immune responses and muscle regeneration. 
However, the role of the adaptive immune system (T lymphocytes) in muscle regeneration 
relatively less well developed. Just as macrophages and cells involved with innate immunity are 
detected during acute muscle injury repair, adaptive immune cells such as T cells are also present 
during the regeneration process (Cheng et al., 2008). When observing the infiltration of innate 
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immune cells into the site of muscle injury a precise timeline is noted, T-cell infiltration also 
adheres to this timeline, with increasing concentrations reported approximately 3 days 
subsequent to cardiotoxin injection and remaining elevated for at least 10 days (Cheng et al., 
2008). Recent studies investigating how T-cells regulate muscular regeneration indicate that T-
cell cytokine secretions promote the proliferative and migratory actions of satellite cells, isolated 
from young muscle (Dumke and Lees, 2011). This finding adds evidence for the T-cell 
regulation of muscle repair. However, while the T-cell stimulus is observed as a positive 
influence on satellite cell proliferation/migration during acute injury repair, in animals that have 
dystrophic myopathies, T-cell suppression results in improved muscle regeneration with 
decreased fibrosis ( Farini et al., 2007). Additionally, it is acknowledged that non-dystrophic T-
cell deficient mice exhibit impaired muscle growth and increased fibrosis (Morrison et al., 
2005). This is indicative of T-cell actions being distinct dependant on whether the response is to 
acute or chronic inflammation. Innate immunity’s regulatory control of muscular regeneration 
is through cytokine and growth factor secretions; similarly, T-cells also release various 
signalling molecules, warranting further investigation. Furthermore, distinguishing between T-
cell sub-phenotypes present during regenerations also important.  
 
1.10.3 REGULATORY T (TREG) CELLS 
 
Regulatory T (Treg) cells, determined as the FoxP3+CD4+ sub-phenotype are  involved in 
immune response regulation (Josefowicz et al., 2012) inhibiting neutrophils and controlling the 
shift from M1 pro-inflammatory macrophages to M2 anti-inflammatory macrophages by IL-10 
production(Figure 1.12) (Burzyn et al.,2013). 
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Figure1.12: The immunological and non-immunological functions of Tregs. The function of 
Tregs in tissues can be divided in to three groups: Control T cell responses, control myeloid populations 
and modulating the non-immunological processes Adapted from (Burzyn et al.,2013). 
 
 Tregs cells  also control non-immunological process. For example, they promote angiogenesis 
by producing vascular endothelial growth factors (VEGF) (Zhou et al., 2015), regulate ischemic 
stroke development (Kleinschnitz et al., 2013), liver cholestasis and fibrosis (Katz et al., 2011). 
Recently, Tregs were detected in large quantities during acute muscle injury repair and 
regeneration (Burzyn et al.,2013). These cells produce regenerative factors such as IL-10, 
CCR1, PGDF and amphiregulin (Areg) that are known to accelerate skeletal muscle repair and 
regeneration(Figure 1.12) (Burzyn et al., 2013).Genetic ablation of T reg has shown that muscle 
Tregs directly enhance satellite cell activation and differentiation by secreting Areg (Burzyn, , 
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et al., 2013) (Figure 1.13). Areg is a member of EGF family and a pro -regenerative that capable 
to initiate its effect on muscle regeneration through EGF receptor (EGFR). EGFR is expressed 
by different cell types involving satellite cells and a myoblast cell line (Burzyn, et al., 2013). 
Once amphiregulin interacts with EGFR on skeletal muscle cells, signalling of both 
Ras/Raf/MAPK/ERK and PI3K/Akt/mTOR are activated (Rundhaug and Fischer, 2010) (Figure 
1.13).  
 
Figure  1.13: The effect of amphiregulin on skeletal muscle regeneration. Adapted from 
(Rundhaug and Fischer, 2010) 
 
Researchers examining the role Foxp3+CD4+ Treg cells (Muscle Treg) play during muscle 
repair have provided some elucidation on T cell/satellite cell interactions. Using mouse models 
with muscular injury induced via cardiotoxin, it was discovered that the Treg cells number 
increases within the injured muscle as the innate immune cells shifts from a pro to anti-
inflammatory phenotype (Burzyn  et al., 2013). The authors of this study also found that 
elimination of Treg cells during the reparative process resulted in reduced regeneration. In 
consideration of these results, it can be appreciated that T cells add another level of complexity 
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to the regulation of muscle regeneration. Genetic ablation of Tregs has shown that muscle Tregs 
directly enhance satellite cell activation and differentiation by secreting amphiregulin (Burzyn 
et al., 2013). 
Age has a significant impact on multiple satellite cells signalling pathways during myogenesis, 
aged satellite cell response to T-cells are no exception. Research conducted by Dumke and Lees 
(Dumke and Lees, 2011) has demonstrated that T-cell cytokine secretions have only a negligible 
progressive impact on satellite cell proliferation and migration, along with suppressed 
differentiation in aged satellite cells. This finding reinforces the concept that there are inherent 
variances in the response to environmental signals, dependant on age, occurring among satellite 
cells isolated from the skeletal muscle. Therefore, the authors speculate that satellite cell 
reactions to T-cell signalling may further age-related reductions in skeletal muscle regeneration. 
Various studies have revealed growth factors and cytokines which influence satellite cell 
functions are secreted from T cells (e.g. FGF2, IFN-γ, TGF-β, TNF-α, and IL-4) (Blotnick et 
al., 1994;  De Rosa et al., 2004;  Levings et al., 2002). The challenge for future studies will be 
to determine the specifics of the T-cell released factors responsible for altering satellite cell 
function during muscular regeneration throughout aging. Allowing for the advancement of 
directed therapeutic mediation in aged and/or diseased muscle. One proposed avenue of research 
that may provide further clarification of the mechanisms involved with T-cell/satellite cell 
interactions is to investigate what effect the secretome of activated lymphocytes has on cultured 
satellite cells. Experiments with C2C12 murine myoblast cell line have demonstrated that the 
secretome from human anti-CD3 activated T-lymphocytes inhibits differentiation while 
promoting proliferation (Al-Shanti et al., 2014). Importantly, the discovery that immune cell 
secretome can be used to manipulate myoblast functions allows for novel studies using human 
cell lines, while concurrently acquiring further intelligence of the constituent parts of the 
immune secretome.  
 
1.11. THERAPEUTIC POTENTIAL OF IMMUNE MUSCLE CELLS 
SECRETOME IN MUSCLE REGENERATION. 
Although the investigation of the immune cell secretome on skeletal muscle satellite cells is still 
in the early stages, studies have been performed using the secretome to enhance wound healing. 
Interesting results have been demonstrated when the secretome collected from young, healthy, 
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human activated T-lymphocyte cultures is applied to punch biopsy wounds on mice. 
Experiments show advanced wound healing in mice treated with the secretome directly (Mildner 
et al., 2013).  Additionally, the authors found that when the secretome was applied to human 
skin cells in vitro, signalling molecules involved with increased proliferation and migration were 
activated. Similarly, promising evidence for the use of the secretome in treating myocarditis has 
been exhibited. When experimental autoimmune myocarditis (EAM) has been induced in animal 
models, it can be attenuated with large doses of mononuclear cell secretome (Konrad 
Hoetzenecker et al., 2013). Recently, we showed that the secretome from young human activated 
lymphocytes markedly induced proliferation and blocked the differentiation of C2C12 cells (Al-
Shanti et al., 2011). In view of these results it can be appreciated that the immunomodulating 
impacts of immune cell secretome has the potential for diverse applications, including skeletal 
muscle regeneration. Therefore, a better understanding of the cross talk between immune cells 
and skeletal muscle cells could help to provide therapeutic strategies for the reduction and 
treatment of muscle wasting with old age. To date, characterisation of immune specific factors 
capable of influencing skeletal muscle cells remain elusive.  In the present work, it was 
hypothesised that as we age, the ability of our immune and skeletal muscle systems to interact, 
and therefore to function optimally, are compromised.  
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1.12 AIMS AND OBJECTIVES 
The overall aim of the work presented in this thesis was to develop a better understanding of the 
role of immune cells (principally lymphocytes) in muscle satellite cell proliferation, migration 
and differentiation, and to determine whether differences exist between immune cells isolated 
from young and from older donors.  
Thus, the objectives are:  
1. To optimise the lymphocytes cell culture conditions, including determination of effective 
activation time, anti-CD3 and CD28 concentrations and cell counts.  
2. To determine effective concentrations of the lymphocytes’ secretome collected from 
young adults when used to enrich the cell-culture medium of C2C12 (p5) cells.  
3. To characterise young and old lymphocytes isolated from fresh blood samples of healthy 
donors by analysing CD25 receptors, amphiregulin expression and FoxP3 receptors. 
4. To identify candidate regulatory factors secreted from young and old lymphocytes that 
have the potential to modify C2C12 activity.  
5. To explore the impact of harvested secretomes from young and old activated 
lymphocytes on C2C12 proliferation and migration, compared to the controls of the 
study. 
6.  To determine the biochemical (MAPK/ERK1/2 and Akt/mTOR signalling pathways) 
and molecular (MyoD and myogenin) adaptations of C2C12 cells treated as above. 
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CHAPTER 2 
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2.1. MATERIALS, GENERAL EQUIPMENT AND SPECIALIZED 
SOFTWARE 
 
2.1.1. CHEMICALS, SOLVENTS AND REAGENTS 
 
  All general chemicals and solvents (analytical (AnalaR)) or molecular biology/tissue culture 
grade) were purchased from Sigma (Poole, UK) and BDH (Poole, UK), unless otherwise 
specified. All inhibitors were purchased from Selleckchem (USA).  
 
2.1.2. CELL CULTURE 
 
  All cell culture experiments were performed under a Class II microbiological safety cabinet 
(Labcaire SC-R Recirculating Class II, North Somerset, UK). All cell incubations were 
performed in Triple Red Laboratory Technology Nuaire DH Autoflow CO2 Air Jacketed 
Incubator (Buckinghamshire, UK). Liquid, media and supernatants were discarded using an IBS 
Integra Biosciences Vacusafe Comfort (Chur, Switzerland). All solutions used for cell culture 
were prepared with distilled water from Elgastat option 4 water purifier (Elga Ltd., High 
Wycombe,UK). Cell microscopy and photography were performed using Leica Microsystems 
(Wetzlar, Germany) CMS GMbH light microscope (Leica DMI6000B) with digital photography 
(Leica CTR 6000), using Leica Application Suite software (Wetzlar, Germany). For fluorescent 
microscopy, images were taken using Leica DMI 6000B imaging system with FITC-
fluorescence L5 filter cube (excitation wavelength=480/40nm). 
 
2.1.3. CELL CULTURE REAGENTS 
 
C2C12 
 
  Sterile Dulbecco’s Modified Eagle’s Medium (DMEM) w/ 4.5g glucose per Litre, w/ L-
Glutamine (584mg/L) was purchased from LonzaBioWhittaker (Wokingham, UK). Heat-
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inactivated (hi) foetal bovine serum (FBS) was purchased from Gibco (Paisley, UK) and hi horse 
serum (HS) - from Southern Group Laboratory (Corby, UK). Sterile penicillin-streptomycin 
solution and 10x trypsin solution were purchased from BioWhittaker (Wokingham, UK). L-
glutamine was purchased from BDH (Poole, UK) and non-sterile gelatine type A from porcine 
skin was purchased from Sigma-Aldrich Chemie (Steinheim, Germany). Phosphate buffered 
saline (PBS) tablets were from Oxoid Ltd. (Basingstoke, UK).All solutions were prepared in 
non-sterile distilled water and were sterilised by autoclaving at 121°Cin a bench-top autoclave 
from Prestige Medical (Birmingham, UK) before usage in cell culture.  
HUMAN LYMPHOCYTES CULTURE 
 
RPMI-1640 was purchased from (Lonza, Belguim), Ficoll–Paque PLUS (GE healthcare Life 
Science, UK),  recombinant interleukin- 2 (rhIL-2, 10µg, R & D System)  and L-glutamine was 
purchased from BDH (Poole, UK). Human anti-CD3 was purchased from (CliagAG, 
Switzerland) and anti-CD28 from (BD Pharmingen TM, San Diego). Sterile AB human serum 
purchased from Invitrogen (Brown Deer, USA).  
 
 
2.1.4. PLASTICWARE 
 
  Tissue culture flasks (T75 and T175), 12 and 6 well Nunclon™Δ surface multi-well dishes 
were purchased from Nunc Life Sciences, Thermo Fisher Scientific (Rockslide, Denmark). 96 
well plates for protein assays were also purchased from Nunc Life Sciences, Thermo Fisher 
Scientific (Rosklide, Denmark). MicroAmp® Optical 96-Well Reaction Plates for Applied 
BiosystemsStepOnePlus Real-time PCR system were purchased from Applied Biosystems 
(Warrington, UK). Cryogenic vials, 15m and 50ml sterile centrifuge tubes, cell scrapers and 
pipette tips for tissue culture, biochemistry and flow cytometry were purchased from Fisher 
Scientific (Loughborough, UK) and 0.25, 0.5, 1.5 ml RNase Free Microfuge tubes for RNA 
work were purchased from Applied Biosystems (Ambion-The RNA Company, Cheshire, UK). 
0.5, 1.5 and 2 ml tubes were also purchased from Eppendorf (Hamburg, Germany). Syringes 
were from Terumo (Leuven, Belgium) and syringe filters (0.22 µM) from Corning (Lowell, MA, 
USA).   
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2.1.5. LIVE IMAGING 
 
  Live imaging microscopy was performed using a Leica DMI6000B microscope equipped with 
an autoflow incubator, CO2 controller, heating unit and temperature controller, thus allowing 
maintenance of 5% CO2, 37°C humidified atmosphere. Videos were generated and exported 
using the Leica Application Suite software (Wetzlar, Germany). 
 
 
2.1.6. REAL-TIME PCR 
 
RNA concentrations and purity were assessed using a Biotech Photometer (WPA UV1101, 
Biochrom, Cambridge, UK). Applied Biosystems StepOnePlus Real-time PCR system. Results 
were analyzed using a StepOne Software v2.2.2 (Applied Biosystems, Life Technologies). 
Reagents for real time PCR were from Applied Biosystems (Carlsbad, CA, USA).  
 
2.1.7. FLOW CYTOMETRY 
 
  Flow Cytometry was performed on a BD FACSCaliburTM (Becton Dickinson, Franklin Lakes, 
NJ, USA) with Cell Quest Pro Software (Becton Dickinson, Franklin Lakes, NJ, USA). Cell 
cycle analysis was performed using ModfitTM software (Verity Software House, Topsham, ME, 
USA). Reagents for Flow cytometry were purchased from BD (BD Biosciences, San Jose, CA, 
USA). 
 
2.2. METHODS AND PROTOCOLS 
 
2.2.1. CELL CULTURE PREPARATION 
 
   Cell culture experiments were performed with the C2C12 cell line, which was purchased from 
the American Tissue Culture Collection (ATCC; Rockville, MD, USA).  
The cell cultures in the study were prepared following thawing the frozen stock. The cells were 
induced to grow to reach the desired population. Then proliferating cells were transferred to 
different conditioned media which were designed for the experiments. Unused cell cultures were 
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preserved by cryopreservation for long- term storage. These procedures used in the preparation 
of cell cultures for the study are described below.  
 
 
2.2.1.1. STIMULATING PROLIFERATION OF MOUSE C2C12 SKELETAL MYOBLASTS. 
 
C2C12, murine skeletal myoblasts, are derived from satellite cells, whose behaviour corresponds 
to that of a progenitor lineage. These cells are a subclone of C2 myoblasts (Yaffe and Saxel, 
1977) which spontaneously differentiate in culture after serum removal (Blau et al., 1983). The 
C2C12 cells were purchased from ATCC (Rockville, MD, USA) and maintained by growing 
cells at a density of  2x106 cell / flask in 0.2% pre-gelatinised  T75 flasks in a humidified 
atmosphere of 5% CO2 at 37°C. The cells were grown in GM Dulbecco’s Modified Eagles 
Media (DMEM), supplemented with 10% foetal bovine saline defined (hi FBS), 1% L-glutamate 
and 1% of 10000U (Penicillin/Streptomycin). Myoblasts undergo myogenic differentiation upon 
replacement of GM with differentiation media (DM), supplemented with 2% horse serum (hi 
HS), 1% Pen-strep and 200mM L-glutamine.  
 
2.2.1.2. CELL PASSAGING 
 
Passaging of cells was performed by aspirating culture media and washing cells with PBS to 
remove any remaining serum. Cells weretrypsinised with 0.05% 
Trypsin/0.02%Ethylenediaminetetraacetic acid (EDTA) for 3-5 minutes at 37°C to detach cells 
adhering  to the substrate and re-suspending the cells in pre-warmed GM (in a ratio of least 1:6 
of trypsin:GM). The purpose of suspending cells in media is to deactivate the action of the 
trypsin (EDTA). Cells were counted using a haemocytometer and the numbers obtained were   
adjusted for dilution and stock volumes. The cells were grown in GM in a flask or a multi-well 
dish, pre-coated with 0.2% gelatine. Working volumes were normally 10ml of media for T75 
flasks, 5 ml in T25 flasks, 2ml of media/well for a 6-well plate and 1ml of media/well for a 12-
well plate.  
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2.2.1.3 CELL CRYOPRESERVATION AND RESURRECTION 
CELL CULTURE PROLIFERATION AND MAINTENANCE OF C2C12 SKELETAL 
MYOBLASTS (GM) 
  For the preparation of cell stocks, confluent cell monolayers were trypsinised and cells counted 
with a Neubauer haemocytometer. Cell numbers were diluted in GM to 1×106 cells/ml. 10% 
dimethyl sulphoxide (DMSO; BDH, Poole, UK) was added to the cell suspension in a drop-wise 
manner and cells were transferred to 1ml cryovials. DMSO partially solubilises and stabilises 
the cell membrane, making it less prone to puncture. This is mainly because draws water out of 
the cells, dehydrating them and protecting intracellular components from ice crystal damage. 
 
Consequently, cryovials were placed into freezing chambers purchased from Nalgene 
(Rochester, NY, USA) containing isopropyl alcohol and the chamber was transferred for 
overnight storage at -80°C. This procedure allows gradual freezing of the cells at a rate of -
1°C/.min, which allows the reduction in metabolism of the cells and allows enhanced survival 
upon resuscitation. Following overnight incubation at -80°C, cryovials were transferred to liquid 
nitrogen for long-term storage. The growth of ice crystals is reduced in liquid nitrogen for long- 
term storage.  
 For restoring cell stocks from liquid nitrogen, cryovialswere placed at room temperature in a 
cell culture safety cabinet until thawed and the cell suspension quickly transferred to a 0.2% 
gelatine pre-coated flask, containing warm GM. 
2.2.1.4. RECONSTITUTION OF INHIBITORS FOR C2C12 TREATMENT 
 
All inhibitors including the Mek inhibitor(UO126) and IGF-R inhibitor (Linsitinib-OSI906) 
were purchased from Selleckchem. Inhibitors were diluted in DMSO according to 
manufacturer’s instructions and stored at -20°C. Both inhibitors were kept inmMconcentration 
stocks which were diluted to working concentrations in appropriate DMEM media before 
treatment. 
 
 
2.3CELL COUNTING BY TRYPAN BLUE EXCLUSION 
 
 
CELL COUNTING BY TRYPAN BLUE EXCLUSION 
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For cell counting, the cell suspension was syringed to destroy  clumps forming and  prepared in 
a 1:1 dilution in trypan blue stain (Bio Whittaker, Wokingham, UK) and cells were counted with 
a Neubauer haemocytometer (Assistent, Sondheim, Germany). Viable cells exclude the trypan 
blue dye and only the dead cells absorb the stain.  
 
PRINCIPLE 
 
Cell counting was performed using a Neubauer haemocytometer consisting of a thick glass with 
a grid of lines etched in the middle. The grid isan arrangement of different sizes of squares which 
makes it possible to count the number of cells in a known volume of solution. The counting 
chamber coverslipshould restfirmlyon a counting chamber at a distance of 0.1mm above the 
base of the slide(Figure 2.1). When cell suspensions fill the chamber, they can be observed under 
the microscope and the cells are counted in a chosen number of squares in fields of view. From 
these counts, the cell number per ml of suspension can be calculated. Percentage of dead cells 
vs.Percentage of viable cells were estimated using trypan blue, which will only penetrate 
membranes of dead/non-viable cells. Viable cells exclude the stain and stay small while dead 
cells become, larger and dark blue 
 
 
PROCEDURE 
 
Prior to use, the haemocytometer was cleaned with 70% ethanol. Edges were moistened and the 
coverslip positioned over the grooves until Newton’s rings were observed.This indicated that 
the coverslip was accurately placedand fixedover the counting area. Equal volumes of cell 
suspension and 0.4% trypanblue  were mixed and pipetted into the chamber by capillary action. 
Cells were counted in quadruplicate with each counting area of the hemocytometer, representing 
a total volume of 0.1mm3. Since 1cm3 is equivalent to 1 ml, the cell concentration per ml was 
calculated using the following equations  
 
Cells per ml = Average cell count × dilution factor × 1×104 cells/ml 
E.g.: average count is 50 cells × dilution factor of 2 × 1×104= 1×106 cells/ml 
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Figure 2.1: Haemocytometer design and dimensions. Adapted from https://www.phe-
culturecollections.org.uk 
 
2.4. BLOOD SAMPLE COLLECTION AND PROCESSING MANAGEMENT 
 
Blood samples were collected from healthy young and old participants predominantly males, 
who were recruited to take part in this study. All recruited participants in this study were healthy 
on a normal diet, not on immunosuppressant or corticosteroids and immunosuppressant 
treatment that affect immune function. During the recruitment process, potential participants 
were provided with the details of this study. Information of this study was provided in verbal 
and written formats in order for potential participants to make an informed decision on whether 
or not to participate. Participants were encouraged to understand this information and make a 
considered decision on their own, away from the researchers. A copy of the signed consent form 
was provided to the participants for their information. Participants had the right to withdraw 
from the experiment at any time. They also completed a medical questionnaire in which all 
recorded details were completely anonymous (free from any potential identification). This was 
achieved by allocating each participant with a non-identifiable participant number (PN). The 
participants were asked to give blood by a phlebotomist. The needle was inserted in an 
antecubital vein to obtain at least 10 ml blood in EDTA tubes. After obtaining the blood, the 
needle was removed and gauze applied at the site of venepuncture. The participants were then 
free to leave the laboratory. All raw samples and data were stored anonymously under a 
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participant number (PN) rather than by name. Data storage complied with the Data Protection 
Act (1998). Participants had the right to withdraw from the study at any time after the 
experimental procedure commenced, all that participant’s samples and data stored in whatever 
format would have been destroyed. 
 
 
 
2.4.1. IN VIRTO ACTIVATION OF HUMAN LYMPHOCYTES FROM FRESH BLOOD 
SAMPLES 
 
Lymphocytes were isolated from fresh blood samples by Ficoll–PaquePLUS depending on the 
gradient density. Diluted blood with PBS (ratio 1:1) was layered carefully over 15 ml Ficoll –
Paque PLUS. The blood - Ficoll-Paque PLUS layers were centrifuged at 500xg for 30 minutes 
at 18°C. Following that, the layer of lymphocytes was carefully removed and washed twice with 
RPMI-1640 media).Prior to lymphocytes culture, monocytes were depleted from the cell 
preparation by pre-plating for 15 minutes at 37°C (Karanfilov et al., 1999). To mimic in vivo 
activation, isolated lymphocytes were cultured  at  1x106 cell/ml  on pre-coated 96 well flat-
bottomed micro well plates with anti-human anti-CD3 (OKT3 ,10ng/ml)(Figure 2.2)(Garland et 
al., 2002; Al-Shanti et al., 2014a)overnight at 4°C. Lymphocytes were developed in RPMI-1640 
containing 10% (v/v) AB human serum, anti-CD28 (Figure 15), 1% Penicillin/Streptomycin and 
50U/ml of  human  recombinant interleukin- 2 (rhIL-2, 10µg, R & D System).In negative 
controls cells were incubated in the absence of anti- CD3/CD28 and supplemented with IL-2 in 
a complete RPMI-1640 media. Cells were cultured at different incubation times to identify the 
optimal stimulation. For cell counting, lymphocytes were re-suspended in a 1:1 dilution in 
trypan blue stain before being counted with a Neubauer haemocytometer. 
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Figure 2.2: Engagement of T cell receptor (TCR) CD3 and CD28 by anti-CD3 and anti-
CD28 of T lymphocytes activation in vitro.  Adapted from http://www.the-scientist.com 
 
 
2.4.2. SECRETOME RECOVERY 
 
A volume of 4 ml of lymphocytes secretomes from each experimental culture time was 
centrifuged in an Ultracel-3 Membrane tube (Figure 2.3) for 30 minutes at 5400xg to prepare 
conditioned media. Alternatively, secretomes were aliquoted and kept at -80ᵒC for multiplex 
immune assay analysis. 
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Figure 2.3: Amicon® Ultra-4 Centrifugal Filter Units for secretome filtration 
 
 
 
 
2.4.3. CONDITIONED MEDIA (CM) PREPARATION AND C2C12 TREATMENT. 
 
A cell-free culture supernatant was used for the conditioned media and prepared by sterile 
filtration of the media in which the lymphocytes were cultured. The conditioned media was 
added to the usual C2C12 culture media at the desired concentration. The remaining concentrate 
of the secretome (200µl) was mixed with DM (DMEM) to form CM. Four types of CM were 
prepared. CM1 contained concentrate filtered obtained from activated lymphocyte culture. CM2 
contained concentrate obtained from non-activated lymphocyte cultured with IL-2 but without 
anti-CD3 and CD28. CM3, was a control containing boiled activated lymphocyte secretome - 
the secretome was boiled for 10 minutes in a water bath to destroy all cytokines. CM4 contained 
concentrate from RPMI-1640 supplemented only with IL-2 but without lymphocytes.  This 
control was included to exclude any effects of the 10% of human AB, which is added to RPMI-
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1460, a lymphocyte culture medium. To treat C2C12 with these CMs, cells were cultured a day 
before in pre –gelatinised 6-well plates at a concentration of 50x103cells/ml of completed growth 
media (GM). Cells were incubated overnight in a humidified atmosphere with CO2 at 37⁰C.  
After 24 hours, cells were washed twice with PBS prior to replacing GM with conditioned media 
(CM1 Young and Old, CM2 Young and Old, CM3 Boiled, and CM4 and incubated for particular 
period of time.  
 
 
2.5 HUMAN SERUM SEPARATION FROM FRESH BLOOD SAMPLES 
 
Blood samples were collected from young and old participants using a serum separated tube 
(SST) and left for an hour to clot at room temperature. The clot was removed by centrifuging at 
1000-2000×g for 10 minutes. Following centrifugation, the liquid component (serum) was 
transferred into a clean polypropylene tube and stored at -80°C for DM preparation.  Serum is 
the blood extract which contains all the proteins not used in blood clotting (coagulation) and all 
the electrolytes, antibodies, antigens and hormones. To destroy heat-labile complement proteins, 
serum samples were heated in a water bath for 30 minutes at 56°C. Serum samples were 
aliquoted and kept at -80°C till further analysis. 
 
2.6. CELL EXAMINATION BY FLOW CYTOMETRIC ANALYSIS. 
 
PRINCIPLE 
 
 Flow cytometry is a widely used analytical tool in biomedical research and clinical diagnostics. 
It is a powerful tool to study the expression levels of both surface-expressed (such as CD4, 
CD69, CD25etc.) and intracellular (such as Foxp3) proteins on a single-cell basis and the data 
can be obtained relatively quickly.Using this technique, multiple molecules can be determined 
simultaneously on the same cells, which can help to identify different cell populations within a 
given sample, and differential expression levels can accurately be measured and compared 
across various cell populations. In addition to the advantages of using flow cytometry in terms 
of its speed, high precision, and accuracy, the constant hardware updates and improved 
capability for software-based data analysis make flow cytometry one of the most advanced 
technologies for cellular quantitative analysis. 
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Flow cytometry is a useful technique in counting and examining the cell characteristics. It 
consists of three main systems: fluidics, optics and electronic systems, as it shown in (Figure 
2.4).The cells are suspended in a fluid sheath and injected into the fluidics system. The latter 
transports the stream of liquid to laser beam .Laser light is scattered by the passing particles and 
any passing fluorescence. Scattered light is collected by detectors.  Forward scatter (FSc) is 
collected by the detectors orientated to the laser beam. The scattered light is an indicator for 
relative particle size, whilst side scatter (SSc) is picked up by detectors aimed perpendicular to 
the laser source, and it is an indication of the internal complexity of the cells. Fluorescent 
detectors may also give information on fluorescent chemicals found in the cells. 
 
 
 
Figure 2.4:  A Schematic overview of the mechanisms of Flow Cytometer. Adapted from: 
www.labome.com 
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2.6.1. MEASUREMENT OF CD25 (IL2R-α) ON LYMPHOCYTES 
 
CD25 (IL2R α) is a ligand-binding alpha subunit of interleukin- 2 receptor alpha (IL-2Rα). It is 
a marker for lymphocyte activation. The expression of CD25 on anti-CD3/CD28- activated and 
non- activated were measured. Cells were homogenised and re-suspended in 500µl of stain 
buffer (FBS) ready made-up (BD Pharmingen™) and stained with 10µl of human anti-CD25-
APC conjugated (Sigma-Aldrich). After 30 minutes of incubation in the dark at room 
temperature (RT), the cells were centrifuged at 300xg for 10 min. The supernatant was 
discarded; single-cell suspensions were prepared in 500µl of sheath fluid solution for each tube 
and transferred to the FACS tubes prior to measurement by a FACS Calibur flow cytometer. An 
isotype -matched control antibody was to establish the threshold for negative staining.   
 
2.6.2. MEASUREMENT OF CD14 MARKER ON HUMAN MONOCYTES 
 
CD14 is the major lipopolysaccharide (LPS)-binding protein. It is synthesised and highly 
expressed by monocytes (Jersmann, 2005). A cell suspension of 1x106 cell/ ml was centrifuged 
at 300xg for 10 minutes. Following centrifugation, the supernatant was discarded and pellet was 
washed with PBS, then re-centrifuged for 10 minutes at 3000xg. The pellet formed following 
centrifugation was homogenised by using a 21-gauge blunt-ended needle. Then the cells were 
incubated in the dark at RT with a volume of   500µl of stain buffer and 20µl of APC Mouse 
anti-human CD14 (BD Pharmingen™). After 30 minutes of incubation at RT, the supernatant 
was discarded; single-cell suspensions were prepared in 500µl of sheath fluid solution for each 
tube for flow cytometric analysis. Isotype was applied as a negative control to establish the 
thresholds for negative staining.  
 
 
 
2.6.3. MEASUREMENT OF FOXP3, A TREG CELL MARKER 
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Activated lymphocytes by anti-CD3/CD28 were harvested following 4 days of activation. Cells 
were homogenised and re-suspended in 200µl of stain buffer (FBS) ready made-up (BD 
Pharmingen™) and stained with 20µl of PE-human FoxP3 antibody (BD Pharmingen™). 
Following 30 minutes incubation at RT protected from light, the cells were centrifuged at 300xg 
for 10 min. The supernatant was discarded; single-cell suspensions were prepared in 500µl of 
sheath fluid solution for each tube and transferred to the FACS tubes prior to measurement by a 
FACS Calibur flow cytometer. Isotype -matched control antibody was used to establish the 
thresholds for negative staining.   
 
2.6.4. PROPIDIUM IODIDE AND CELL CYCLE EXAMINATION 
 
Flow cytometry is a useful technique that is used to measure cell cycle progression. To perform 
this, propidium iodide (PI) is used. PI is a fluorescent intercalating agent that binds to the nucleic 
acid. 
Cells life cycle involves different phases. In theG1 phase the cell division has not initiated but 
the centrioles start replicating. In the S phase, DNA starts replicating so more DNA contents 
will form. In the G2 /M phase, the final preparation for mitosis in which DNA is fully 
synthesised and the contents become twice of the G1 phase (Figure 2.5). In flow cytometry 
analysis, the intensity of PI binding to DNA will be higher. Therefore, if cells have been induced 
to proliferate, more DNA content will form, and the cells in S phase will be accumulated thus, 
the percentage of fluorescence intensity will be increased  
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Figure 2.5: DNA content through cell cycle phases. Adapted from 
http://www.grc.nia.nih.gov/ 
 
METHOD 
 
To assess the proliferation and differentiation of CMs- treated C2C12myoblasts, cells were 
washed with PBS twice and trypsinised. Then the cells were collected in 15ml tubes and 
centrifuged at 300xg for 10 minutes. The PBS supernatant was aspirated and cells werewashed 
twice with PBS and centrifuged at 300xg for 10 minutes. After centrifugation, the PBS 
supernatant was removed and cells were fixed with 3ml of 75% EtOH, which was added in a 
drop wise manner to the cell pellet while vortexing (ethanol helps PI to intercalate into double-
strand DNA).Samples were stored overnight at -20°C. Following fixation with 75% EtOH, cells 
centrifuged for 10 minutes at 300xg. Following centrifugation, the EtOH supernatant was 
removed, and cells were re-suspended and centrifuged twice with 1 ml PBS. Cells were then 
mixed and transferred to 3ml BD Falcon flow cytometry tubes (BD Biosciences, San Jose, CA, 
USA). The volume of 10ul of PI (50 µg/ml) was added to the cell suspension. Stained samples 
were incubated in the dark at RT for 30 minutes then samples were stored at 4°C before flow 
cytometric analysis was performed.  
 
2.7. WOUND HEALING ASSAY WITH LIVE IMAGING EXAMINATION. 
 
  In order to investigate the migration potential of C2C12 cells in response to specific factors, a 
wound healing assay was established. In the wound healing assay, a scratch/wound was created 
in a monolayer of confluent cells, usually using a pipette tip. Live observation of wound closure 
progress over the time was undertaken by using live imaging microscopy that can provide useful 
information not only on the migration of cells but also on morphology and migrating distance 
in response to particular factors. 
 
WOUND HEALING METHOD 
 
C2C12 were grown in 12-well plates in GM until 80% confluent. Cell monolayers  were washed 
twice with PBS and incubated for 20 hours in DMEM, supplemented with 0.1%HS to attain a 
quiescent state. After removing the medium, cells were pre-incubated with MitomycinC 
(10ug/ml) (Rogel et al., 2011; Gamell et al., 2008) for 3hrs (Gamell et al., 2008) to arrest the 
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proliferation phase (Frommer, 2008). C2C12 monolayers were washed three times with 
quiescence medium and scratched using a 200µl sterile pipette tip. The cells were washed 3 
times to remove dead cells and debris. They were cultured in the various experimental CMs for 
18 hrs at 37˚C and 5% CO2.  Images were obtained at 0 and after 18 hours of migration using a 
Leica DMI6000B microscope, ensuring the same X and Y coordinates were imaged each time. 
The number of cells migration towards the central area, from which the cells were initially 
evacuated following the scratch, was quantified using ImageJ in each treatment 
 
2.8. MORPHOLOGICAL DIFFERENTIATION AND QUANTIFICATION OF THE 
PROLIFERATION AND DIFFERENTIATION PARAMETERS. 
 
Two fluorescent  stains were used to evaluate morphological parameters of  CMs- treated  
C2C12 :Texas Red®-X Phalloidin is a fluorescently- labelled stain  which binds specifically  to 
F- actin in skeletal muscle cells  and anti-Myosin Heavy Chain (MyHC) Alexa Fluor® 488 that 
binds to heavy chains of myosin. 
 Cells  after CMs treatment were  fixed in 3.7% formaldehyde solution and incubated at RT for 
5 min. Fixed cells were washed 3 times with PBS before permealisation  with 0.1% Triton-X-
100 for 5 min. Following Triton removal, cells were stained with either Texas Red®-X Phalloidin 
(200 unit/ml, Sigma Aldrich, Pool, UK) or anti-Myosin Heavy Chain (MyHC) Alexa Fluor® 
488 (eBioscience, UK) and DAPI nuclear counterstain solution (5mg/ml, IHCWORLD). After 
30 min of incubation, the treated cells were observed using a fluorescent microscope. The 
differentiation parameters were assessed using ImageJ software(Schneider,  andEliceiri, 2012) 
to evaluate the morphometric parameters for myotube development. The differentiation 
parameters  involved were : fusion index (FI) which was calculated by dividing the total number 
of infused nuclei per a myotube (>2 nuclei) to the total number of nuclei counted over the field 
, total myotubes area (MA), calculated by  counting the total area of myotubes in a field over 
the entire image(Ren et al., 2008; Ricotti et al., 2011). Aspect ratio (AR) which was calculated 
by dividing the length of myotubes to their width (Grubišić, et al., 2014). Ten microscopic fields 
were scanned for each parameter. Images were obtained using a Leica DMI 6000B imaging 
system and a FITC-fluorescence L5 filter cube. 
 
2.9. RNA EXTRACTION 
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Highly purified RNA is required for real-time Reverse Transcription Polymerase Chain 
Reaction (real time RT-PCR). RNA was isolated from cells using Guanidiniumthiocyanate-
phenol-chloroform extraction, with Trizol® reagent (Invitrogen, Life Technologies, Paisley, 
UK). Trizol® contains phenol and Guanidiniumthiocyanate, which have cell lysing and protein 
denaturing actions, therefore it prevents the activity of RNAse and DNAse enzymes. Following 
appropriate treatment, 330μl of Trizol® was added to each well of a 6-well plate and 500 µl for 
each 1x106 lymphocytes. Then the cells were left for 5 minutes at RT and stored at -20C° until 
further processing. Cell monolayers were collected by scraper to disturb the cells, while the 
lymphocyte suspension was homogenised by repeated pipetting prior to storage.  For RNA 
isolation, chloroform and Trizol® in a  1:5 ratio were added to the lysate, the solution was mixed, 
then incubated for 10min at RT and centrifuged for 16min at 12,000xg. Chloroform, along with 
the phenol contained in the Trizol® reagent, causes the proteins to denature and precipitate and 
separates the RNA into an aqueous supernatant. Following addition of chloroform and 
centrifugation, separation of the solution into three phases is visible (aqueous phase, interphase 
and organic phase), as shown in Figure 2.6. The majority of the RNA is present in the aqueous 
phase, while DNA and proteins are in the interphase and organic phases respectively. After 
separation of the solution into three phases, the aqueous phase was transferred to a new tube and 
an equal volume of ice-cold isopropanol was added. Isopropanol precipitates and recovers the 
RNA from the aqueous phase, which becomes visible as a pellet after 10min of centrifugation 
at 12,000xg. The RNA pellet was washed with 75% EtOH, centrifuged at 8,000xg for 10min 
and air dried. Tris-EDTA (TE) buffer (Applied Biosystems, Ambion, Cheshire, UK) was added 
to reconstitute the RNA. 
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Figure 2.6: Phases separation using Trizol®reagent.The formation of three phases after 
chloroform addition to the Trizol® lysate and centrifugation. RNA is isolated from the aqueous phase. 
Adapted from www.openwetware.org 
After reconstitution in TE buffer, RNA concentration and purity were assessed by UV 
spectroscopy, using a Biotech Photometer (NanoDrop, Wilmington, DE, USA). The absorbance 
of the diluted RNA sample was measured at 260 and 280 nm. A ratio of 260/280 is indication 
for high purity of RNA.  It is known that A260 reading of 1.0 is equivalent of 40µg/ml of RNA.  
A RNA samples of high purity  were stored at −80 °C for the use of real-time PCR.  
 
 
 
 
2.10. REAL-TIME PCR 
 
PRINCIPLE 
 
  Gene expression can be altered in response to various conditions or different stages of cell 
development and is a key step in how many cellular processes, including differentiation, are 
accomplished. Real-time PCR (RT-PCR) is a commonly used method for investigating gene 
expression. It quantifies the amount of mRNA molecules produced by a specific gene after it 
has been transcribed. The method depends on reverse transcription of the previously isolated 
mRNA (section 2.9) into complementary DNA (cDNA) and amplifying the cDNA to be detected 
and measured as the reaction progresses (hence, the method is named real-time PCR). The 
detection of amplified product is performed by labelling the DNA with molecules emitting 
fluorescence, which is proportionally increased with the amplification of the cDNA molecules 
with each cycle of the reaction. Two commonly used fluorescent tags in real-time PCR are 
SYBR® Green dye and TaqMan® probes. SYBR® Green dye is the cheaper alternative - it 
binds to all double-stranded DNA and is able to detect non-specifically all amplified double-
stranded DNA molecules. In contrast, TaqMan® probes are more expensive, but can be 
synthesised for each unique target sequence and therefore emit fluorescence only when the 
specific PCR product is amplified. Comparison of both chemistries is presented in Figure 2.7. 
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Figure 2.7: Comparison of PCR products in real-time PCR between SYBR® Green and 
TaqMan®.TaqMan® detection is more specific, as it uses a specially designed probe for each target 
sequence, which emits fluorescence only when the target sequence has been replicated. SYBR® Green 
dye is less specific, as it binds to any double stranded DNA present in the reaction. 
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The increase in fluorescence with each cycle is detected. This enables estimation of the rate of 
amplification and the abundance of the cDNA molecules generated. The higher the gene 
expression, i.e. the starting concentration of cDNA, the fewer number of amplification cycles it 
will take for the levels of fluorescence to obtain a certain threshold (represented as the Ct value). 
Thus, the Ct value is inversely proportional to the gene expression level (i.e. the higher the Ct 
level the lower the amount of target nucleic acid in the sample). Comparison of Ct values 
between different samples is therefore indicative of how gene expression between these samples 
differs. Representation of an example of 3 samples with different gene expression levels and 
how this is represented by their Ct values is shown in Figure 2.8. 
 
 
 
Figure 2.8: Ct value of real time PCR. Real-time PCR analysis demonstrates the number of cycles 
required for 3 different samples to reach a specific fluorescence threshold (represented by their Ct value). 
The lower the Ct value or the number of cycles required to reach the fluorescence threshold, the higher 
the expression of the gene. Thus, the sample represented by the green curve is the one with highest gene 
expression (Ct=21.75), followed by the blue one (Ct=26.5) and the red sample is the one with the lowest 
gene expression (Ct=27.1). Adapted from www.appliedbiosystems.com. 
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TAQMAN® METHOD 
For TaqMan® detection, TaqMan® RNA-to-CT™ 1-Step Kit was used (Applied Biosystems, 
San Jose, CA, USA). The kit contains both AmpliTaq Gold® DNA polymerase, required for 
DNA amplification and ArrayScript™ UP reverse transcriptase, the enzyme required for the 
reverse transcription of mRNA into cDNA. The final volume per reaction was 20µl, composed 
of 8.5µl of RNA (50ng/µl for C2C12 and 80ng/ µl for lymphocytes), 10µl master mix containing 
the DNA polymerase enzyme, 1µl of primer mix and 0.5µl RT enzyme. Applied 
BiosystemsStepOnePlus real-time PCR system with StepOne Software v2.2.2 (Applied 
Biosystems, Life Technologies) was used. The following program cycles were used: 
 
Stage Step Temperature Time 
Holding Reverse Transcription 48ºC 15 min 
Holding Activation of TAQ 
polymerase 
95ºC 10 min 
Cycling 
(40 cycles) 
Denaturation 95ºC 15 sec 
Annealing/Extension 60ºC 1min 
 
 
The following primer sets for C2C12 were ordered from Applied Biosystems and were used 
with the TaqMan® detection method: GAPDH (mm99999915_m1), MyoD 
(mm00440387_m1), Myogenin(mm00446194_m1) and for lymphocytes 
GAPDH(Hs00950669-m1),Amphiregulin(hs00950669-m1) and GDF11 (Hs00195156-m1). 
 
ANALYSIS 
 
Relative quantification of gene expression was determined automatically by Opticon Monitor 
version 3.1.32 (MJ Geneworks Inc., Bio-Rad Laboratories, Inc., Hercules, CA, USA) and 
StepOne Software v2.2 (Applied Biosystems, Life Technologies). The relative quantification is 
based on analysing changes in gene expression relative to a reference sample (control). One 
sample from the experiments was set as a calibrator/control and fold change with respect to this 
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calibrator was determined for all samples of the experiment. All samples were normalised to a 
housekeeping gene (GAPDH), which expression is known to remain consistent in C2C12 cells 
and lymphocytes, regardless of the treatment and activation respectively. 
 
 
 
2.11. PROTEIN EXTRACTION AND ESTIMATION OF PROTEIN CONCENTRATION 
 
PROTEIN EXTRACTION FROM C2C12 MONOLAYERS  
 
Following appropriate treatments, samples for protein assay were prepared by adding 200µl of 
ice-cold cell signalling lysis buffer (Merck, MA, USA) per well (for 12-well plates). Following 
removal of cells from the substrata using a scraper, lysed cells were collected and centrifuged 
for 2min at 8,000xg at 4°C to form a pellet and discard insoluble debris; samples were stored at 
-20°C for protein estimation 
 
EXTRACTION AND ESTIMATION OF PROTEIN CONCENTRATION 
 
PROTEIN EXTRACTION FROM C2C12 MONOLAYER  
 
 Following  appropriate treatments,  samples for protein assay were prepared by adding 200µL 
of ice cold  cell signalling lysis buffer(Merck MA, USA) per well (for 12well plate).   Following 
removal of cells from the substrata, using a scraper, lysed cells were collected and centrifuged 
for 2min at 8,000xg at 4°C to pellet and discard insoluble debris; samples were stored at -20ºC 
for protein estimation. 
 
ESTIMATION OF PROTEIN CONCENTRATION 
 
PRINCIPLE OF Pierce™ BCA PROTEIN ASSAY 
 
The bicinchoninic acid protein (BCA) assay depends on BCA is sensitive reagent for total 
protein determination. The principle of this protein assay depends on formation of a Cu1+protein 
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complex. BCA in this method acts as a detector reagent for Cu1+ which is formed when CU2+ is 
reduced by protein in an alkaline environment. The purple-coloured reaction product is formed 
by the chelation of two molecules of BCA with one cuprous ion (Cu1+). Thus, the amount of 
Cu2+ reduction is proportional to the amount of BCA-Cu+ complex colour. The macromolecular 
structure of the protein, the number of peptide bonds and the presence of four particular amino 
acids (Cysteine, Cystine, Tryptophan and Tyrosine) are reported to be responsible for colour 
formation with BCA. The reaction is summarised in the following equations: 
 
  
1.     Protein (peptide bonds) + Cu2+ → tetradentate-Cu+   
       complex 
2.    Cu+complex + Bicinchoninic Acid (BCA) → BCA-Cu+   
      complex     
    (Purple coloured) 
          ↓  
Read  absorbance at 540nm-
590nm 
   
 
 
METHOD 
 
For the protein determination, BSA protein standards were prepared in lysis buffer (at 
concentrations of 2000, 1500, 1000, 750, 500, 250, 125 and 25.0μg/ml as illustrated in the table 
below.  
For the protein determination, BSA protein standards were prepared in lysis buffer (at 
concentrations of 2000, 1500, 1000, 750, 500, 250, 125, 25,0μg/ml. As illustrated in table below 
 
 
 
 
Table 2.1: Serial dilution standards for BCA protein assay. 
 
 60 
Vial Volume of lysis 
buffer(µl) 
 
Volume and Adapted 
of BSA 
Final BSA 
concentration 
(µg/ml) 
A 0 300 from stock 2000 
B 125 375 from stock 1500 
C 325 325 from stock 1000 
D 175 175 of vial B dilution 750 
E 325 325f of vial C dilution 500 
F 325 325 of vial E  dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G dilution 25 
I 400 0 0 
 
 
  The protein assay was performed using BCA Protein Assay purchased from Pierce (Rockford, 
IL, USA). BCA reagents A & B were mixed in a ratio of 1:50.  The volume of 200µl of the 
mixed solution was added in a 96 well plate with 10µl of the protein samples or standards. The 
96-well plate was incubated at 37⁰C and absorbance was read at 562nm using a Bio-Tek ELISA 
plate reader (Winooski, VT, USA). Standard curves were generated automatically by plotting 
the average blank-corrected 630nM measurement of the loaded BSA standards against pre-
programmed known concentrations in mg.ml-1 and sample concentrations were calculated from 
the standard curve.  The average 562 nm absorbance measurement of the blank standard 
replicates was subtracted from the 562nm absorbance reading of all individual standard and 
unknown sample replicates. 
 
 
 
2.12. MULTIPLEX IMMUNOASSAY 
 
Multiplex bead immunoassay was performed to quantify cytokines existing in harvested young 
and old secretomes obtained from lymphocytes (Th1/Th2) and IGF-1. In addition, this technique 
was applied to quantify the potential candidates of activated proteins in cell extracts of C2C12 
following treatment with CM. The results were read using the Luminex 200 system (Bio-Plex) 
running the xPONENT analytical software. 
 
PRINCIPLE 
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In multiplex bead immune assays, beads (microspheres) are internally labelled with two 
fluorescent dyes, one labelling the capture antibody and the second labelling the detection 
antibody. A biotinylated detection antibody is introduced after the beads capture an analyte from 
the sample. Thus, the ratio of signals emitted by the two-labelled antibodies reveals the analyte 
concentration. The reaction mixture is then incubated with the reporter molecule streptavidin- 
PE conjugate to complete the reaction on the surface of each microsphere.  Following 
incubation, the ratio of the fluorescent signal emitted from each discrete antibody couplet in the 
array is scanned by two lasers. The first laser (green colour) excites the reporter streptavidin-PE 
dye of the assay. The second laser (red colour) is used to excite the dyes inside the beads (Figure 
2.9). The ratio of the fluorescent signal emitted from each discrete antibody couplet in the array 
is measured and identified using high-speed digital signal processors. 
 
 
 
 
Figure 2.9: The schematic representation of multiplex immune assay steps. Adapted from 
(http://www.bio-rad.com/en-ae/applications-technologies/bio-plex-multiplex-immunoassays). 
 
 
2.12.1 MEK-1/ERK1/2 AND AKT/MTOR SIGNALLING MGNETIC BEADS ASSAY 
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METHOD 
Proteins of treated cells were extracted and estimated as described in 2.10. Samples were diluted 
according to the manufacturer’s protocol to attain the final concentration of 10µg/well.  A 
volume of 25 µl of beads suspension was added to each well. Twenty-five µl of assay buffer 
was added to blank wells and 25ul of lysates to the controls and samples well. The controls of 
MAPK/SPAK and Akt/mTOR are shown in the table below. The plates were incubated for 18 
hours on shakers at 800rpm at 4°C. Lysates were removed by a vacuum manifold (EMD 
Millipore, USA) and incubated with a Biotin-labelled detection antibody in the dark at RT. 
Following removal of the detection antibody, 25ul of Streptavidin-Phycoerythrin (SAPE) was 
added to each well and incubated for 15 min. with shaking at RT with the dark. SAPE was 
removed and 25ul of amplification buffer was added and incubated for 15 min. on a shaker at 
4°C. Amplification buffer was  aspirated from all the wells which were then loaded with 150ul 
of assay buffer prior to reading the plates on a Luminex 200 TM.  
2.12.2. TH1/TH2 MULTIPLEX IMMUNOASSAY 
 
The human cytokines Affymetrix magnetic dead assay (AffymetrixeBioscience, USA) was 
performed according to manufacturer’s instructions. Briefly, an aliquot of the supernatant 
collected from lymphocyte cultures (described above) was thawed. Fifty µl of each sample and 
50 µl of standards and controls were added to the wells. The plate was incubated overnight on a 
shaker at 4°C. Following washing twice with wash buffer, 25 µl of detection antibody was added 
to each well and incubated at RT in the dark for 30 min. Following washing, 50 µl of 
Streptavidin-PE was added to each well. The plate was sealed and kept at RT in the dark for 30 
min. The samples were aspirated and beads re-suspended in 120 µl of reading buffer for 5 min. 
The plate was read using a Luminex  200TM. 
 
2.12.3. HUMAN IGF-1 IMMUNOASSAY 
 
The assay was performed according to the manufacturer’s protocol using a human magnetic 
bead panel (EMD Millipore, MA, USA). The plate was washed with assay buffer then 25 µl of 
standards and controls were added to the appropriate wells and 25 µl of sample was added to 
each well. A volume of 25 µl of bead suspension was added to all wells which were then 
incubated overnight on a plate shaker (500-700rpm) at 4°C. The wells were then washed three 
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times with wash buffer. A volume of 50 µl of detection antibody was added to each well and the 
plate was incubated for 1 hour at RT. Streptavidin-Phycoerythrin was added to each well and 
incubated for 30 min at RT. All wells were washed three times and 100μl of sheath fluid were 
added prior to reading on a Luminex 200 TM plate reader. 
 
 
2.13. MEASURMENT OF AMPHIREGULIN USING ENZYME-LINKED 
IMMUNOSORBENT ASSAY (ELISA) 
 
 
Amphiregulin human enzyme-linked immunosorbent assay (ELISA) of 96-well plate (Abcam, 
UK) was applied for the quantitative measurement of Amphiregulin in young and old 
secretomes. Briefly, standards were prepared according to Table 2.2.  A volume of 100 µl of 
samples and standards were added to their appropriate wells and incubated overnight with gentle 
shaking at 4°C. Following incubation, the plate was washed with 1X wash solution and 100 µl 
of 1X biotinylated Amphiregulin detection antibody was added to all wells. The plate was 
incubated for 1 hour at RT with gentle shaking. The plate was re-washed four times with 1X 
wash solution and 100ul of 1X HRP-Streptavidin solution was added to all wells. The plate was 
sealed and incubated for 45 minutes at RT with gentle shaking. The solution was discarded from 
all wells and washed four times with 1X wash solution. A volume of 100ul of TMB one-step 
substrate reagent was added to each well. The plate was sealed and kept at RT for 30 minutes in 
the dark with gentle shaking. The plate was read at 450nm by a Bio-Tek ELISA plate reader 
(Winooski, VT, USA) immediately after adding 50µl of stop solution to each well. The protocol 
is summarised below in Figure 2.10.    
 
 
 
 
 
 
 
 
 
 
 
Table 2.2:  Standard dilution preparation. 
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Figure 2.10: Assay summary of Amphiregulin human ELISA. Adapted from www.abcam.com. 
 
 
 
 
 
 
 
 
 
 
2.14 PROTEOMICS STUDY  
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Harvested secretomes obtained from young and old participants were transferred into clean 
polypropylene tubes. Secretome samples   were kept at -80°C and sent to Liverpool John Moores 
University for proteomics analysis.  Prior to start the procedure, the protein concentrations were 
measured and albumin was depleted by centrifugation according to manufacturer’s protocol.  
Briefly, Albumin Depletion Resinwas placed in a collection tube and centrifuged at 12000xg for 
1 minute to remove access liquid. A volume of 200µl of binding /wash buffer was added to the 
spin column prior to centrifugation at 12000xg for 1 minute. Following removal of   access fluid 
was discarded; a spin column was placed into a new collection tube. Twenty -five µl of albumin 
containing sample was added to resin and incubated for 2 min at RT to ensure maximal albumin 
binding. Samples were centrifuged at 12000xg for 1 min and spin column was transferred to a 
new collection tube. Resin was washed three times by 50µl of Binding buffer and centrifuged at 
12000xg for 1 minute. For mass spectrometry analysis, aliquots of 50µg of protein (Albumin- 
depleted) were precipitated in 5 volumes of acetone for 1 h at −20 °C. Pellets were re-suspended  
in 0.1% (w/v) Rapigest SF (Waters; Milford, MA, USA) in 50 mM ammonium bicarbonate and 
incubated at 80°C for 15 min DTT was added to a final concentration of 1 mM and incubated at 
60°C for 15 min  followed by incubation  in  dark at 4°C in the presence of 5mM  of 
iodoacetamide. A protein was digested overnight at 37°C by adding sequencing grade trypsin 
(Promega; Madison, WI, USA) at ratio of 1:50.  The reaction was ended by the addition of 2µl 
concentrated TFA and centrifuged at 13000xg for 5 min.  Label-free liquid chromatography-
mass spectrometry (LC-MS) analysis was performed using a quadrupole-high capacity ion-trap 
(HCT Ultra ETD II; Bruker Daltonics, Bremen, Germany) coupled online via an electrospray 
ionisation source to a nano-flow HPLC system (Ultimate 3000; Dionex, Sunnyvale, CA, USA). 
Tryptic digests (0.8 µg/µl) were diluted with aqueous 0.1% formic acid (FA) at ratio 1:10  and 
5 µl loaded via a Zorbax 300SB C18 5µm, 5 × 300 µm pre-column (Agilent Technologies Ltd.). 
Peptides separation was performed using a Zorbax 300SB C18 3.5 µm, 15 cm × 75 µm analytical 
reverse phase column (Agilent Technologies Ltd.) at a flow rate of 300 nL min−1 using a non-
linear gradient rising to 40% acetonitrile 0.1% FA over 160 min.. Mass spectra for LC-MS 
profiling were recorded between 200 m/z and 2,500 m/z using Standard Enhanced mode [8,100 
(m/z)/s]. From triplicate analysis of a pooled standard including each HCR and LCR sample, 
equivalent data-dependent tandem mass spectrometry (MS/MS) spectra were collected. 
MS/MS spectra of collision-induced dissociation fragment ions were recorded for the 5 most 
abundant precursors from each survey scan (350 m/z to 1,600 m/z). MS/MS spectra were 
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exported in Mascot generic format and searched against the Swiss-Prot database (2011.6) 
restricted to “Rattus” (7617 sequences) using a locally implemented Mascot server (version 
2.2.03). The enzyme specificity was trypsin allowing one  missed cleavage, carbamidomethyl 
modification of cysteine (fixed), deamidation of asparagine and glutamine (variable), oxidation 
of methionine (variable) and an m/z error of ± 0.5 Da.    
 
 
 
2.15. STATISTICAL ANALYSIS 
Statistical analyses and significance of data were determined using GraphPad Prism version 5.00 
(GraphPad Software, San Diego, California USA, www.graphpad.com). Statistical significance 
for the difference between more than two groups was determined using One way ANOVA and  
Bonferroni multiple comparisons test. Statistical significance was set at P< 0.05. All 
experiments were performed at least 3 times in triplicate. 
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CHAPTER 3 
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3. OPTIMISATION OF LYMPHOCYTE CULTURE: HARVESTING OF 
CONDITIONED MEDIA TO IMPROVE C2C12 PROLIFERATION 
 
3.1 INTRODUCTION 
Immune cells are required for skeletal muscle repair and regeneration (Tidball and Villalta, 
2010). Following injury, immune cells infiltrate to damaged areas and release numerous 
cytokines, chemoattractants/interleukins and growth factors. The infiltrating immune cells and 
their secretome function to clear the injury site to provide a clean environment for muscle 
regeneration (Aurora and Olson, 2014). Thus, alterations in the systemic microenvironment, 
constituting immune cells and their secretome, directly affect satellite cells and myogenesis. For 
instance, recent evidence suggested that the high levels of fibroblast growth factor (FGF) in the 
aged muscle tissue niche impair asymmetric self-renewal and myogenic differentiation of aged 
mouse satellite cells (Bernet et al., 2014). Interlukin-6 (IL-6) released by neutrophils and 
lymphocytes, as well as from myofibres in response to exercise, contributes to satellite cell 
activation and myofibre regeneration, but high levels of IL-6 have been linked to an age- related 
muscle wasting (Haddad et al., 2005).T-lymphocytes are the main contributing factor to the local 
milieu of satellite cells in injured/damaged muscle. In rodent models, following muscle injury, 
infiltrating T cells remain elevated for 10 days post-injury (Bondesen et al., 2006; Cheng et al., 
2008).It is well established that the concentration of T lymphocytes increases in blood after 
exercise (Pedersen and Toft, 2000; Grounds, 1998), however, very little is known about the 
specific function in skeletal muscle satellite cell proliferation and differentiation. Stimulated 
lymphocytes release numerous growth factors and cytokines (this includes, but is not limited to, 
transforming growth factor-β (TGF-β), IL-10, IL-7 and IL-4), which may be involved in the 
early inflammatory stages that trigger muscle regeneration (Cannon and St Pierre, 1998; Tidball, 
1995). A study conducted on the csid/mdx model (mdx: dystrophic mouse, scid: immune 
deficient mouse) to examine the cross talk between T lymphocytes and skeletal muscle found 
that these mice exhibited reduced fibrosis and degeneration ( Farini et al., 2007). Therefore, it is 
crucial to develop and optimise an in vitro system to activateC2C12, as occurs in vivo during 
regeneration, in the presence of the immune-influenced environment. Hence further studies need 
to be conducted to ascertain the optimal activation time of lymphocytes and preparation of 
optimal conditioned media from harvested secretomes. In this chapter the optimisation 
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conditions were applied to young lymphocytes only. Some results of this chapter have been 
published in one journal paper (Al-shanti et al.,2014) 
 
3.2. AIMS, HYPOTHESIS AND OBJECTIVES 
The aim of the word presented in this chapter was to optimise human lymphocytes culture 
by isolating and activating them in vitro and collecting the secreted proteins/cytokines 
(secretome).  The secretome was used to prepare conditioned media for skeletal muscle cell 
cultures and the effects on proliferation and differentiation recorded. This was an important 
step needed to address the overall hypothesis that activated lymphocytes contain cytokine and 
growth factors able to induce muscle cell proliferation and differentiation. Therefore, the 
objectives were, firstly, to optimise the lymphocytes cell culture (to determine optimal 
activation time, anti-CD3 concentration, anti-C28 concentration and secretome volume). 
Secondly, to use the lymphocyte secretome to enrich the cell-culture medium of C2C12 (p5) 
cells and to examine the effects on C2C12 proliferation and differentiation. Methods are outlined 
in figure 3.1.  
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Figure 3.1: Optimisation of lymphocytes culture and conditioned media. 
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3.3 METHODS 
3.3.1. ISOLATION OF HUMAN LYMPHOCYTES FROM VENOUS BLOOD 
Ethical approval for the study was granted at Manchester Metropolitan University. Fresh venous 
human blood was collected from healthy volunteers (n=20, 3 female and 17 male, aged 18-25 
years old) after their informed written consent. Lymphocytes were isolated by Ficoll–
PaquePLUS and incubated in supplemented RPMI-1640 (as described in 2.2.3)in the presence 
or absence of anti-CD28  at 37°C, 5% CO2 for 2, 4 and 6 days. The harvested secretomes were 
kept at -80ᵒCfor multiplex analysis to quantify cytokine concentration at different activation 
culture times.   
3.3.2. ADHERENT CULTURE TO DEPLETE MONOCYTES (MACROPHAGES) 
In order to purify isolated lymphocytes from fresh blood samples (as described in 3.3.1.), cells  
were suspended in supplemented  RPMI-1640 and pre-plated in a tissue culture dish for 15 
minutes at 37°C, 5% CO2. This procedure eliminates adherent cells (monocytes)(Karanfilov et 
al., 1999). The non-adherent cells were then removed, and prepared for CD14 marker 
measurement as described in 2.6.2.  
3.3.3 OPTIMISATION OF ANTI-CD3 CONCENTRATION 
To achieve the optimal anti-CD3 concentration for lymphocyte activation, lymphocytes were 
cultured in pre-coated 96- well plates with four different concentrations of anti-CD3 (0.12, 0.25, 
0.5 and 1µg/ml). These lymphocytes were counted using a haemocytometer (as described in 
2.3.6) to determine the best proliferation rate of lymphocytes after anti-CD3 activation.The 
negative control was non-activated lymphocytes. 
3.3.4. OPTIMISATION OF ANTI-CD28 CONCENTRATION 
A co-stimulatory signal to activate the CD28 receptor is essential to induce the T-cell receptor 
(TCR) and stimulate the IL-2 and IL-2 receptors, leading to full activation of lymphocytes. To 
achieve the optimal anti-CD28 concentration for lymphocyte activation, anti -CD28 was added 
at different concentrations to the cell suspension (2.5, 5 and 7.5 µg/ml) prior to culturing in pre-
coated anti-CD3 plates. Following 4 days of incubation, lymphocytes were counted using a 
haemocytometer to determine the best proliferation rate of lymphocytes upon anti-CD3/CD28 
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activation. Non-activated lymphocytes (cultured in the absence of ant-CD3/anti-CD28) were set 
as controls for this experiment. The secretomes of anti-CD3/CD28 -activated young 
lymphocytes and non-activated were kept at -80ᵒC for ELISA multiplex analysis.  
3.3.5. MEASUREMENT OFCD25 (IL-2Á R) MARKER 
CD25 (IL2R α) is a ligand-binding alpha subunit of interleukin- 2 receptor alpha (IL-2Rα). It is 
a marker for lymphocytes activation.  The expression of CD25 of anti-CD3/CD28-activated 
young lymphocytes at 0, 2, 4 and 6 days of incubation were measured as described in 2.6.1. 
3.3.6. HARVESTING LYMPHOCYTE SECRETOME 
 
The secretome includes all of the proteins secreted from the activated/cultured lymphocyte cells. 
The lymphocytes secrete the proteins into the surrounding culture media and the media is 
processed so that the protein concentrate can be harvested from the supernatant of the culture 
media. The secretome contains numerous enzymes, growth factors, cytokines and interleukins 
or other immune soluble mediators. Most cytokines secreted from lymphocytes are of low 
molecular weight, ranging between 8-25 kDa (Paul and Seder, 1994). In this protocol, the 
secreted cytokines from lymphocytes following activation with anti-CD3/CD28 were purified 
by using an Amicon®Ultra-4 centrifugal filter device (Millipore, Watford, UK). This device is 
used to filter and purify proteins found in tissue culture, which weigh more than 3kDa. Following 
2, 4 and 6 days of lymphocyte culture (experiment to establish the optimal culture period for the 
lymphocytes), the supernatant (secretome) was collected and filtered, as the manufacture 
recommended. Then, 4 ml of lymphocytes secretome from each experimental culture time was 
centrifuged in an Ultracel -3 Membrane tube for 30 minutes at 5400xg to be applied later in 
conditioned media preparations.  
3.3.7. DETERMINATION OFTHE QUANTITY OF CYTOKINE SECRETION IN DAY 
2 AND 4 ACTIVATED LYMPHOCYTES 
 
Harvested secretomes from day 2 -and 4- activated and non-activated lymphocytes were 
analysed using Multiplex ELISA-based analysis. Eight cytokines EGF, IFNα-2, IFN-γ,IL-1, IL-
3, IL-6, IP-10 and TNF-β were measured by multiplex in a single plate of  96 -wells  as described 
in 2.12.2 
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3.3.8. CONDITIONED MEDIA (CM) PREPARATION AND VOLUME 
OPTIMIZATION 
 
Conditioned media was prepared by sterile filtration of the media in which the lymphocytes 
were cultured. The harvested secretome from activated and non-activated lymphocytes was 
added to the usual C2C12 culture media at the concentrate of the secretome was mixed with 3.8 
ml of DM to obtain conditioned media. Three volumes of concentrated secretome obtained from 
activated lymphocytes were mixed with3.8 ml DM: 50, 100 and 200μl to make up the optimal 
conditioned media.  Four conditioned media were set up. CM1 young contained the secretome 
obtained from activated anti-CD3/CD8-lymphocytes (positive control treatment).CM2 young 
contained the secretome obtained from non -activated lymphocytes (negative control). CM3 
boiled young contained boiled secretome obtained from young lymphocytes. CM4 contained 
the RPMI-1640 and IL-2 without lymphocytes (negative control). This control was included to 
determine the effect of 10% human serum). 
3.3.9. C2C12 CULTURESAND TREATMENT WITH CONDITIONED MEDIA 
 
C2C12, murine skeletal myoblasts were  maintained by growing cells at a  density of 2x106 cell 
/ flask in 0.2% pre-gelatinised  T75 flasks in a humidified 5 % CO2 at 37°C. The cells were 
grown in GM. In order to examine the effect of designed CMs on C2C12 regeneration,C2C12 
cells were cultured in pre –gelatinised 6-well plate at concentration of 50x103 cells/ ml of 
completed growth media (GM). Cells were incubated overnight in a humidified atmosphere CO2 
at 37⁰C. After 24 hours, cells were washed twice with PBS prior to replacing GM with 
conditioned media (CM1, CM2, CM3, and CM4) and DM. 
Morphological studies were performed at 24, 48, 72 and 96 hours of CM incubation using a 
Leica DMI6000B microscope. Cell counts using a haemocytometer and cell-cycle analysis were 
performed at 96 hours 
 
3.3.10. CELL CYCLE 
 
After 96 hours of CM incubation, cells were collected and prepared for cell cycle analysis. 
Sample preparation and the propidium iodide method for FACS are described in 2.6.4.  
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3.11. STATISTICAL ANALYSES 
 
Results were analysed using GraphPad Prism version 6 software. Statistical analysis between 
more than two mean of treatment was determined using one- way ANOVA and Bonferroni 
correction for multiple comparisons. Two- way ANOVA followed by Bonferroni post-test 
analysis was used to determine the comparison among groups of treated cell. All results were 
presented as ± standard deviation of the mean (±SD). Results were statistically significant at the 
level of 5% (P<0.05) and indicated on figures *, whereas p<0.01 was marked **, p<0.001 was 
marked *** and p<0.0001 marked as ****. The percentages of Coefficient variation (%CV) 
were determined for repeated independent experiments by dividing standard deviation by the 
mean for each group of treated cells .  
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3.4. RESULTS 
 
3.4.1. ADHERENT CULTURE TO DEPLETE MONOCYTES (MACROPHAGES) 
Monocytes expressing CD14 were measured before and after depletion culture. A small 
percentage of CD14 was found before depletion culture (20±5%).This percentage was reduced 
significantly to (8±3%) following 15 minutes of depletion culture (Figure 21A and B). A minor 
percentage of lymphocytes was found 5±2. No monocytes expressing CD14 were found after 4 
days of incubation (Figure 3.2A and B).  
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Figure 3.2: Lymphocytes depleted of monocytes. A) The comparison between CD14 expression 
before and after depletion culture at 0 time. Data represent the means ±SD (n=6 blood samples). 
Significant decrease was observed in CD14/Monocytes expression following 15 minutes of depletion 
culture (p<0.05). Results were presented as ±SD (n=5) of the mean.  B) Histograms for CD14 receptors. 
Upper panel represents isotype control; middle panel represents lymphocytes before (left) and after 
(right) depletion at 0 time. Bottom panel; activated lymphocytes after depletion (left) and non- activated 
lymphocytes (right). C) A contrast image representing the adherent monocytes following 15 minutes 
incubation of isolation lymphocyte suspension from blood. Image obtained at 10x magnification. Scale 
Bar=50µm 
 
 
3.4.2. OPTIMISATION OF ANTI-CD3 CONCENTRATION 
In this study, four concentrations of anti-CD3 were prepared to identify the optimal activation 
of lymphocytes. The best activation was achieved at a concentration of0.5 µg/ml. This finding 
was confirmed by cell counting and morphological assessments. The proliferation rate of 
activated lymphocytes at 0.5µg/ml was 2-to-3 fold higher than the base line. Lymphocyte counts 
increased from 1x106 to 3.5±0.6 x106 cells /ml. The concentration of 0.12µg/ml and 0.25µg/ml 
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of anti-CD3 resulted in lower cell counts compared with 0.5ug /ml. Cell counts for 0.12 and 
0.25µg/ml were 0.9± 0.1x106 and 2.12±0.4 x106cells/ml respectively (Figure 3.3A). The highest 
concentration of 1 µg/ml showed cytotoxic effects on lymphocytes and inhibited their 
proliferation. Cells counts decreased from 0time to 96 hours dramatically (1x106 to 0.7±0.2 x105 
cells/ml) (Figure 3.3A). Phase contrast images were taken as shown in Figure 3.3B.  
A 
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Figure 3.3: Optimisation of anti-CD3 concentration. A) Cell count of lymphocytes after 4 days 
of activation). The proliferation rate of activated lymphocytes at 0.5µg/ml was the highest compared to 
the anti-CD3-activated lymphocytes at 0.12 and 0.25 µg/ml. The results represent mean of ±SD (n=5). 
B) Phase contrast images of lymphocytes at different concentrations of anti-CD3 after 4 days of 
incubation. Images obtained at 10x Magnification. The largest lymphocyte colonies were found after 
incubation with 0.5 µg/ml anti-CD3. Variations in the background brightness resulted from taking images 
from different sites of the well plate. 
 
3.4.3. OPTIMIZATION OF LYMPHOCYTE INCUBATION TIME 
Activated and non-activated lymphocytes were cultured for 2, 4 and 6 days to determine the 
optimal activation time. Lymphocytes cultured for 4 days exhibited higher cell counts and 
formed bigger colony-forming units than cells cultured for 2 and 6 days (2.7±0.11 x 106 cell/ml 
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vs 1.58±0.10 x 106 cell/ml and 1.6±0.15 x 106cell/ml respectively, p<0.0001).  Activated cells 
at day 2 were not significantly higher compared to non- activated cells (1.58±0.10 cells/ml x 106 
vs 1.24±0.09x 106 cells/ml, p>0.05)(Figure 3.4 A, day 4, left panel).The counts of activated cells 
at day 4 and day 6 were significantly different compared to their non- activated cells (2.7±0.11 
x 106cells/ml and 1.6±0.15x 106cells/ml vs 1.1±0.12 x 106 and 0.5±0.08 x106 cells/ml;p>0.0001, 
respectively)(Figure 3.5) 
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            Anti-CD3 activated lymphocytes            Non-activated lymphocytes        
 
Figure 3.4: Optimisation of culture time for Anti-CD3 activated vs non-activated lymphocytes 
at days 2, 4 and 6.  Activated cells formed colony units (left panel) whereas non-activated did not 
(right panel).  At day 4, the number and size of colony forming of activated lymphocytes was higher 
compared to those in days 2 and 6 (upper and lower images, left panel).  Homogeneity of immune cells 
at day 2, 4 and 6  varies.  At day 4 (left panel) the dominant population of immune cells was characterised 
by having a circular shape (see arrow), whereas immune cells at days 2 and 6 were heterogeneous in size 
and shape (see arrow). Non-activated immune cells density in day 6 was lower compared with day 2 and 
4 non-activated cells (right panel).  Lymphocytes images were obtained at 10 x 1.6 Mag. Scale bar: 
100µm. 
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Figure 3.5:  Cell count of anti-CD3 activated vs non-activated lymphocytes at days 2, 4 and 6. 
Activated cells at day 4 had the highest proliferative rate compared to days 2 and 6, p>0.0001.The number 
of lymphocytes decreased at day 6. Data represent means ±SD (n=10) undertaken in duplicates. 
 
3.4.4. OPTIMISATION OF ANTI-CD28 CONCENTRATION 
Lymphocytes were activated with 0.5ug/ml of anti-CD3 and a range of anti-CD28 
concentrations (2.5, 5, and 7 µg/ml). Following 4 days of activation, the proliferation rate was 
assessed to determine the optimal concentration for anti-CD28 with anti-CD3 by cell counting. 
The findings show that the cell count of activated lymphocytes atanti-CD3/anti-CD28;5µg/ml) 
was significantly higher (5x106µg/ml) than anti-CD3/CD28;2.5µg/ml); 
(3.5x106cells/ml;p>0.05),anti-CD3/CD28(7µg/ml)(2.5x106cells/ml; p>0.001) and the cell count 
for negative control (CD3+/-CD28)(3.12x106cells/ml; p>0.001)(Figure 3.6). 
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Figure 3.6: Optimisation of anti- CD28 concentrations for activated young lymphocytes 
following 4 days’ incubation. Lymphocytes were activated at different concentrations of anti-CD28 
and cultured in (0.5µg/ml) anti-CD3 pre-coated wells for 4 days. The data represent means ±SD (n=4) in 
triplicate. % CV for non –activated; 15%, CD3 0.12µg/ml; 7%, CD3/0.25µg/ml16%, CD3/0.5µg/ml;10% 
and CD3/1µg/ml; 35%.  
 
3.4.5. OPTIMAL VOLUME OF SECRETOME TO MAKE CONDITIONED MEDIA 
(CM1) 
 
C2C12 cells were cultivated in three conditioned media of anti-CD3- activated cells (CM1) for 
96 hours. In order to identify the optimal concentration of secretome to add to the C2C12 DM, 
three volumes of secretome (50µl, 100µl and 200µl) were mixed with 4ml DM to make the 
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conditioned media. C2C12 cells grown in conditioned media including 50µl secretome exhibited 
differentiation and  myotube formation (Figure 3.7A), whereasC2C12 cells grown in 
conditioned media composed of 100 µl of secretome and DM exhibited proliferation (no 
myotube formation)(Figure 3.7 B).  C2C12 cultivated in conditioned media with 200 µl of 
secretome did not grow in a healthy manner (Figure 3.7 C). 
 
 
 
 
 
 
 
3.4.6. CD25 (IL-2Α R) MARKER ANALYSIS 
 
IL-2Rα analysis was used for lymphocyte detection as a first step to evaluate the effect of 
lymphocytes on skeletal muscle generation. CD25 analysis was conducted on activated and non-
activated lymphocytes after 2, 4 and 6 days incubation. CD25 is an early activation marker for 
T lymphocytes and essential for activation and proliferation of T cells (Chao et al., 2002; Smith 
and Cantrell, 1985).The results showed that CD25 expression on day 4 activated lymphocytes 
Figure 3.7: C2C12 cultivated at 50x1000cell/ml in CM1for 96 hours. Myoblasts treated in 
CM(A) exhibited differentiation and myotube formation, whereas (B) C2C12maintained 
proliferation.  C2C12 grown in (C) did not exhibit healthy growth. The data represent at least 4 
experiments. Scale presents 75µm. 
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was significantly higher compared to day 2 and 6 activated cells (87±8.4 % vs 49.5±2.5%; 
(p<0.05) and 18.7±10%;(p<0.0001)( Figure 3.8  A and B). 
 
A) 
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B) 
 
Figure 3.8: The expression of CD25 lymphocytes at 0, 2, 4 and 6 days of activation. A) At 0 
time resting lymphocytes express only 1.8% anti-CD25 (upper panel). From day 2 of activation (second 
panel) to day 4 of activation (third panel), the expression of the IL-2α receptor on lymphocytes increased 
from (55%) to (85%). At day 6, the expression of CD25 marker decreased significantly to 8% (lower 
panel). B) The graph represents the mean value of CD marker expression on activated and non activated 
lymphocytes at day 2, 4 and 6. The data represent means ±SD (n=5) in triplicates. 
 
 
3.4.7. QUANTITY OF CYTOKINE SECRETION IN DAY 2- AND 4 -ACTIVATED 
LYMPHOCYTES 
In order to gain some insight into the quantity of secreted cytokines from activated/non- 
activated   lymphocytes at day 2 and 4 incubation, eight cytokines in the secretome were 
screened. Briefly, the level of cytokines’ expressed by day 2 was lower than for cytokines in day 
4 -activated lymphocytes. IL-3 was significantly higher expressed by day 4activated 
lymphocytes (469ng/ml) than non-activated; (10.3ng/ml);( p<0.001). Similarly, tumour necrosis 
factor-alpha (TNF-α) and interferon –gamma (IFN-γ) were detected at higher concentrations in 
activated lymphocytes compared with non- activated. TNF-α was detected at a concentration of 
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248ng/ml vs 30ng/ml in activated vs non- activated secretomes. IFN –γ was quantified at 2235 
ng/ml in activated lymphocyte secretomes vs 1533 ng/ml in non-activated secretomes.  
 
 
3.4.8. C2C12 TREATMENT WITH CONDITIONED MEDIA 
C2C12 myoblasts were treated with CM1 or CM2 of lymphocytes following 2, 4 or 6 days of 
C2C12 culture. CM3-4 and DM were set as control treatments in this study. A morphological 
examination of CM1-4 treated myoblasts was at 96 hours.  The CM1 (anti-CD3/CD28 activated 
lymphocytes) treated myoblasts at day 2 exhibited myotube formation and were not significantly 
different to other controls CM2-4 and DM at 72 hours, whereas day 4 CM1- treated myoblasts 
showed accelerated cell proliferation and did not exhibit multinucleated myotube formation at 
the same time point (Figure 3.9).Myoblasts cultivated in day 6 CM1 also showed an extended 
proliferation, but there was also myotube formation and more dead cells were detected. 
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Figure 3.9: C2C12 treated with conditioned media (CMs). Myoblasts cultivated with CM1 (first 
panel), CM2 (second panel), CM3 boiled (third panel) CM4 (forth panel) or DM only for 96 hours. 
Images obtained at 10x1.6 Mag. 
 
3.4.9. CELL CYCLE ANALYSIS 
Cell cycle analysis was measured by flow cytometry, which is a widely used procedure to 
analyse cell proliferation and differentiation through assessing the S phase of dividing cells. This 
analysis was used to assess cell cycle progression of myoblast treated in conditioned media. The 
results showed that % S phase of day2 CM1- treated cells (22%±5) was not significantly 
different compared with CM2-4 (15%±5, 25%±5 and 20%±5, respectively) and S% phase of 
DM was 15%±2 (p>0.05). Similar to the C2C12 myoblast count, %S phase of day 4 CM1- 
treated cells was significantly higher than the various control conditions used in this study. 
Percentages of S phase of CM1 was 60±5% (p<0.001) compared with CM2-4. Percentages of S 
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phase were 15±5, 25±5 and 20±5% respectively, and in DM was 10±5% (Figure 32). Day 6 
CM1 treated myoblasts (28% ±2) showed higher proliferation rates than day 2 CM1, but 
compared to controls, the proliferation rate was not significantly different compared with CM2-
4; %S phase;20%±5,20%±5,25%±5 and DM 10%±5 (p>0.05)(Figure 3.11). 
 
Figure 3.10: % S phase of myoblasts treated with day 4 conditioned media (CM1-4) and 
DM at 96 hours. 
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Figure 3.11: The percentage of S phase of myoblasts treated in conditioned media CM1- 4 
and DM following 2, 4 and 6 days of activation. Data represent means ±SD (n=5) in duplicates. 
. 
 
 
 
 
 
3.5 DISCUSSION 
3.5.1. OPTIMAL ANTI-CD3 CONCENTRATION FOR LYMPHOCYTE  ACTIVATION 
According to the cell count study for cultured lymphocytes, the concentration of 0.5µg/ml anti-
CD3 induced the greatest lymphocyte proliferation (Al-Shanti et al., 2014). Lymphocyte 
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numbers increased from time point 0 to 96 hours from 1x106to5x106cells/ml.  Lymphocyte count 
at anti-CD3 concentrations of 0.25 and 0.12 µg/ml was significantly lower than for 0.5µg/ml 
(p<0.001). Also, at this concentration of 0.5µg/ml lymphocytes grew in colony forming units 
that were larger than the colonies shown at the lower anti-CD3 concentrations (0.25µg/ml and 
0.12 µg/ml)(Holmes, 2008; Zheng et al., 2008)(Figure 3.3 A and B). 
3.5.2. OPTIMIZATION OF ANTI-CD28 CONCENTRATION 
The results clearly showed that 5µg/ml of co-stimulatory anti-CD28 was the optimal 
concentration to obtain the highest proliferation rate of lymphocytes in the presence of 0.5µg/ml 
of anti-CD3.The cell count of activated lymphocytes at concentrations of 2.5µg /ml and7µg/ml 
was significantly lower compared to 5µg/ml. 
Anti-CD3 is  a central signalling pathway for lymphocytes proliferation but addition of anti-
CD28 provides co- stimulation for the expanding cells to release (Li and Kurlander, 2010; 
Schwartz, 1990) through activation of multiple signalling pathways including ERK and  JNK 
and nuclear factor-kappa-B(NF-kappa-B)(Jerome, 2008). These findings were supported in that 
our study found the cell count of anti-CD3 at day 4 was significantly lower (p>0.0001) than anti-
CD3 and anti-CD28 activated lymphocytes at the same period of activation.  
3.5.3. OPTIMAL DURATION FOR LYMPHOCYTE ACTIVATION 
Lymphocytes were activated by anti-CD3 and IL-2 (Tsoukas et al., 1985) at different incubation 
periods for 2, 4 and 6 days at 37°C in a humidified atmosphere.  The optimal duration time for 
anti-CD3/IL-2 activated lymphocytes was found at day 4. This was confirmed by: 1) the size of 
colony forming units of lymphocytes at day 4 was larger than at days 2 and 6; 2), the cell count 
of lymphocytes at day 4 was significantly higher compared with days 2 and 6 (p<0.05)(Curti et 
al., 1996). 3) at day 4, the immune cells proliferated into large homogenous groups characterised 
by round regular shapes and small spherical nuclei (see arrows in Figure 3.4). 4) The lymphocyte 
culture in 2 and 6 days exhibited heterogeneous populations of immune cells that could represent 
other innate immune cell groups (see arrows in Figure 3.4). 5) The cell count and size-forming 
unit of lymphocytes started to reduce at day 6, and higher number of dead cells were detected in 
non-activated lymphocytes culture (Figure3.4 and 3.5). 
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3.5.4. CD25 MARKER (IL-2α R) MEASUREMENT ON LYMPHOCYTES 
FOLLOWING 2-& 4- ACTIVATION 
To investigate the presence of activated lymphocytes, the CD25 marker (IL-2αR) was measured 
in lymphocyte cultures from days 2 and 4. CD25 is a specific marker for T cell activation and 
proliferation (Tsoukas et al., 1985; Brocardo et al., 2001). The data demonstrated that the 
expression of CD25 was higher in day 4(87±4) than day 2 (49±2), while at day 6 activation, the 
expression decreased significantly to (18±10, p>0.0001) (Figure 3.8 A and B).This finding was 
expected because most of the cells died. The peak expression of the IL-2 receptor following day 
4 activation could indicate that IL-2 receptors expressed on lymphocytes were already engaged 
by the exogenous IL-2 that was added in the lymphocytes culture medium. Therefore, the 
number of un-bound IL-2 receptors to conjugate with anti-CD25 was very limited. Additionally, 
CD25 is the middle T- lymphocyte activation marker (Rea et al., 1999) and  the way of activating 
lymphocytes by using anti-CD3/CD28/IL-2 is effectively expansion of  lymphocyte 
proliferation and enhanced endogenous IL-2 production leading to increased IL-2 R expression 
(Schwartz, 1990; Jerome, 2008). Another possibility is that CD25 was expressed on 
immunoregulatory T cells (Treg) which represent 5-10% of CD4+Tcells (Piccirillo and 
Shevach, 2004). 
 
3.5.5. QUANTITATION OF CYTOKINE SECRETION IN DAY 2 AND 4- 
ACTIVATED LYMPHOCYTES 
Our data suggest that factors secreted by lymphocytes can extend the period of proliferation of 
myoblasts.  It is therefore of interest to identify which secreted factors promote this regulatory 
role. Based on findings of the multiplex assay carried out on the lymphocyte secretomes, it seems 
that the cytokines and growth factors released by day 2 activated T lymphocytes were not 
sufficient to exhibit their mitogenic effects on CM1 treated myoblasts. The results indicated that 
the concentration of cytokines released from day2-activated lymphocytes was lower than for 
day 4. The cytokines which were expressed at high concentrations after 4 days of lymphocyte 
activation were IL-1, IL-3, TNF-β and IFN-y. 
In addition, the study results have shown that IL-1 concentration was higher in the secretome of 
day 4 activated lymphocytes compared with non-activated lymphocytes. Moreover, the IL-1 
concentration in day 4 activated lymphocytes was 1-2 fold higher compared to day 2-activated 
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lymphocytes. It is well established that IL-1 is a key stimulator of IL-2, 3, 6 and TNF (Tidball, 
1995). IL-3, 6 and TNF are secreted by CD4+ Th2, while IL-3 and TNF-α are produced from 
CD4+Th1 cells (Mosmann and Sad, 1996). TNF-α is known to have a mitogenic effect on 
skeletal muscle myoblasts (Li, 2003). This finding also was supported by Al-Shanti. et al., 
(2008) who suggested that the combined effect of IL-6 and TNF-α induced satellite cell 
proliferation (Al-Shanti et al., 2008). Surprisingly, IFN-γ was also detected at similar 
concentrations in the secretome of day 4 activated and non-activated lymphocytes. IFN-γ 
secreted by activated lymphocytes has been shown to promote skeletal muscle regeneration and 
to stimulate wound healing (De Rosa et al., 2004; Krug et al., 1996). However, another finding 
demonstrated that INF-γ could negatively affect skeletal muscle proliferation. It was shown that 
blocking the receptor of IFN-γ decreased proliferation rate of the C2C12 myoblasts (Foster et 
al., 2003).  
 
3.5.6. OPTIMAL VOLUME OF SECRETOME TO MAKE CONDITIONED MEDIA 
Since the ultimate aim of this study was to extract the secretome of activated lymphocytes and 
use it to enrich the growth medium of C2C12 cells, it was necessary to determine the optimum 
volume of secretome.  Three different volumes of secretome (50µl, 100µl and 200µl) were 
assessed to determine the response of C2C12 cells treated in CM1. The lower volume of day 4 
activated lymphocytes (50µl) did not stimulate C2C12 proliferation (Figure 3.7 A), possibly 
because the existing cytokines were not at sufficiently high concentrations to exhibit their 
proliferative effects on skeletal muscle myoblasts. The conditioned media supplemented with 
the highest volume of secretome impaired satellite cells growth and caused C2C12 cell death 
(see arrows in Figure 3.7C). This finding raises the possibility that high concentrations of 
cytokines negatively affect cell growth and development, although this would have to be 
confirmed in follow-up studies. Several studies showed a strong relationship between muscular 
atrophy (muscle wasting) and high concentrations of cytokines. For example, cachexia, cancer 
and sarcopenia are strongly related to high concentrations of TNF-α and IFN-γ (Yeh and 
Schuster, 1999; Lutz and Quinn, 2012). The conditioned media supplemented with 100 µl of 
secretome was the optimal volume because cultivated C2C12 in this volume exhibited higher 
proliferation rates (Figure 3.7 A). The C2C12 cell count was significantly higher after 
enrichment of CM1 with 100µl of secretome compared with other secretome volumes (p<0.05). 
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3.5.7. MYOBLAST CULTIVATION IN FORMULATED CONDITIONED MEDIA 
The results showed that CM controls did not inhibit differentiation of myoblasts to 
multinucleated myotubes. All CM controls were not significantly different from one another. In 
the main experiment, C2C12 cells were cultured in CM1 (composed of secretome of anti-
CD3/CD28 activated lymphocytes at day 2, 4 and 6). The results showed that the conditioned 
media from day2 activated lymphocytes exhibited differentiation to myotube formation over a 
normal timescale (Figure 3.9 upper panel). Cell counts were not significantly different compared 
with CM2-4 control conditions (Figure 3.9, upper panel).The C2C12 cells cultured with CM1 
enriched with the secretome of day 4 activated lymphocytes showed the highest proliferation 
rates and no myotubes formation (Figure 3.9, middle panel). The cell count of CM1 enriched 
with the day 4-activated lymphocytes was significantly higher compared with CM controls, 
CM2-4 and DM. On the other hand, myoblasts treated with CM2 (day 4 non-activated 
lymphocytes) displayed fusion of mononucleated cells to form multinucleated myotubes in the 
normal way that was not significantly different from control conditions CM3-4. However, 
C2C12 cultured in CM1 (secretome of day 6 activated lymphocytes) exhibited proliferation but 
was not significant compared to controls (Figure 3.9; lower panel). Moreover, more dead 
myoblasts were detected at 96 hours in day 6 CM1 culture. 
 
3.5.7. CELL CYCLE ANALYSIS 
 
Cell cycle progression is a commonly used method to characterise the development of satellite 
cells (Andres and Walsh, 1996). Data from this study was supported by S phase assessment of 
each CM. Consistent with other findings that suggest the CM1 enriched with the secretome of 
4-day activated lymphocytes is the optimal condition, the S phase of myoblasts treated with 
CM1 day 4 increased significantly compared with other CM2-4 controls (Figures 3.10 and 3.11).  
In contrast, S phase of day 2 and day 6 were not significantly increased compared to the controls 
(Figure 3.11). 
The day 6 incubation time of activated lymphocytes was excluded from the optimisation study 
due to the low lymphocyte count following their culture, low %S phase of myoblasts, low 
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myoblast count and high numbers of dead cells after 96 hours of incubation in conditioned 
media. Based on the results obtained from this study, the secretome of day 4 activated 
lymphocytes had an inhibitory influence on the differentiation of CM1-treated myoblasts, and 
instead extended the period of proliferation. Extending the proliferative capacity of muscle 
precursor cells is highly relevant and the results obtained by Mildner et al., (2013) demonstrated 
that the secretome from human mononuclear cells accelerate proliferation and wound healing of 
skin post injury (Mildner et al., 2013). Another study demonstrated that the anti-inflammatory 
mediators harvested from the secretome of mononuclear cells effectively attenuated the 
development of autoimmune myocarditis (Hoetzenecker et al., 2013). Taken together, these 
results clearly identify a primary role for the immune cells in promoting the proliferation of 
precursor muscle cells and the regeneration of tissue. Details of the possible muscle-immune 
interactions are considered below. 
Activated T-cells produce cytokines and growth factors that have mitogenic effects on skeletal 
muscle regeneration (Dumke and Lees, 2011). These secreted proteins include fibroblast growth 
factor-2 (FGF-2)(Srully Blotnick et al., 1994), (IFN-γ) ( De Rosa et al., 2004; Mann et al., 2011), 
TGF-β (Megan K Levings et al., 2002), TNF-α (Mann et al., 2011); (Schaerli et al., 2004) and 
(IL-4)(Fritsch et al., 2005; De Rosa et al., 2004). Interestingly, TNF-β and IFN were detected at 
high concentration in the secretome of day 4 activated lymphocytes by multiplex assay. It is 
known that mitogens activate cell proliferation and prevent differentiation (Sharon A. Coolican 
et al., 1997; Delmas et al., 2001). Another explanation could be the effect TGF-β which is 
strongly associated with T cells infiltration. Reduced expression of T- cells was associated with 
a decreased level of TGF-β in patients with Duchenne muscular dystrophy (DMD). The third 
possibility relates to possible effects of insulin like growth factor (IGF), which promotes satellite 
cell proliferation (Machida and Booth, 2004). It is possible that IGF is one of a number of 
proteins secreted by T-cells. A previous study showed that the synergistic effect of IGF with IL-
6 extended the period of proliferation of C2C12 myoblasts in a similar way to that observed in 
the present study following enrichment of the growth medium with the lymphocyte secretome 
(Al-Shanti et al., 2014). However, it is well established that IGF promotes fusion of 
mononucleated myoblasts and stimulates hypertrophy via increasing the number of myonuclei 
and the size of myotubes in vivo (Yin et al., 2013). 
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3.6. CONCLUSION 
 The results show that culturing activated CD3/CD28- lymphocytes for 4 days is the optimal 
period of activation evidenced by the highest cells count, CD25 expression and cytokine 
secretion. In addition, It is suggested that the cytokines released by day 4 activated lymphocytes 
were able to induce proliferation of C2C12 following 4 days’ incubation with CM1 compared 
to CM2, CM3 boiled and CM4. As a consequence of the results obtained in this chapter, it was 
decided to apply the same optimised experimental design to study the effect of secretome 
obtained from elderly participants on C2C12 regeneration. 
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4.  AGE- RELATED DIFFERENCES IN THE CHARACTERISTICS OF  
YOUNG AND OLD LYMPHOCYTES. 
4.1 INTRODUCTION 
Ageing related changes to the immune system increases vulnerability of older people to 
infectious disease and tumours (Vasto et al., 2009). The reasons for the age-related declines in 
immune function are not well understood. However, genetics and environmental risk factors as 
well as thymic dystrophy are thought to contribute (Salam et al., 2013). A decline in thymus 
activity reduces the immune system’s homeostatic response to antigens and leads to a 
corresponding reduction in T-cell production and more generally, an overall decrease in 
circulating T-cells (Qi et al., 2014). This is not the only age-dependent change to immune cells, 
as the remaining T-cells also undergo alterations to their gene expression which affects their 
function.In vivo, T-cells are activated either by antigens or chemokines and respond by releasing 
cytokines, chemokines and growth factors to combat antigens or to orchestrate tissue repair. The 
activation of T-cells can be mimicked in vitro by anti-CD3 and/or anti-CD28 (Schwartz, 1990). 
In vivo and vitro studies have shown that naive T CD4 cells from aged mice exhibit remarkable 
age-related changes to proliferation (Swain et al., 2005; Haynes et al., 1999). These changes 
resulted in part from alterations in signalling pathways in T cells including tyrosine 
phosphorylation, NFAT and NFƘB (Haynes et al., 2004; Grossmann et al., 1991; Grossmann et 
al., 1995).The defects in proliferation of naive T CD4cells following stimulation generate fewer 
effector populations that are smaller, less differentiated and that released lower levels of Th1 
and Th2 cytokines (Swain et al., 2005). 
The findings from the previous chapter demonstrated that T-cells collected from human 
volunteers and cultured in vitro with anti-CD3/CD28 showed their maximal activation after 4 
days of culture, as evidenced by the highest CD25 expression. The secreted proteins harvested 
from activated T-cells from young adults were shown to increase the rate of proliferation of 
skeletal muscle C2C12 cells. However, it remains unclear which molecular mechanisms 
underlie cellular activation of young and old lymphocytes, and subsequently influence the 
behaviour of myoblasts contributing to muscle regeneration. It is well known that Tregs, 
expressing FoxP3 (+) CD25 (+), are important for muscle repair via amphiregulin expression in 
addition to their potential role in suppressing immune responses (Burzyn et al., 2013 ) 
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Furthermore, recent reports found that circulating Growth Differentiation Factor-11 (GDF11) 
levels improved the functional and strength of muscle in aged mice aged 22 months (Sinha etal., 
2014). Thus, the purpose of this study was to identify Tregs, FoxP3, Amphiregulin and GDF11 
expression in T-cells collected from young and older human volunteers. 
 
4.2 AIMS, OBJECTIVES AND HYPOTHESIS 
The aim of this study was to measure the expression of GDF11 and amphiregulin by Tregs 
FoxP3 cells collected from young and older adults and then cultured in vivo and activated (or 
not) by anti-CD3/anti-CD28.The objectives were, firstly, to assess CD25 and FoxP3 receptors 
on young and old T –lymphocytes. Secondly, to measure the expression of amphiregulin and 
GDF-11 in young and old T-lymphocytes which are related to muscle repair. The hypothesis 
was that Treg FoxP3, CD25 markers and expression of amphiregulin and GDF-11 would be 
higher in young individuals compared to old individuals. 
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4.3 METHODS 
4.3.1 HUMAN LYMPHOCYTES CULTURE 
Lymphocytes were isolated from fresh blood samples by Ficoll-Paque PLUS (as described in 
2.4.1). Lymphocytes were activated by CD3/CD28 and incubated in the presence of IL-2 in 
completed RPMI-1640 media for 4 days in a humidified 5% CO2 atmosphere at 37°C. In 
negative controls, the cells were incubated without anti- CD3/CD28 and supplemented with IL-
2 in a completed RPMI-1640 media. It was assumed that the optimal culture conditions which 
were established using young lymphocytes will be optimal for culturing old lymphocytes. In all 
the experiments, un-pooled secretomes were applied for conditioned media preparations.   
4.3.2 RNA ISOLATION AND REAL TIME PCR 
 RNA extraction and TaqMan® Real time PCR methods were performed as described in sections 
2.9 and 2.10 respectively. The following predesigned primer sets were obtained from Applied 
Biosystem and were used in TaqMan® detection method: GAPDH (Hs00950669-m1), a house 
keeping gene, Amphiregulin (Hs00950669) and GDF-11(Hs00195156-m1). GAPDH was used 
as a reference gene for lymphocytes (Duran et al., 2005; Lai et al., 2003; Carolan et al., 2014; 
Rao et al., 2006) and performed in parallel with target genes. mRNA was isolated from  
lymphocytes obtained from young participants ( 5 male, aged 18-25) years and old participants 
( 5 male,  aged 75-86) . 
4.3.3 MEASUREMENT OF CD25 AND FOXP3 EXPRESSED BY YOUNG AND OLD 
LYMPHOCYTES 
Detection of transcription factor FoxP3 (Treg marker) and CD25 (activation marker) were 
performed on activated young and old lymphocytes. After 4 days of activation, cells were 
harvested and stained with CD25 (as described in 2.6.1). To detect FoxoP3 Tregs, samples were 
centrifuged at 300xg for 10 minutes. The supernatant was removed and cells were fixed with 
4% of Paraformaldehyde solution for 10 minutes in the dark at RT. Following incubation, cells 
were washed with 2 ml of Stain Buffer and centrifuged at 300xg for 10 minutes. Wash buffer 
was removed and cells were incubated with  premeabilization buffer (1X BD Prem , San Diego, 
CA, USA ) for 30 minutes in the dark at RT.  To wash cells, 2 ml of stain Buffer was added and 
samples centrifuged at 300xg for 10 minutes.  The supernatant was discarded and cells were 
stained with anti-human FoxP3 (as described in 2.6.3). CD25 and FOXP3 receptors expression 
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were assessed on lymphocytes obtained from young participants (5 male, aged 18-25) years and 
old participants (5 male, aged 78-86). 
 
4.3.4 QUANTITATIVE MEASUREMENT OF AMPHIREGULIN IN YOUNG AND OLD 
SECRETOMES 
Amphiregulin human ELISA of 96-well plate (abcam) was applied for the quantitative 
measurement of amphiregulin in young and old secretomes (as described in 2.13). Protein 
estimation for all samples was determined prior to quantitative measurement of Amphiregulin 
concentration (as described in 2.10). Amphiregulin concentrations were measured from 6 young 
secretome obtained from young individuals (6 male aged 18-25 years and old secretome from 
old individuals (5 male and one female, aged 78-86 years). 
 
4.5 STATISTICAL ANALYSIS  
One-way ANOVA was used to compare effects between all the experimental conditions of 
activated and non-activated lymphocytes followed by Bonferroni post test analysis. Results were 
presented as mean ± standard deviation (±SD). Results were statistically significant at the level 
of 5% (P<0.05) and indicated on figures or in tables using*, whereas p<0.01 was marked **, 
p<0.001 was marked *** and p<0.0001 marked as ****. The percentages of CV were 
determined for repeated independent experiments to compare the degree of variation from one 
experiment to another. % CV(s) were calculated by dividing standard deviation by the mean for 
each group of treated cells .  
 
 
  
 
 
4.4RESULTS 
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4.4.1 GENE EXPRESSION ANALYSIS OF AMPHIREGULIN IN HUMAN YOUNG 
AND OLD T LYMPHOCYTES. 
 
As it is shown in Figure (4.1), the fold difference of Amphiregulin expression in secretomes of 
Young activated lymphocytes compared with non-activated was significantly higher compared 
to Old activated vs non-activated lymphocytes (2.14±0.7 vs 0.54±0.08 respectively; p<0.0001).  
 
 
Figure 4.1:  Amphiregulin gene expression in young and old activated lymphocytes after 4 
days of incubation. All values are represented as a fold change to young not activated lymphocytes. 
Young activated lymphocytes significantly express 4 folds higher compared to Old activated 
lymphocytes (p<0.0001). The controls for this experiment were not significantly different. Results 
represent SD± means of (n= 5young aged 18-25 years) and (n=5old aged 75-86 years) in triplicates. AC: 
Activated,  NA: Non-activated.  %CVfor Young (AC); 34%, Young (NA); 0%, Old (AC);16% and 
Old(NA);7%. 
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4.4.2 GENE EXPRESSION ANALYSIS OF GDF-11 IN HUMAN YOUNG AND OLD T 
LYMPHOCYTES 
 The results indicated that there were no significant differences in GDF-11 gene expression in 
Young and Old activated lymphocytes compared with their levels seen in non-activated 
lymphocytes (0.8±0.4 vs 0.8±0.2; p>0.05 respectively)(Figure 4.2).    
 
Figure 4.2: GDF-11 gene expression in young and old activated lymphocytes. Fold changes 
of GDF-11 for activated Young and Old lymphocytes were not significantly different (p>0.05). 
Results represent SD± of (n= 5 young aged 18-25 years) and (n=5 old, aged 75-86years) in triplicates. 
AC: Activated, NA: Non-activated. %CV for Young (AC); 52%, Young (NC); 0%, Old (AC); 
23% and Old (NC);14%. 
 
4.4. 3 QUANTITATION OF AMPHIREGULIN IN YOUNG AND OLD SECRETOMES 
Quantitative analysis for Amphiregulin in Young and Old secretomes showed that the 
concentrations of amphiregulin in Young activated secretomes were significantly higher 
compared to Young non-activated and Old activated secretomes (904±323pg/ml vs 266±237 
pg/ml; p<0.05 and 367±208pg/ml; p<0.001 respectively). Slight difference was observed 
between Old activated and non-activated secretomes but the difference did not reach statistical 
significance (367±244pg/ml and 183±208pg/ml; p>0.05)(Figure 4.3). 
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Figure 4.3: Amphiregulin concentration in secretomes of young and old lymphocytes. The 
concentration of Amphiregulin in young secretomes was significantly higher (p<0.05) compared to old 
secretomes. Data   represent means ±SD (n=6samples of each young aged (18-25 years) and old (78-86 
years) in triplicates. Ac: Activated, NA: Non-activated. %CV for Young (AC) ; 36%, Young (NA); 89%, 
Old (AC)67% and Old (NA); 13%.  
 
4.4.4 MEASUREMENT OF CD25 and FOXP3 EXPRESSION BY YOUNG AND OLD 
LYMPHOCYTES 
The results of CD25 analysis in Figure (4.4 B) indicated that %CD25 expression was 
approximately 3 folds higher on Young activated compared to Old activated lymphocytes 
(67.6±10.3% vs 24.6±5.5% respectively; p<0.001). In addition, a significant difference was 
observed between Young activated and non-activated lymphocytes in % CD25 expression 
(67.6±10% vs 9.7±5%; p<0.01). Similarly, the percentage of CD25 was significantly higher in 
Old activated compared to non activated (24.6±5.5% vs 4.1±3%; p<0.05)(Figure 4.4 and 4.6). 
Data analysis for FoxP3 percentage revealed that Old activated lymphocytes expressed 
approximately 2 folds higher than Young activated lymphocytes (35±13% vs 15±5%; p<0.05). 
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Also, significant difference was observed between Old activated and non-activated in 
percentages of FoxP3 expression (35±13% vs 10.5±1.3%; p<0.05) (Figure 4.5 and 4.6). 
 
Figure 4.4: % of CD25 Young and Old lymphocytes. CD25 expression was significantly higher 
on Young compared to Old cells (p>0.001). Data represent means ±SD (n=5) of each young 
(22±3years) and old (80±5 years) in duplicates. Ac: Activated and NA: Non-activated. 
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Figure 4.5:% FoxP3 in young and old lymphocytes. % FoxP3 was significantly higher on Old 
compared to young lymphocytes (p<0.05). Data represent means ±SD (n=5) of each young (18-
25 years) and old (75-86 years) in duplicates. 
 
 
 
 
 
.  
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Figure 4.6: Flow cytometric analysis of PE-anti human FoxP3 and APC- anti human CD25 
on lymphocytes.%FoxP3 expression was significantly higher in Old activated lymphocytes (lower 
panel- left) compared to Young activated lymphocytes (middle panel -left). %CD25 expression was 
significantly higher on Young activated (middle panel -left) compared to Old activated lymphocytes 
(lower panel -left).  Each dot plot includes 4 quadrants which are: Upper right (+FoxP3), Lower right (-
FoxP3), Upper left (+CD25+FoxP3) and Lower left is +CD25). 
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4.5 DISCUSSION 
The results from the present study indicate that CD25/FoxP3 Tregs and Amphiregulin growth 
factor are subject to change with ageing. No difference was observed in the gene expression of 
GDF11. A recent report has shown that muscular Treg Foxp3 cells potentiate    muscle repair 
and regeneration via amphiregulin growth factor (Burzyn et al., 2013). The results presented 
here provide the first evidence, to our knowledge, that Amphiregulin expressed by Young 
activated lymphocytes was higher compared to old activated lymphocytes. Our results were 
confirmed by measuring gene expression and quantification of secreted amphiregulin in young 
and old secretomes. Also, the current results demonstrated that reduction % of Treg FoxP3   in 
young activated lymphocytes tended to correspond to increase amphiregulin production. 
Parabiosis studies showed that elevated  levels  of  circulatory GDF-11 may enhance skeletal 
muscle repair, reverse impairment of skeletal muscle dysfunction in aged mice (Sinha et al., 
2014), promote neurogenesis (Katsimpardi et al., 2014) and  reverse  cardiac hypertrophy in 
aged mice (Loffredo et al., 2013). Since GDF-11 is closely related to myostatin, which is known 
as a negative regulatory factor for skeletal muscle regeneration (Rı´os et al., 2002; 
Trendelenburg et al., 2009; Sartori et al., 2009), it seems surprising that GDF-11 positively 
enhanced myogenesis, in contrast to the demonstrated negative effects induced by myostatin. A 
recent manuscript reported that GDF-11 is similar to the myostatin, increases with ageing 
contributing to decreases in satellite cell proliferation and attenuates skeletal muscle 
regeneration in aged mice (Egerman et al., 2015). The finding of this latter study is more reliable 
and specific compared to the previous studies mentioned above, as the techniques applied for 
this work were more specific and reproducible. However, our data did not reveal any preferential 
influence of ageing on GDF-11 expression. One possible reason for this finding is that our work 
was restricted to the cytokines and growth factors secreted from lymphocytes. 
However, the finding of increased Treg FoxP3 with ageing is comparable to previous studies 
conducted on humans which demonstrated that there is a measurable increase in the percentage 
of Treg FoxP3 cells in old compared to young subjects (Lages et al., 2008; Gregg et al., 2005; 
Gottenberg et al., 2005; Ruby and Weinberg, 2009). Others showed that the percentage of Treg 
FoxP3 cells following antigen stimulation was higher in skin biopsies from old compared to 
young individuals (Agius et al., 2009). In addition, further results from mice found expansion 
of absolute number of Treg FoxP3 in mice with advancing age (Chiu et al., 2007; Sharma et al., 
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2006). Thus the age-related variations in immune competence may partially be a reflection of 
changing function in Tregs (Dejaco et al., 2006). 
Muscular Tregs are different from other counterparts existing in lymphoid and non-lymphoid 
tissues (Burzyn et al., 2013). They display a distinct transcriptome, gene expression profile and 
TCR repertoire for an antigenic selection. The substantial difference in these characteristics 
could add an advantageous effect of muscular Tregs on skeletal muscle repair and satellite cell 
expansion. In vivo and in vitro studies have shown the direct effect of FoxP3 Treg on 
myogenesis, enhancing satellite cell proliferation and promoting effective skeletal muscle 
regeneration in mice (Castiglioni et al., 2015).  
 The most recent studies have shown that depletion of muscular Tregs altered the physiological 
features of muscle repair and attenuated lymphoid cells shifting from the pro-inflammatory to 
the anti-inflammatory phenotype in injured muscle with Ctx in mice. It is well known that 
myeloid cells are crucial for efficient muscle repair and that any change in the proportion of 
lymphoid cells can negatively affect the series of events that orchestrate muscle repair and 
regeneration (Tidball & Villalta, 2010). Recently, a novel study highlighted the role of Treg 
FoxP3 in recruiting proper muscle repair. The study demonstrated that skeletal muscle in aged 
mice (aged 6 months) failed to undergo proper muscle repair as a result of reducing infiltration 
of Treg cells in injured muscle skeletal muscle regeneration compared to young mice (2 months) 
(Kuswanto et al., 2016). However, in the current study, the findings of an increase in the 
percentage of Treg FoxP3 was not comparable to the findings of muscular Treg in the other 
studies mentioned. The reason could be that the measurement of % FoxP3 was conducted on in 
vitro stimulated lymphocytes from fresh blood samples of young and aged participants, not on 
muscle–infiltrating Treg cells.   
 
In addition to the age-related changes in FoxP3, our data showed that there is a decline in CD25 
expression, which is known as a key marker of IL-2 production upon T cell receptor (TCR) 
stimulation (Chao et al., 2002).  The reduced expression of CD25 is consistently observed in the 
aged, naive CD4 T cells as a result of reduce thymic output (Salam et al., 2013; Weng, 2006). 
This is reflected in our results which showed that the young lymphocytes responded differently 
compared to old to the exogenous addition of IL-2 in vitro.  This age- related defect in CD25 
expression leads to poorly differentiated of Th1 and Th2 subsets (Goronzy et al., 2007; Arnold 
et al., 2011; Haynes et al., 1999). For example, it has been shown for CD4 + T cells that Th1 
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cell numbers decrease first, followed later by Th2 cells (Chiu et al., 2002). Th2 subset is a source 
of amphiregulin production (Paul and Zhu, 2010; Licona-Limón et al., 2013; Qi et al., 2009; 
Zaiss et al., 2006). Thus, suppression of CD25 expression in aged people (Salam et al., 2013) 
could lead to poor production of amphiregulin, which is known as inducer factor for Treg FoxP3 
(Zaiss et al., 2006). Other factors were also shown to induce amphiregulin biological function. 
These include IL-1β and TNF-α (Streicher et al., 2007; Woodworth et al., 1995), IL-3and IL-4 
(Qi et al., 2012). Taken all together, our data suggested that accumulating Treg FoxP3 cells,   
suppressor T- cells,   in old adults attenuate the activation of old   T- cells (Saito et al., 2010; 
Fessler et al., 2013) resulting in lower CD25 expression.  This may explain, at least in part, the 
age-related impairment of the regulation of the immune response.  
 
 
4.6. CONCLUSION 
The percentage of Treg FoxP3 increases with ageing. The concentration of Amphiregulin 
growth factor is inversely associated with the percentage of Treg FoxP3 cell population.  Defects 
of immune cells with ageing contribute to the changes of cytokines and growth factors 
production.   
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5. CHARACTERISATION OF YOUNG AND OLD SECRETOMES 
OBTAINED FROM LYMPHOCYTES 
5.1 INTRODUCTION 
A reduction in thymus output with ageing is partly compensated by homeostatic proliferation of 
existing naive CD4 T cells in addition to the shifting in other T cells compartments (Linton and 
Dorshkind, 2004; Swain et al., 2005). The long- term maintenance of naive T cells through 
homeostatic mechanisms generates defects and functional characteristics of T cells. For 
example, it was shown that naive CD4T cells show less proliferative capacity and IL-2 
production in response to antigens compared to naive CD4T cells that have not undergone 
homeostatic expansion (Swain et al., 2005). In addition, aged T- cell populations express lower 
levels of CD25 expression and T-cell receptor TCR repertoire (Swain et al. 2005; Salam, et al. 
2013). In vivo and in vitro studies showed that in aged mice, naive T cells express lower levels 
of CD25 receptors and release less IL-2 following stimulation with antigen or anti-CD3/CD28 
(Swain et al. 2005). These defects in the immune response attenuate the quality of TCR 
signalling cascades, reducing the clonal expansion and cytokine production from naive T cells 
(Haynes et al., 2004). Furthermore, memory T cells from old mice exhibit major defects in initial 
signalling pathways, cytokine production and proliferative capacity (Haynes et al., 1999). All 
these observations suggest that the accumulation of impaired memory T cells in old mice could 
play a role in the changes of cytokines production. Alteration in cytokines production from aged 
naive T cells are accompanied by shifting of T cell subsets (Nagelkerken et al., 1991) resulting 
in an accumulation of Treg FoxP3 cells and memory cells at the expense of naive T cells (Seddiki 
et al., 2006, Hwang et al., 2009). 
However, the possible effect of ageing on T cell subsets of human cytokines is very limited and 
controversial with studies indicating that the production of TNF-α. INF-y and IL-4 may be 
elevated, unchanged or reduced (Fagiolo et al., 1993; Sindermann et al., 1993). 
In the previous chapter, the results clearly showed that aged lymphocytes express higher levels 
of FoxP3 and lower levels of CD25 compared to young lymphocytes. These observed 
differences may play a role in the production of cytokines, interleukins and growth factors. Thus, 
in this part of the study, the production of cytokines (Th1and Th2) and growth factor (IGF-1) 
from young and old individuals was examined for possible differences in T cell populations of 
young and old people. To achieve this, the concentrations of 15 Th1/Th2 cytokines and IGF-1 
were analysed in the secretomes of6 of each young and old individuals, activated and non-
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activated lymphocytes after 4 days of in vitro incubation. 
 
5.2 AIM, OBJECTIVES AND HYPOTHESIS 
The aim was to determine whether activated young and old lymphocytes show differences in 
cytokines and IGF-1 production. The objectives were to quantify the cytokines and IGF-1 from 
young and old lymphocytes. The hypothesis was that there are differences in cytokines and IGF-
1 production from young and old lymphocytes.   
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5.3 METHODS 
5.3.1 ISOLATION OF LYMPHOCYTES FROM FRESH BLOOD SAMPLES 
Lymphocytes were isolated from fresh blood samples obtained from healthy young and old 
participants. Lymphocytes were isolated using Ficoll–Paque PLUS (as mentioned in 2.4.1). 
Prior to counting and culturing the lymphocytes, macrophages were depleted (as mentioned in 
2.4.1). To mimic in vivo activation, isolated lymphocytes from both aged groups were cultured 
as described in 2.4.1. Proteins estimation (2.11) for secretomes obtained from young and old 
subjects were performed prior to immunoassay analysis. It was assumed that the optimal culture 
conditions which were established using young lymphocytes will be optimal for culturing old 
lymphocytes. In all the experiments, un-pooled secretomes were applied for conditioned media 
preparations.   
5.3.2 IMMUNOASSAY ANALYSIS 
Harvested secretomes from young and old participants that were used to prepare conditioned 
media (CM1 and CM2) were screened by multiplex analysis. Fifteen cytokines were quantified 
from young (n=5, aged 25-30 years) and old (n=5, aged 75-81) and IGF-1 were quantified from 
young (n=6, aged 25-30 years) and old (n=6, aged 75±8 years) participants (as described in 
2.12.2 and 2.12.3) respectively.   
 
5.3.3 STATISTICAL ANALYSIS 
Two- way ANOVA was used to assess the interaction effect of age and activation status 
(activated or non-activated lymphocytes) on the cytokines followed by Bonferroni post-test 
analysis. Results are presented as mean and standard deviation (±SD) of the mean. Analyses 
were carried out using GraphPad and significance accepted as p<0.05. The percentages of CV 
were determined for repeated independent experiments by dividing standard deviation by the 
mean for each group of treated cells .  
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5.4 RESULTS 
5.4.1 Th1/Th2 cytokines concentration in young and old secretomes 
Table 5.1 shows the concentrations of 15 Th1/Th2 cytokines that were detected in the 
secretomes of young and old, activated and non-activated lymphocytes. Seven cytokines were 
significantly different in the secretome from Old activated lymphocytes compared with the 
Young activated lymphocytes. Old activated lymphocyte secretome had lower concentrations of 
TNF-α, IL-1β, INF-γ and IL-12 compared to Young (all p<0.05), and higher concentrations of 
IL-4, IL-5 and IL-8 (all p<0.05). Furthermore, cytokine concentrations in Old activated 
lymphocyte secretome were significantly lower than the non-activated lymphocyte secretome 
(p<0.05). Similarly, all cytokines in old activated lymphocyte secretome were significantly 
higher than in old non-activated lymphocyte secretome. No significant difference was observed 
between activated young and old secretomes in the concentrations of IL-18, MIP-α (macrophage 
inflammatory protein-α), SDF (stromal cell-derived factor), IP-10 (interferon gamma-induced 
protein 10) and GM-CSF (granulocyte macrophage-colony stimulating factor). 
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Table 5.1: Multiplex reading foranti-CD3/CD28 activated and non-activated  lymphocyte 
secretome from young and old participants.  
 
 
All data were statistically analysed by one-way ANOVA and two-way ANOVA, p values of young vs 
old only were shown in the table.is young activated vs old activated. indicates young activated vs 
young non-activated. ‡ indicates old activated vs old non-activated. ¥ indicates the interaction effect of 
age and activation status on the cytokines. Results represent the mean ±SD for 105 young and 5 old) 
subjects. Samples were tested in triplicate. 
 
 
5.4.1 IGF in young and old secretomes 
 
The concentrations of IGF-I was measured directly from the secretome (i.e. the secretome was 
used directly, not after dilution into the conditioned media). The young lymphocytes, activated 
in vitro using anti-CD3/CD28, secreted approximately 30% more (1100 ±84 ng/ml; p<0.005) 
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IGF-I compared to Old CM1 (845 ±68 ng/ml; p<0.005) and compared to the non-activated 
Young lymphocytes (both p<0.05). There was no significant difference between the Old 
activated and non-activated lymphocytes in IGF-I concentrations. Data are shown in Figure 5.1. 
 
 
Figure 5.1: IGF-1 concentrations in young and old secretomes of activated and non-
activated lymphocytes. The concentration of IGF-1 in young positive secretomes was significantly 
higher compared to old activated secretomes (p<0.01). Results represent the mean ±SD for 12 (6 young 
and 6 old) subjects. Samples were tested in triplicate .%CV for Young Activated;7%, Young Non-
activated ;7%, Old Activated ;10% and Old non-activated 17%. 
 
 
5.5 DISCUSSION 
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Age associated thymic involution has been proposed as aprinciple factor that influences the 
hormones and cytokines production(Salam et al., 2013). 
Our results showed that IGF -1 concentration in the old secretome was significantly lower 
compared to young activated secretome. IGF-I is secreted by skeletal muscles and plays a key 
role in their growth, differentiation and repair. Two previous reports showed that IGF-I is also 
secreted by activated T-lymphocytes (Leng et al., 2009; Merchav et al., 1988; Johnson et al., 
1992). Our results showed 30% (1100ng/ml± 84) higher IGF-I levels secreted by young 
activated lymphocytes compared to old (845ng/ml±68) when measured directly from the 
secretomes.  
The multiplex cytokine results showed that IL-1β, TNF-α, IL-12, and IFN-γ were significantly 
lower in old activated lymphocytes compared to young, while IL-4, IL-5 and IL-8 were higher 
in old compared to young. Previous work demonstrated that TNF-α and IL-6 were decreased in 
old  participants compared to young men following in vitro LPS stimulation (Bruunsgaard et al., 
1999). The finding of this study support our study that showed decreased levels of inflammatory 
cytokines IL-6 and TNF-α in old subjects. It was suggested that TNF-α promotes skeletal muscle 
wasting by inhibiting the IGF signalling pathway (Grounds, 2002). These results are similar to 
our findings which showed lower concentrations of TNF-α, IL-6 and IGF in old activated 
compared to young. 
 
Our data showed that IL-2, IL-12 and IFN-y were lower in old secretomes compared to young. 
Several studies have reported that the combination of these cytokines is essential for T 
lymphocyte recruitment and activation.  IL-12 is an inducer for Th1 responses (Van der Pouw 
Kraan et al., 1997) augments IFN-γ production and induces IL-2R alpha-chain (CD25 
expression) resulting  in the expansion of Th1 clones (Kohno et al., 1997; Leong et al., 2014). 
In addition IL-12 is a critical factor required for optimal IL-2-dependant proliferation, 
stimulation and clonal expansion of T lymphocytes (Valenzuela et al., 2002). This effect is 
mediated through up-regulation of CD25 expression. Moreover, both cytokines act 
synergistically to induce IL-12αR expression, promoting cross-regulation of receptor expression 
(Valenzuela et al., 2002). 
Production of IL-2 is indicative marker for TCR stimulation of naive CD4 cells. TCR 
stimulation leads to proliferation and differentiation to Th1 and Th2. It is well known that IL-2 
reduces with ageing, resulting in poor regeneration of either Th1 or Th2 response and altered 
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cytokines production. However, our results showed lower production of IL-2 from old 
lymphocytes compared to young was not significant, this could be due to the exogenous addition 
of IL-2 that may have  restored the capacity of T cells to respond to IL-2. 
The results of the current study show an age –related increase of IL-4. Our data was confirmed 
by prior studies which showed increased IL-4 production with age (Sindermann et al., 1993; 
Arnalich et al., 1994; Nijhuis et al., 1994; Born et al., 1995). IL-4 is as anti-inflammatory 
cytokine released from Th2 cells. It has pleiotropic effects on the secretion of other cytokines. 
For example, IL-4 was found to attenuate the secretion of IL-6, TNF-α and IL-1-β.  Hence, the 
reduction of IL-1-β, TNF-α and IL-6 in old secretomes could result from the inhibitory effect of 
IL-4 (Nolan et al., 2005; Te Velde et al., 1990; Zhou et al., 1994). 
Age-related increase in IL-8 production was also observed. This finding is in agreement with a 
study that found elevated expression of IL-8 by stimulated lymphocytes of the elderly (Rink et 
al., 1998). Consistently, another study demonstrated detection of elevated level of pro-
inflammatory IL-8 in plasma of aged individuals (Podkowka et al., 2001). 
Altered production in IL-18, MIP-a, SDF, IP-10 and GM-CSF were also observed in secretomes 
of activated young and old secretomes. Albeit the changes in expression of these cytokines were 
not statistically significant, but they may exert some effects in combination with each or other 
cytokines, although this cannot be confirmed from the present studies. 
 
IL-18 was higher in young compared to old secretomes. This factor is known as  an inducer for 
INF-y (Dinarello, 2006), however, in the current study, the elevated expression of INF-y in 
activated young secretomes  is unlikely to be induced by IL-18 since its concentration is slightly 
different in old compared to young secretomes. 
 Similarly, our data showed higher concentration of GM-CSF in activated young compared to 
activated old secretomes (Kim et al., 2011). Decline in GM-CSF levels with ageing affects the 
transmembrane signalling and function of immune cells, which in turn increase the susceptibility 
to infections (Seres et al., 1993). 
Low concentrations of SDF were detected in old secretomes compared to young. This candidate 
is involved in mediating migration of mesenchymal stromal cells in vivo and in vitro (Marquez-
Curtis and Janowska-Wieczorek, 2013); its influence is accelerated in combination with TNF-α 
(Fu et al., 2009). 
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 MIP-α is a chemokine which is associated with the development of several diseases such as 
rheumatoid arthritis and coronary heart disease. Our results showed higher levels of MIP-α in 
activated old secretome compared to activated young. Elevated expression of MIP-α in the 
supernatant of old lymphocytes caused an enhanced leukocyte chemotaxis response compared 
to old (Chen et al., 2003), suggesting that the age-related change in T-cell chemokine expression 
influences the functional consequence of immune cells. 
In our case, these factors acting separately or combined may have resulted in a comprise in the 
efficiency of the immune system and ultimately affect the capability of lymphocytes to produce 
cytokines as well as growth factors. 
 
5.6 CONCLUSION 
 
In conclusion, significantly lower concentrations of TNF-α, IL-1β, INF-y and IL-12 were 
detected in the secretome from old activated lymphocytes compared to young activated 
lymphocytes, and higher concentrations of IL-4, IL-5 and IL-8.  Old activated secretome had 
lower concentrations of SDF, IL-18 and GM-CSF compared to young activated secretome and 
lower concentrations of MIP-α.   
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6. THE EFFECT OF YOUNG AND OLD ACTIVATED CONDITIONED 
MEDIA ON C2C12 PROLIFERATION AND MIGRATION 
6.1 INTRODUCTION 
The progressive loss of skeletal muscle mass and strength characteristic of old age is associated 
with a failure to appropriately activate the satellite cells (Goldspink et al., 1994; Corsetti et al., 
2008), impaired proliferative capacity to produce enough myoblasts essential for muscle 
regeneration (Conboy et al., 2003) and also slowed rates of migration(Price et al., 2007). The 
failure to activate and proliferate satellite cells in older age is not necessarily related only to 
intrinsic deficiencies, but the microenvironment is also implicated (Dumke and Lees, 2011; 
Barberi et al., 2013). For example, skeletal muscle grafted from a young rat and transplanted 
into an old host showed impaired regeneration, but conversely muscle tissue grafted from an old 
rat showed extensive regeneration after transplantation into a young host(Carlson and  Faulkner, 
1989). In a Heterochronic Parabiosis model, skeletal muscles of older mice regenerated after the 
circulation was shared with younger mice (Conboy et al., 2005). In addition, young satellite cells 
cultured with serum from old mice showed impaired proliferation, while old satellite cells 
cultured with young plasma proliferated normally (Conboy et al., 2005). These findings suggest 
that circulating factors, inherent in aging, negatively impact satellite cell activation and muscle 
regeneration. In Chapter 3, the results show that the proteins secreted by young activated 
lymphocytes elicit marked regulatory effects on skeletal muscle proliferation and differentiation; 
enhancing the former and postponing the latter (Al-Shanti et al., 2014). In addition, the results 
of the previous chapters show that activated lymphocytes from young donors show differences 
from old donors in CD25, amphiregulin and FoxP3 expression, and also in their cytokines and 
IGF-1secretion.  Therefore, in this chapter, the secretome from freshly isolated peripheral blood 
mononuclear cells (PBMC) derived from young and older men was examined for their effects 
on the rates of proliferation, differentiation, and migration of myoblasts.  
In this study, lymphocytes were isolated from the fresh blood of young (n=20, aged 21±3 
years)and old (n=18, aged 81±3 years) men. After 4 days of activation and prior to C2C12 
treatment with young and old secretome, lymphocytes from both groups were counted and the 
protein concentration for young and old secretomes were estimated.  The un-pooled harvested 
young and old secretomes were used to prepare conditioned media(CM1-CM3) for C2C12 
experimentation. The C2C12 cells were cultured with differentiated media (DM) containing 
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serum obtained from young volunteers (n=7, aged 18-25 years) and old volunteers (n=7, aged 
78-85 years). Conventional DM supplemented with horse serum was set as control for C2C12 
differentiation. The morphological changes, differentiation parameters and migration for young 
and old CM- treated myoblasts were determined. All the results in this chapter were published 
in Physiological Reports (Al-Dabbagh et al., 2015). 
6.2 AIMS, HYPOTHESIS AND OBJECTIVES 
The aims of this part of the research were to establish whether age –related changes in cytokines 
and growth factors released by lymphocytes affect C2C12 proliferation, differentiation and/or 
migration. The objectives in this chapter were firstly; to compare the effect of young and old 
conditioned media, which was prepared from activated young and old secretomes, on C2C12 
proliferation and migration. Secondly, to compare the ability of myoblasts to terminally 
differentiate in the presence of 2% of either young or old human serum and the conventional 
DM. 
The hypothesis was that conditioned media prepared from lymphocytes isolated from young 
adults would improve proliferation and migration of C2C12 cells, while the effects of 
lymphocytes from older adults would attenuate proliferation and migration. Similarly, the age 
of human serum donors would have a different effect on the differentiation of C2C12 compared 
to horse serum. 
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6.3 METHODS 
6.3.1 ISOLATION OF LYMPHOCYTES FROM FRESH BLOOD SAMPLES 
Lymphocytes were isolated from fresh blood samples obtained from healthy volunteers (n=20, 
3 female and 17 male, aged 18-25years) and healthy old participants (n=18, 2 female and 16 
male, aged 78-85 years). Lymphocytes were isolated using Ficoll–Paque PLUS (as mentioned 
in 2.4.1). Prior to counting and culturing the lymphocytes, macrophages were depleted (as 
mentioned in 3.3.2). Cells were cultured at 37°C, 5% CO2 for 4 days (Al-Shanti et al., 2014) in 
supplemented RPMI- 1640 in the absence or presence of 5µg/ml anti-CD28.  Following 4 days 
of activation, lymphocytes obtained from young and old participants were counted by 
haemocytometer. In all the experiments, un-pooled secretomes were applied for conditioned 
media preparations.   
 
6.3.2 RECOVERY OF SECRETED CYTOKINES 
The secretome was harvested for each treatment group separately (activated and non-activated; 
young and elderly) filtered and purified using an Ultracel-3 membrane tube. The method is 
detailed in 3.3.6. The harvested secretomes were assessed for protein concentration (as described 
in 2.10) and equal concentrations were used in all the following experiments. In all experiments 
un-pooled secretomes were applied for conditioned media preparations.   
 
6.3.3 CONDITIONED MEDIA (CM) PREPARATION AND C2C12 TREATMENT 
Using the methods described in section 3.3.6, four different CMs were prepared from 
 young and old secretomes. These were as follows: CM1 young and old (test treatment), CM2 
young and old (negative control); CM3 boiled young and old and CM4 (negative controls). 
C2C12 myoblasts were maintained by growing cells in (GM) as described in 2.2.1.1 and treated 
with CMs as described in 2.4.3. 
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6.3.4 MORPHOLOGICAL DIFFERENTIATION AND QUANTIFICATION OF THE 
PROLIFERATION AND DIFFERENTIATION PARAMETERS. 
After 4 days of CMs treatment, C2C12 cultures were stained and incubated with Texas Red®-
X Phalloidin, Anti-Myosin Heavy Chain (MyHC) Alexa Fluor® 488 and DAPI nuclear 
counterstain solution as described in 2.8. The parameters of differentiation were assessed using 
ImageJ software (Schneider, Rasband, Eliceiri, et al., 2012) to evaluate the morphometric 
parameters for myotube development as described in 2.8. The differentiation parameters 
included: fusion index% (FI %), the total myotube area% (MA %), (Ricotti et al., 2011; Ren et 
al., 2008) and the aspect ratio (AR) (Grubiši et al., 2014).Ten random microscopic fields were 
scanned for each parameter at 10x magnification.  
 
6.3.5 CELL CYCLE ANALYSIS 
After 4 days of CMs treatment, C2C12 cells were collected for analysis by flow cytometry. The 
method was discussed in section 2.6.4.  
6.3.6 MIGRATION STUDY 
 
Migration study was undertaken as described in section 2.7. 
 
6.3.7 QUANTIFICATION OF DIFFRENTIATION PARAMETERS OF C2C12 
CULTURED IN DM SUPPLEMENTED WITH YOUNG AND OLD HUMAN SERUM 
Human sera were separated from fresh blood samples from young volunteers (n=7, male, 
aged20-28 years) and old volunteers (n=7, male, aged 78±81 years) as described in 2.5. Two 
types of DM were prepared ;Young human sera DM (DMEM), supplemented with  1% L-
glutamate and 1% 10000U (Penicillin/Streptomycin) and 2% heat inactivated (hi)  young human 
serum; and old human serum DM (DMEM) media supplemented with  1% L-glutamate and 1% 
of 10000U (Penicillin/Streptomycin) and 2%  hi old human serum. In all experiments were 
devised using unpooled sera to prepare DM. 
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6.3.8 MORPHOLOGCAL ASSESSMENT HUMAN SERA CELL CULTURE 
Cells were grown in pre-gelatinised 12 well- plate in GM until confluency of 70-80% was 
attained. Following 24 hours, cells were washed with PBS and young and old human sera DM 
was added to cell monolayers and incubated for 5 days in a humidified incubator at 37 °C and 
5% CO2. Conventional DM was also set as a control. Media was refreshed at day 3. Cells were 
stained with (MyHC) Alexa Fluor® 488 and DAPI nuclear counterstain as described in 2.2.4. 
The morphological differentiation parameters of myotubes including FI % (%Fusion Index), 
Aspect Ratio (AR) and Myotube Area% (MA %) were calculated using image J as described in 
2.8.  
6.3.9 STATISTICAL ANALYSIS 
 
One-way ANOVA was used to compare effects between all the experimental conditions 
followed by Bonferroni post test analysis. Results were presented as mean ± standard deviation 
(±SD). Analyses were carried out using GraphPad and significance accepted   as p<0.05 and 
marked with * where p<0.001 marked with **, and p<0.0001 denotes with ***. The percentages 
of  CV were determined for repeated independent experiments by dividing standard deviation 
by the mean for each group of treated cells .  
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6.4 RESULTS 
6.4.1 MOPHOLOGICAL DIFFERENCES IN THE C2C12 MYOBLASTS TREAED 
WITH CMs OF YOUNG AND OLD SECRETOME 
To evaluate the degree of differentiation and proliferation, immunofluorescence of a Texas 
Red®-X Phalloidin (Figure 6.1 ) and a high affinity Alexa Fluor-488 MyHC and DAPI nuclear 
counterstain were  performed (Figure 6.2). 
 Analysis of differentiation parameters FI%, MA% and AR, (Figure 6.3) showed that Young 
CM1-treated myoblasts exhibited reduced differentiation and extended proliferation, while in 
Old CM1-treated myoblasts the majority of cells exhibited myotube formation, thus confirming 
data above. This was evident as lower FI% in Young compared to Old CM1 (5±0.7% vs 
14.7±1.6%; respectively. p<0.001.) and few myotubes as shown by very low %MA in Young 
compared to Old (2.4±0.9% vs 12±0.8%; respectively, p<0.001). The AR was significantly 
higher for myotubes in Old CM1 compared with Young CM1 (13.3±1.3, 2.8±8.7, respectively; 
p<0.05). 
There was no significant difference in % FI, %MA and AR for the control conditions of Young 
and Old CM2 and CM3 and CM4 (24±3.6, 34±8 vs 29±4, 32±2.5 vs 41±2, respectively; 
p>0.05),(15.6±6, 18±2 vs 25±2, 25±3 vs 15±3, respectively; p>0.05) and (17±4, 15±1 vs 16±3, 
15±3 vs 14±3; respectively; p>0.05). 
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Figure 6.1: Representative images of C2C12 cells   following 4 days incubation with CMs. 
C2C12 cell cultures stained with Texas Red®-X Phalloidin and DAPI (blue) nuclear counterstain. Young 
CM1-treated myoblasts exhibited an extended proliferation (upper left panel), while the majority of Old 
CM1-treated myoblasts exhibited differentiation to myotubes formation (upper right panel). All negative 
controls develop myoblasts fusion into myotubes following 4 days of incubation. Images were obtained 
by a Leica microscope at x10 Mag. Scale bar=75µm. 
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Figure 6.2: Immunofluorescence analysis of skeletal myosin heavy chain (MHC). 
Representative images of C2C12 after 4 days of CMs treatment (right panel) and C2C12 stained 
immunofluorescence of a high-affinity MHC (marker of differentiation) heavy-chain Alexa Fluor-488-
MyHC (green) and DAPI (blue) nuclear counterstain (left panel). CM2, CM3 and CM4 develop 
myoblasts fusion into myotubes following 4 days of incubation. Images were taken from random fields 
by Leica DMI6000B microscope at x10Mag. Scale bar: 75µm. 
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Figure 6.3: Differentiation parameters analysis of young and old secretome treated- 
myoblasts. %FI: Young CM1-treated myoblasts exhibited less differentiation and an extended 
proliferation thus lower FI%, lower fused nuclei and extended mononuclear cells compared to Old CM1-
treated myoblasts that  exhibited differentiation to myotubes formation and significantly higher fused 
nuclei per myotubes (>2 nuclei),(p<0.001). AR: The aspect ratio (AR) of myotubes in cells treated with 
old CM was higher compared to cells cultured in young CM, (p<0.05). MA%:  The total area of myotubes 
over the entire image in cells cultured with young CM1 was significantly lower compared to cells treated 
with Old CM1, (p<0.0001). Ten random microscopic fields were scanned for each parameter at 10x 
magnification. The data represent the means ±SD (n=20) from young and (n=17) from old in duplicates. 
CM1: Activated conditioned media, CM2: Non-activated conditioned media,CM3: Boiled activated 
conditioned media and CM4 : no lymphocyte conditioned media. 
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6.4.2 DIFFERENTIATION OF C2C12 FOLLOWING YOUNG CM1 WITHDRAWAL 
Differentiation is a key step during myogenesis. Young CM1 was withdrawn following two days 
of culture and a standard differentiation media was applied for the subsequent five days. The 
myoblasts differentiated by aligning and fusing to form myotubes (Figure 6.4). 
 
 
Figure 6.4: Differentiation of C2C12 following young CM1 withdrawal. Shifting CM to DM 
after 2 days incubation of myoblasts cultured in young CM1. The proliferative myoblasts form 
myotubes following 3 days of incubation with DM. Scale bar: 100µm. 
 
 
6.4.3 CELL CYCLE ANALYSIS 
Analysis of myoblast cell cycle progression showed that %S-phase of Young CM1-treated cells 
was significantly higher than Old CM1-treated cells (59.8±5.7% vs 23±1.3%, respectively, 
p<0.001) and higher than all other control conditions CM2, CM3, CM4 (60±5 vs 24.6±8, 26.7±5, 
26±4, 20±7 and 23.7±3 respectively; p>0.01)( Figure 6.5 A and B).  There were no significant 
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differences among Young and Old CM2, CM3 or CM4 (24.6±8 vs 26.7±5 vs 26 ±4, vs 20±7 vs 
23.7±3 respectively; p >0.05)( Figure 6.5 A and B). 
A) 
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B) 
 
Figure 6.5:%S phases of myoblasts treated in conditioned media CM1-4 after 4 days. A) 
Representative photographs of C2C12 cell cycle analysis. B) The graph represents % S phases of C2C12 
treated in CMs. Young CM1 treated myoblast showed higher %S phase compared to Old CM1 treated 
myoblasts, P<0.001. All controls of our study were not significantly different, p>0.05. The graph 
represents four independent experiments. The results represent means ±SD (n=20) from young and 
(n=17) from old.: Activated conditioned media, CM2: Non-activated conditioned media, CM3: Boiled 
activated conditioned media and CM4: no lymphocytes conditioned media. % CV: for CM1 young ;9%, 
CM1 old; 40%, CM2 young ;34%, CM2 old; 19%, CM3 young; 23%, CM3old ;28% and CM4 ;14%. 
CM1 
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6.4.4. MIGRATION STUDY 
Using a scratch assay, migration was assessed 18 hrs after the cells were removed from a small 
section in the middle of the well (artificial ‘injury’ model). Young CM1 induced significant 
myoblast migration that was almost 4-fold higher than the migration that occurred in the Old 
CM1 condition (73.3±6.02 cells vs 20.7±2.5 cells, respectively P<0.001; Figure 6.7). There were 
no significant differences between the Young and Old CM2, CM3 and CM4 (24.6±6 vs 26 ±5 
vs 20±7 vs 23 ±3 respectively; p>0.05; Figure 6.7). 
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Figure 6.6: Representative images of wound healing assay for C2C12 treated with young 
and old secretomes. A phase contract images to compare the effect of young and old secretomes 
on C2C12 myoblast migration to the wound area after 18 hours. Scale bar=100µm. 
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Figure 6.7: Cell count analysis for wound healing assays of C2C12 treated with young and 
old secretomes.  A quantitative analysis of the invaded area was obtained was 4 folds higher in the 
presence of young secretome vs old, p<0.0001. All CMs (CM2-4) were not significantly different, 
p>0.05. The results represent the means of ±SD (n=5) of young and (n=5) of old in triplicates CM1: 
Activated conditioned media, CM2: Non-activated conditioned media, CM3: Boiled activated 
conditioned media and CM4: no lymphocytes conditioned media. . %CV for CM1 young ; 6%, CM1 old; 
9%, CM2 young ;12%, CM2 old 20%, CM3 young ;15%, CM3 old ;25% and CM4 ; 15%. 
 
 
6.4.5 DIFFRENTIATION PARAMETERS OF C2C12 CULTURED IN DM 
SUPPLIMENTED WITH YOUNG AND OLD HUMAN SERA 
The evaluation of   differentiation degree was performed. FI%, AR and MA% were calculated 
for myoblasts stained with a high affinity Alexa Fluor-488 MyHC and DAPI nuclear 
counterstain. The results showed that following 5 days incubation, Young DM, old DM and 
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conventional DM treated myoblasts exhibited extended differentiation; higher C2C12 expressed 
MHC protein (Figure 6.8 A). This was evident as AR was not significantly different among 
Young DM, Old DM and conventional DM treatments (16.3±1.1, 13.7±2 and 15 ±1, p >0.05, 
Figure 6.8 B). MA% of Old DM was slightly lower compared to Young DM and conventional 
DM but statistically not significant (17.4 ±3% vs 24.5±1.9% and 25.5±2%, p>0.05, Figure 6.8 
B). However, as it is shown in figure 4.6,  FI% of  Old  DM treated cells was significantly lower 
compared to   young and conventional DM (15±2% vs 28±2%, p<0.05  and vs  37±2% 
respectively, p>0.001, Figure 6.8 B).  
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A) 
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B) 
 
Figure 6.8: Immunofluorescence analysis of skeletal myosin heavy chain (MHC). A) C2C12 
myoblasts treated with DM composed 2 %Young sera %( upper panel) or 2% old serum (middle panel) 
or 2% horse serum (lower panel). B) Differentiation parameters for myotubes development following 5 
days of incubation with young, old and horse DM.  C2C12 myoblasts  were stained with the  high-affinity 
MHC (marker of differentiation) -heavy-chain Alexa Fluor-488-MyHC (green) and DAPI (blue) nuclear 
counterstain. Images were taken from random fields by a Leica DMI6000B microscope at x10Mag. The 
data represents the means of ±SD of young men (n=7) and old men (n=7) in duplicates . 
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6.5 DISSCUSSION 
6.5.1 MOPHOLOGICAL DIFFERENCES IN C2C12 MYOBLASTS TREAED WITH 
CM1 OF YOUNG AND OLD 
The C2C12 cells treated with young CM1 were found to show markedly increased proliferation 
(as assessed by FLOW cytometry) whereas control treatments CM2-4, regardless of their 
formulation, displayed basal proliferation. Under these control treatments, C2C12 myoblasts 
maintained their ability to align, fuse and form elongated multi-nucleated myotubes, as occurs 
normally under low serum culture conditions (Blau et al., 1983) and was evident in myoblasts 
treated with old CM1 and all control conditions, regardless of the age of the donors. 
In agreement with the above findings, anti-CD3- activated splenic T- cells significantly 
enhanced the proliferation of young satellite cells isolated from the gastrocnemius and plantaris 
compared to activated T lymphocytes from 32-mo-old rats (Dumke and Lees, 2011a). Similar 
to these findings, Mildner et al., (2013) demonstrated that the secretome from human 
mononuclear cells accelerated proliferation and wound healing of skin post injury (Mildner et 
al., 2013). Likewise, in another in vivo study conducted by Carlson & Faulkner (Carlson and  
Faulkner, 1989) old rat muscle transplanted to young rat exhibited a high potential for 
regenerative capacity, while young muscle transplanted into older rats did not regenerate due to 
inadequate proliferation signals. Consistently, the results of a study by Conboy et al. indicated 
that old progenitor satellite cells were activated upon exposure to the young secretome and in 
response to the secretome expressed high levels of Notch signalling proteins (Conboy et al., 
2005) 
This cross-talk between immune cells and muscle is biologically relevant, as cells in vivoare not 
stimulated with one cytokine in isolation, rather a cytokine cocktail instructs gene expression 
through the integration of multiple signalling pathways.  
 
 
6.5.2 DIFFERENTIATION OF C2C12 FOLLOWING YOUNG CM1 WITHDRAWAL 
 
Having observed increased proliferation rate in young CM1 treated myoblasts, it was 
investigated whether young CM1 treatment blocked differentiation. Muscle regeneration starts 
with activation of satellite cells which undergo several rounds of proliferation before they exit 
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the cell cycle to begin differentiation. Thus, differentiation is a necessary step in the regenerative 
process. Therefore, we sought to confirm that the Young CM1, which increased the rate of 
proliferation with minimal differentiation, did not terminally block differentiation in the 
myoblasts. Exchanging the Young CM1 for the usual differentiation media restored the ability 
of the C2C12 cells to differentiate, fuse and form myotubes. 
6.5.3 MIGRATION STUDY 
 
Migration is a critical step for successful muscle regeneration. Defective migration of 
transplanted myoblasts is one contributing factor that leads to ineffective therapy for muscular 
dystrophy (Price et al., 2007). In order to verify the effect of Young and Old CM1 on wound 
healing, C2C12 myoblasts were scratched and cultured 18 hours in Young, Old CM1 and control 
treatments. 
Our data showed that Young CM1 induced an approximate 4-fold higher migration capacity of 
myoblasts compared to Old CM1 and control treatments (CM2 CM3 and CM4). These results 
were strongly supported by a study (Collins‐Hooper et al., 2012),which suggested that satellite 
cells isolated from the  extensor digitorum longus of young mice migrate significantly faster 
than old satellite cells.  Moreover, Dumke and Lees (Dumke and Lees, 2011) reported that 
activated T-cells improved the regenerative capacity of satellite cells isolated from young rats 
by enhancing their migration capacity when compared to those isolated from aged animals. 
Taken together, these findings show intrinsic differences in key regulatory factors between 
young and old activated lymphocyte secretomes that regulate proliferative, migratory and 
ultimately the regenerative capacity of skeletal muscle satellite cells. Although we have not 
directly identified which factors might be principally involved in the effects shown here, the 
results from the previous chapter do provide some indications. We identified some potential 
candidates (cytokines and IGF-1) in the lymphocytes secretome. IGF-I is secreted by skeletal 
muscles and plays a key role in their growth, differentiation and repair. Previous reports showed 
that IGF-I is also secreted by activated T-lymphocytes (Leng et al., 2009; Merchav et al., 1988; 
Porras et al., 1998). Our results showed 30% higher IGF-I levels secreted by young activated 
lymphocytes compared to old when measured directly from the secretomes. However, the 
myoblasts were not exposed directly to these very high IGF-I concentrations, since our 
experimental approach used the secretomes to prepare the conditioned media, which reduced 
concentrations of IGF-I by around 20–fold. IGF -I is the only growth factor known to both 
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accelerate skeletal muscle proliferation (Machida and Booth, 2004) and differentiation (Musarò 
et al., 2001; Duan et al., 2010). It also limits fibrosis in injured muscle, potentiates the healing 
process by increasing the expression of myo-fibroblasts (Musaro et al., 2001; Werner and Grose, 
2003) and prevents protein degradation (Karalaki et al., 2009). High IGF-I concentrations in 
vitro (50-200ng/ml) favour proliferation, whereas lower IGF-I concentrations (5-10ng/ml) 
promote differentiation (Sharon A. Coolican et al., 1997). Therefore, it is possible that the 
enhanced proliferation of myoblasts  exposed  to  the  young  CM1  was  in  part  accounted  for  
by  higher  IGF-I concentrations (Foulstone et al., 2001).  
 
The multiplex cytokine results presented in a previous chapter showed that IL-1β, TNF-α, IL-
12, and IFN-γ were significantly higher in young activated lymphocytes compared to old, while 
IL-4, IL-5 and IL-8 were lower in young compared with old. Previous work demonstrated that 
TNF-α and IL-6 were decreased in old participants compared to young men following in vitro 
LPS stimulation (Bruunsgaard et al., 1999). TNF-α in combination with IL-6 is essential to 
maintain skeletal muscle strength and strongly associated with muscle repair after injury 
(Warren et al., 2002). TNF-α by activation of NFƙ-β, a transcription factor in the cytosol, induces 
the expression of IL-6 leading to increased myoblasts proliferation and inhibits myogenic 
differentiation in vitro (Muñoz‐Cánoves et al., 2013). TNF-α promotes myoblast proliferation 
directly and indirectly through IL-1β (Tidball and Villalta, 2010; Li, 2003) and endorses 
migration of mesoangioblasts, a subgroup of stem cells able to differentiate to skeletal muscle 
cells (Galvez et al., 2006). It is also essential for activation of P38 signalling in muscle 
regeneration (Chen et al., 2005). Recently, it was reported that pro-inflammatory cytokines (IL-
6 and IL-1β) induce proliferation of C2C12 (Otis et al., 2014).  
A study reported that INF-γ and IL-12 are potential candidates due to their anti-fibrotic effects 
(Mann et al., 2011). It is well documented that INF-γ regulates myogenesis and has potential 
mitogenic effects on C2C12 (Londhe and Davie, 2011; Villalta et al., 2011) as well as 
accelerating wound healing in skeletal muscle (De Rosa et al., 2004) and combating fibrosis 
(Cheng et al., 2008).Interestingly, this also supports our migration study findings, which 
demonstrated that the number of migrating cells to wound area was significantly higher in 
C2C12 treated with young secretome compared to old.  
The results in previous chapter showed higher concentration of IL-4 in old secretome compared 
to young. It has been reported that IL-4 promotes myoblast fusion and increases myotubes size 
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(Horsley et al., 2003), which support the progression towards differentiation and myotube 
formation in old-CM1 treated myoblasts.  
 
 
6.5.4 CULTURING CELLS IN DM SUPPLEMENTED WITH YOUNG OR OLD 
HUMAN SERUM 
The main finding of this part of the study was that culturing C2C12 in DM containing young 
sera or old sera resulted in no difference in myotubes development. Generally, the three types 
of serum conditions induced strong differentiation, a robust MHC expression and a higher 
differentiation index including AR and MA%.  Only FI% of nuclei inside myosin heavy chain 
myotubes was significantly lower in C2C12- treated old sera compared to young sera. These 
results are in agreement with a previous study, which demonstrated that, young and old serum 
equally sustain differentiation of human myoblasts extracted from muscle biopsy (George et al., 
2010). However, our findings showing no age- related impairment in C2C12 myoblasts  are in 
contrast with the results obtained from studies in mice (Carlson and Conboy, 2007;  Brack et al., 
2007) and humans (Carlson et al., 2009) where it was found that  serum obtained from old 
participants  inhibits the ability of satellite cells from young and old donors to express myogenic 
factors, Pax 7, MRF5, Myo D and desmin. The results of this experiment were not expected and 
consistent with our findings which showed that young secretome was a potent inducer for C2C12 
proliferation compared to old secretome. However, it is possible that the small quantities of 
serum (2%) from young and old donors did not contain sufficient concentrations of effectors to 
impact on degree of differentiation. Also, it is important to note that the heat inactivation process 
could destroy heat-labile growth factors and cytokines eliminating any differences between 
young and old serum.    
 
6.6 CONCLUSION 
 
The conditioned media from old activated lymphocytes had no effect on proliferation and 
migration and instead C2C12 showed a high degree of differentiation, whereas  conditioned 
media from young activated lymphocytes enhanced proliferation and migration of C2C12 
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myoblasts. Young secretome enhanced C2C12 proliferation and differentiation was restored 
successfully upon replacement of CM1 with DM.  Both DM supplemented with young and old 
hi human serum was successfully able to induce differentiation and myotubes development of 
C2C12 that were comparable to the conventional differentiation media. 
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CHAPTER 7 
 
 
 
 
 
 
 
 
 
 
 
 146 
7. C2C12: CELLULAR AND MOLECULAR ADAPTATION OF C2C12 
CELLSTREATED WITH YOUNG AND OLD CONDITIONED MEDIA 
7.1 INTRODUCTION 
The findings from the study presented in the previous chapter demonstrated that young 
activated-lymphocyte secretomes stimulate proliferation and migration of C2C12 myoblasts, 
while old activated lymphocyte secretomes had no discernible effects on C2C12 proliferation 
and migration and thus behaved similar to the various control conditions (which included non-
activated lymphocyte secretomes and denatured secretomes). These findings suggest that 
factors released from the activated lymphocytes of young adults can initiate signalling within 
C2C12 cells to up regulate proliferation and migration. . The results in chapter 5 showed that 
cytokines, IGF-1 and amphiregulin were highly expressed in the secretome of young activated 
lymphocytes but it is not clear which of these factors are directly involved in sustained 
proliferation and migration of young CM1- treated C2C12. 
In this chapter the status of C2C12 anabolic signalling pathways were assessed after incubation 
in the presence of the young and old activated lymphocyte secretomes (CM1). 
Since it is not yet known which signalling pathways within C2C12 cells might be affected by 
the lymphocyte secretome, several candidate molecules that regulate anabolic processes were 
assessed. This included the C2C12 cell mRNA expression of myogenic factors (MyoD and 
Myogenin) as well as the phosphorylated anabolic signalling proteins Akt/mTOR and 
Mapk/Erk. The protein kinase concentrations were assessed at several time points in 
preliminary experiments to identify an ‘optimal’ time-point in order to intervene by blocking 
selected signalling pathways. The Mapk inhibitor‘UO126’ was applied at different 
concentrations to block the Mapk/Erk pathway in C2C12 cells. The C2C12 IGF-IR receptor 
was also blocked and subsequent analyses of the cell cycle as well as Akt/mTOR levels were 
determined. Finally, in an effort to identify novel molecular regulators of the lymphocyte 
secretome-C2C12 interactions, a proteomics study was undertaken. 
The blood samples obtained, for conditioned media preparations, to perform the experiments 
in this chapter were from young, n=15, male (aged 18-30 years) and old (n=15, male, aged 73-
82 years) participants 
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7.2 AIMS AND OBJECTIVES 
In these studies, the aim was to identify whether the C2C12 myogenic factors MRFs (Myogenin 
and MyoD) and phosphorylated proteins (Akt/mTOR and MAPK/Erk) were involved in the 
enhanced proliferation and migration of C2C12 cells after incubation with the young activated 
lymphocyte secretome. The objectives were: 1) to compare C2C12 expression of Myogenin 
and MyoD after incubation with young CM1 vs old CM1. 2) to investigate the phosphorylation 
status of Akt/mTOR and Mapk/Erk molecules, as potential regulators of the C2C12 
proliferation and migration, after incubation with young CM1 vs old CM1. 3) to establish 
whether the enhanced proliferation  of C2C12 cells observed after incubation with the young 
CM1 could be attenuated by blocking key anabolic signalling pathways in the C2C12 cells. 
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7.3 METHODS 
7.3.1 CULTURE OF C2C12 MYOBLASTS AND TREATMENT WITH CM1-4 
C2C12 myoblasts were maintained by growing cells in the usual growth media (GM) as 
described in 2.2.1.1 before culturing them with young or old CM1-4 as described in 2.4. CM1: 
Activated conditioned media, CM2: Non-activated conditioned media, CM3: Boiled activated 
conditioned media and CM4: no lymphocytes conditioned media. CMs-treated cells were incubated 
for 4 days in a humidified atmosphere using 5% CO2 at 37°C. 
 
7.3.2 RNA ISOLATION AND REAL-TIME PCR 
RNA extraction and TaqMan ®PCR methods were performed as described in sections 2.8 and 
2.9 respectively. The following predesigned primer sets were used in the TaqMan® detection 
method: GAPDH (mm99999915_m1), MyoD (mm00440387_m1) and Myogenin 
(mm00446194_m1). GAPDH was used as a reference gene for C2C12 myoblasts (Langen et 
al., 2004; Amabile et al., 2009) and performed in parallel with myogenic target genes.  All 
reactions were performed in triplicate. 
7.3.3 OPTIMAL TIME POINT TO ACTIVATE PHOSPHO-PROTEIN CASCADES 
 In order to determine the optimal time point for signalling proteins induction in response to 
CM1-2 and 4, C2C12 myoblasts were treated with Young CMs at 4 times points (5, 15, 25, and 
60) min. Cell lysates were harvested for proteins estimation as described in section 2.10. The 
levels of Akt/mTOR /IRS-1 were determined using magnetic beads panel as described in 
2.12.1. The results were analysed using a Luminex 200TM. 
7.3.4DETERMINATION OF MYOBLAST LEVELS OF MAPK/ERK AND 
AKT/mTOR AFTER TREATMENT WITH YOUNG AND OLD CONDITIONED 
MEDIA 
 
The measurement of MAPK/ERK and Akt/mTOR in the following experiments was conducted 
according to the optimal time point obtained. The MAPk inhibitor, UO126 was applied to 
Young CM1 at different concentrations (3, 5, 8 and 10µM). CM1-treated C2C12 cells (without 
UO126) were set as control conditions. For each experimental condition (3, 5, 8 and 10µM of 
UO126), the levels of pAkt and p-mTOR were determined following 25 min treatment using a 
magnetic beads panel and analysed by a Luminex 200TM plate reader as described in section 
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2.12.1. Phase contrast images of the C2C12 cultures were taken using a Leica DMI 6000B 
microscope after treatment with CM1+UO126 for 4 days at 37°C in a humidified atmosphere 
with 5% CO2.  
 
7.3.5 MULTIPLEX/IMMUNOASSAY PROTOCOL 
The assays were conducted using the Luminex 200 system (Bio-Plex) running the xPONENT 
analytical software, the Milliplex MAP Kits of MAPK/ SPAK and Akt/mTOR signalling 
magnetic beads panel  (EMD Millipore). The samples were tested as described in 2.12.1.  
 
7.3.6 INVESTIGATING THE EFFECT OF IGF-1 ON C2C12 PROLIFERATION. 
C2C12 treatment with IGF-1R inhibitor OSI-906 (Linsitinib) 
C2C12 myoblasts were maintained by growing the cells in growth media (GM) as described in 
2.2.1.1.  CM1 was prepared as described in 2.4.2 and 2.4.3. In order to examine the role of 
IGF-1 on C2C12 proliferation, OSI-906 was reconstituted (as described in 2.2.1.4) and diluted 
with DMEM to final concentrations of 0.5µM and 0.8µM.  Cell monolayers were washed with 
PBS and treated with the reconstituted inhibitor for 30 min in a humidified atmosphere of 5% 
CO2 at 37⁰C (Philippou et al., 2009). Following OSI-906 treatment, C2C12 cells were washed 
with PBS and CM1 or DM were added.  C2C12 cells were incubated for 3 days in a humidified 
atmosphere of 5% CO2 at 37⁰C.  Phase contrast images were taken by a Leica microscope, 
cells were counted (as described in 2.3) and cell cycle analysis was performed (as described in 
2.6.4). Protein estimation of cell lysate was performed prior to assessment of activated Akt and 
mTOR levels   by multiplex immunoassay as   described in 2.12.1.  
7.4 STATISTICAL ANALYSIS 
Statistical analysis of data was undertaken using GraphPad Prism. One-way ANOVA was used 
to compare the effects between all the experimental conditions followed by Benferroni post-
test analysis. Two-way ANOVA was performed to investigate the effects of time points and 
the experimental conditions on phosphorylated protein levels, followed by Benferroni post-test 
analysis. Results were presented as mean ±SD. All values of p< 0.05 were considered 
statistically significant. The percentages of CV were determined for repeated independent 
experiments by dividing standard deviation by the mean for each group of treated cells .  
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7.5 RESULTS 
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7.5.1 GENE EXPRESSION ANALYSIS OF MYOD AND MYOGENIN FOR YOUNG 
AND OLD CM1-4- TREATED MYOBLASTS. 
To investigate the effect of CMs on muscle specific regulatory factors (MyoD and Myogenin), 
RT-PCR was performed. The expression level of MyoD and Myogenin in myoblasts treated 
with (CM2-4) was not significantly different (Figure 7.1 and 7.2). The levels of MyoD and 
Myogenin in C2C12-treated with Young CM1 were significantly lower by over 5% compared 
to CM2-4). The expression level of MyoD and Myogenin in cells treated with old CM1 was 
significantly lower compared to CM4 –treated cells.  Similarly, the gene expression of MyoD 
and Myogenin in C2C12 treated with Young CM1 was significantly lower compared to Old 
CM1- treated cells (0.46±0.12 and 0.34±0.05 vs 0.7±0.07 and 0.6±0.05, respectively p<0.05).  
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Figure 7.1: RT-PCR analysis of MyoD mRNA gene expression following 4 days of 
incubation with young and old CM1-4. C2C12 myoblasts were treated with CM1-4 for 96 hours 
before RNA collection. All values are represented as fold difference compared with the calibrator 
(CM4). None of the control conditions (CM2-4) were significantly different from CM4 (p>0.05). 
Expression of MyoD in Young CM1 treated myoblasts were significantly lower compared to Old CM1 
treated myoblasts (p<0.05).Expression level of MyoD in Old CM1 treated cells were significantly lower 
compared to CM4 control condition. Data represent the means ±SD (n=5) in triplicates of CM1: 
Activated conditioned media, CM2: Non-activated conditioned media, CM3: Boiled activated 
conditioned media, CM4: no lymphocytes conditioned media. % CV: for CM1 Young; 27%, CM1 Old 
;10%, CM2 Young; 10%, CM2 Old ; 21%, CM3 Young; 9% and CM3 Old;19% and CM4; 0%.  
 
 
 
 
 
 
 
Figure 7.2: RT-PCR analysis of Myogenin mRNA gene expression following 4 days of 
incubation with young and old CM1-4. C2C12 myoblasts were treated with CM1-4 for 96 hours 
before RNA collection. All values are represented as fold difference compared with the calibrator 
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(CM4). None of the control conditions (CM2-4) were significantly different from CM4 (p>0.05). 
Expression of  Myogenin in Young CM1 treated myoblasts were significantly lower compared to Old 
CM1 treated myoblasts (p<0.05).Expression level of Myogenin was in Old CM1 treated cells were 
significantly lower compared to CM4 control condition. Data represent the means ±SD (n=5) in 
triplicates of CM1: Activated conditioned media, CM2: Non-activated conditioned media, CM3: Boiled 
activated conditioned media and CM4: no lymphocytes conditioned media.  % CV for CM1 Young; 
10%, CM1 Old; 8%, CM2 Young; 8%, CM2 Old; 11%, CM3 Young; 22%, CM3 Old; 12% and CM4 
0%.  
 
 
 
7.5.2 OPTIMAL DURATION TIME TO ACTIVATE PHOSPHO-PROTEINS 
CASCADES 
 
Having established that myogenic factors were downregulated in CM1-treated C2C12 cells, 
the level of phosphorylated proteins MAPK1/ERK1/2 and Akt/mTOR were investigated 
because they have a known role in C2C12 proliferation and diffrentiation. Initial experiements 
were undertaken to establish the optimal activation time ofpAktby comparing effects at 5, 15, 
25 and 60min after treatment with Young CM1, CM2 and CM4. The results showed that the 
median of fluorescence intensity (MFI) of pAkt levels was significantly higher in myoblasts at 
25min after first exposure to young CM1and CM2 compared to time points 5, 15 and 60min. 
The 25 min time point also had higherMFI of pAkt after treatment withCM4 compared to 5min. 
Data are shown in Figure 7.3.  
The activation ofmTOR after exposure to CM2 and CM4 was significantly higher at 25min 
compared to 5 and 60 min. The mTOR levels in C2C12 cells after exposure to CM1 and CM2 
were similar at 25 min compared with 15 and 60 min. Data are shown in Figure 7.4. 
The MFI levels of phosphorylated IRS-1 were highest at 25min in CM1 and CM4-treated cells, 
while the 25 min and 60 min time points for CM2 were similar, and both were higher than time 
points 5 and 15 min. Data are shown in Figure 7.5.  
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Figure 7.3: MFI of pAkt levels in myoblasts treated with CM1, CM2 and CM4  at 5, 15, 
25 and 60 min. MFI levels of pAkt in response to CMs treatment were highest after  CM1 treatment 
at 25 min vs CM1 at 5 min ;(p<0.01,represented as α•) and in CM1 at 15 and 60 min, (p<0.05 , 
represented as αx ).There was a  significant increase in CM2 at 25min vs CM2 at 5 min; (p<0.0001, 
represented asβt)vs CM2 at 15(p<0.05, represented as β x), vs CM2 at 60min(p<0.01, represented as 
β•). The significant increase in CM4 at 25 min vs CM4 at 5min (p<0.01, is represented as y•). Data 
represent means ±SD (n=5) performed in duplicates. 
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Figure 7.4: MFI of mTOR levels in myoblasts treated with CM1, CM2 and CM4  at 5, 15, 
25 and  60 min. MFI levels of mTOR  in response to CMs treatment indicated a significant increase 
in CM2 at 25min vs CM1 at 5min (p<0.05). Similarly, CM4 had higher levels of mTOR at 25min vs 
60min (p<0.01). No significant difference was observed in CM1 over different time points (p>0.05). 
Data represent means ±SD (n=5) in duplicates. CM1: Activated conditioned media, CM2: Non-
activated conditioned media and CM4: no lymphocytes conditioned media 
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Figure 7.5: MFI of IRS-1  levels in myoblasts treated with CM1, CM2 and CM4  at 5, 15, 
25 and  60 min. MFI levels of IRS in response to CM1, CM2 and CM3 treatment indicated a 
significant increase in CM1 at 25min vs 5 min (p<0.01, represented as α•). Also the level of IRS-1 in 
CM1was significantly higher at 60 min vs 5 min (p<0.05, represented as αx). A significant increase was 
observed in CM2 at 25min vs 5 min (p<0.05, represented as β•). Also, the IRS-1 level in CM2 at 60min 
was significantly higher vs 5 min (p<0.05, represented βx). The IRS-1 level was significantly higher in 
CM4 at 25 min vs 5 min (p<0.001, represented as yt). A significant difference was observed in CM4 at 
15min compared to 60min (p<0.01, represented as y•). Significant difference in CM4 at 25 min vs 60 
min was observed (p<0.05, represented as yx). Data represent means ±SD (n=5) in duplicates .CM1: 
Activated conditioned media, CM2: Non-activated conditioned  media and CM4 : no lymphocytes 
conditioned media. 
 
7.5.3 MEK1/ERK 1/2 SIGNALLING PATHWAYS ARE INDUCED IN RESPONSE 
TO YOUNG CM1BUT EFFECTS ARE ATTENUATED IN RESPONSE TO OLD 
CM1 
 
Using the 25 min time point (identified above as the optimal time to measure signalling events), 
experiments were undertaken to examine the activation of MAPK/ERK1/2 and AKT/mTOR 
pathways after exposure to the various CMs from young and old.  
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The level of pMEK was significantly higher in Young CM1 compared to Old CM1(724.8±140  
vs 528±80; p<0.05) and was higher in Young CM1 compared to Young CM2 and CM4 
(724±140 vs 308±118; p<0.001 and  320±81, p<0.005, respectively). No significant difference 
was observed between theOld CM1, CM2, CM3 and CM4 (528±140 vs 311.8±98:p>0.05; 
255±67:p>0.05 and 320±81:p>0.05, respectively, Figure 7.7). 
Following the finding that 25min is the optimal timepoint  to trigger the signalling pathway, 
the level of MAPK/ERK  and AKT/mTOR were investigated. Our results showed that  the 
level of pMEK was significantly higher in Young CM1 compared to Old CM1( 724.8±140  vs 
528±80; p<0.05). Also, the MFI of MEK indicated a significant increase in Young CM1 
compared to CM2 and CM4 (724±140 vs 308±118; p<0.001 and  320±81, p<0.005 
respectively). No significant difference was observed among Old CM1 and CM2, CM3 and 
CM4 (528±140 vs 311.8±98;p>0.05, 255±67; p>0.05 and 320±81; p>0.05 
respectively)(Figure7.6). 
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Figure 7.6: MFI for MEK1 in CM1 Young and Old treated C2C12. Levels of MEK1 were 
significantly higher in Young CM1 vs Old CM1, CM2 and CM4; p<0.05, 0.001 and 0.01 respectively. 
Data represent means ±SD (n=5) in triplicates: young and O: old.CM1: Activated conditioned media, 
CM2: Non-activated conditioned media, CM3: Boiled activated conditioned media and CM4: no 
lymphocytes conditioned media. %CV for CM1(y); 19%, (o) 19%), CM2(y); 38%, (o); 31%, CM3(y); 
38%, (o); 26% and CM4; 25%.  
 
 
The MFI of Erk1/2 was significantly higher in Young CM1 compared to Old 
CM1(3368±1105vs1141±668; p<0.0001) and compared to all other conditions. The Old CM1 
was not significantly different compared to CM2-4 (1141±668 vs 1140±186, 933±510 and 
914±98; p>0.05 respectively Figure 7.7). 
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Figure 7.7: MFI levels for ERK1/2 in Young and OldCM1, CM2, CM3 and CM4- treated 
C2C12 myoblasts. A significant increase in ERK1/2 levels of Young CM1 vs Old CM1 and controls 
was found p<0.0001. No significant different in Old CM1 vs CM2-4; p<0.05 was found. Data represent 
means ±SD (n=5) in triplicates .Y: young and O: old.CM1: Activated conditioned media, CM2: Non-
activated conditioned media, CM3: Boiled activated conditioned media, CM4: no lymphocytes 
conditioned media. %CV for CM1 (y); 33%,(o); 58%, CM2(y);13%, (o)16%, CM3 Boiled(y); 48%, 
(o); 55% and CM4 11%.  
 
 
7.5.4. AKT/mTOR SIGNALLING PATHWAY IS LOWER IN RESPONSE TO 
YOUNG CM1 COMPARED WITH OLD CM1 
pAkt was significantly lower in Young CM1-treated cells compared to Old CM1-treated 
cells.However, no significant differences existed between the Young or Old CM1 compared to 
their corresponding CM2-4s (Figure 7.8). Similarly, the phosphorylated mTOR levels were 
lowerin Young CM1 compared to Old CM1. The Phosphorylated mTOR did not differ across 
the Young CM1-4, while the Old CM1 was significantly higher than the Old CM2 and CM3 
(Figure 7.9). 
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Figure 7.8: MFI of pAkt levels in Young and Old CM1, CM2, CM3 and CM4- treated 
C2C12 myoblasts. pAkt levels were significantly  higher in Old CM1 compared to Young CM; 
p<0.05.  Data represent means ±SD (n=4) in triplicates. : Young and O: old. CM1: Activated 
conditioned media, CM2: Non-activated conditioned media, CM3: Boiled activated conditioned media, 
CM4: no lymphocytes conditioned media. . % CV for CM1(y); 33%, (o); 58%, CM2(y); 13%, (o); 16%, 
CM3 Boiled (y); 48%, (o); 55% and CM4; 11%. . 
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Figure 7.9: MFI of mTOR level in Young and Old CM1-4-treated C2C12 myoblasts. A 
significant increase in mTOR levels was found in Old CM1 vs Young CM; p<0.001 and compared to 
Old CM3;p<0.01. Data represent means ±SD (n=4) in triplicate: Y:young and O: old.CM1: Activated 
conditioned media, CM2: Non-activated conditioned media,CM3: Boiled activated conditioned media, 
CM4 : no lymphocytes conditioned media. %CV for CM1(y);12%, (o);22%, CM2(y)37%, (o); 14%, 
CM3 Boiled (y)52%, (o);14% and CM4;10%..                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
 
 
7.5.5THE MAPK INHIBITOR UO126 ATTENUATES THE YOUNG CM1-INDUCED 
MYOBLAST PROLIFERATION. 
 
Initial trials to determine the optimum concentration of UO126 showed higher pAkt levels in 
C2C12cells treated with Young CM1+8µM UO126, compared with 3µM, 5µM and 10 µM 
UO126 (369.6±33.8 vs 78.9±6.11;p<0.001, 119.9±4.16; p<0.0001 and 103±7.6; p<0.0001). No 
significant difference was observed between treatments of CM1+8µM UO126 and 
CM1+10µM UO126 (561.4±110.5 vs 568±162; p>0.05; Figure 7.10). Similarly, 
phosphorylated mTOR was highest in C2C12 cells treated with CM1+8µM UO126 compared 
to other concentrations (Figure 7.10, right panels). All concentrations of UO126 (3,5,8 and 
10µM) significantly decreased the level of Erk1/2 compared to myoblasts treated with CM1 
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alone (p<0.0001) in an apparent concentration-dependent manner, although no differences in 
ERK1/2 levels existed between the trials that included any concentration of UO126 (Figure 
7.10, right panel,bottom). 
Phase contrast imagesobtained following 4 days treatment with the CMs (Figure 7.10, left 
panels)showed greater myotube formation after incubation with Young CM1+UO126vs CM1 
alone, with progressively larger myotubes developing with increasing UO126 concentrations. 
 
Figure 7.10: Levels of activated Akt/mTOR and ERK1/2 in C2C12 cells treated with CM1 
and 3, 5, 8 and 10µM of UO126. pAkt levels in response to CM1+8µM of UO126 were significantly 
different compared to other concentrations applied ;p<0.0001. Similarly, mTOR levels in cells treated 
with CM1+8µM were significantly higher compared to CM1+3µM and CM1+5µM of UO126; 
p<0.0001 and higher than CM1+10µM and CM1 alone; p<0.05 and 0.001 respectively. Images 
indicated well-developed myotube formation in response to 8µM vs other concentrations and CM1. 
Data represent means ±SD (n=4) in triplicate. CV: Coefficient of variation. Scale bar=75µm 
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7.5.6 PROTEOMICS STUDY 
In order to identify other novel candidate regulators of C2C12 myoblast proliferation or 
differentiations and the differences in protein concentrations in the secretomes of the CM1 
between young and old, secretome samples were prepared for proteomics analyses. However, 
no results were obtained from these studies. The main reason was that the samples were 
dominated by a very small number of very highly abundant proteins, with serum albumin 
causing particular problems that prevented identification of any secreted, relatively low 
abundance proteins (see appendix 1).  
 
7.5.7 THE PROLIFERATION OF YOUNG CM1-TREATED C2C1 
CELLSWASPARTIALLY ATTENUATEDBY THE IGF-1R INHIBITOR OSI-906 
The cell count of OSI-906 pre-treated cells cultured in CM1 was significantly lower compared 
to Young CM1-treated cells (120±10x104 vs 171±10x104 cells/ml: p<0.01), but was higher than 
treatment with OSI-906+ DM alone or DM alone. The cell count of differentiating cells pre-
treated with OSI-906+DM was significantly lower compared to CM1 treated cells (63±15 x 
104 vs 171±10 x 104 cells/ml: p<0.0001 respectively). No significant difference in cell count 
existed between the control conditions of OSI-906 + DM and the DM-alone (63.3±15x104 vs 
50±10x104 cell/ml: p>0.05 respectively). Cell count data are shown in figure 7.11, bottom 
panel. 
 Flow cytometric cell cycle analysis was undertaken to assess the proliferation of cultured cells. 
Such analyses confirmed that %S phase of OSI-906 pre-treated cells cultured with  Young 
CM1  was significantly lower compared to CM1 treated cells (36.6±2.8% vs  49.6±4.5% ; 
p<0.01 respectively). %S phase of OSI-906 pre-treated cells cultured with DM was 
significantly lower compared to CM1treated cells (24.6±1.5 vs 49.6±4.5; p<0.0001 
respectively). A significant difference was observed between OSI-906 pre-treated cells 
cultured with CM1 and DM (36.6±2.8 %vs 24.6±1.5%; p<0.01 respectively). No significant 
difference was observed between OSI-906-treated and untreated cells cultured with DM 
(24.6±1.5%vs 18±2%; p>005). Cell cycle data are shown in Figure7.11, bottom panel. 
Morphological assessment of OSI-906 + young CM1 treated cells showed that the usual 
increase of proliferation observed after Young CM1 treatment was attenuated after OSI-906 
treatment. Nevertheless, the OSI-906 + young CM1 treated cells did not develop myotube 
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formation, as did occur in the control DM-alone conditions, indicating that blocking the IGF-
1R was only partially effective at blunting the enhanced proliferation seen after treatment with 
Young CM1. Cells treated with OSI-906 alone did not grow well enough for any measurements 
to be taken. 
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Figure 7.11: Morphological assessment, cell count and cell cycle analysis for OSI-906-pre-
treated and un-treated cells cultured with CM1, DM and controls after 3 days. Scale 
bar=100µm. Data in graphs represent means ±SD (n=4) in triplicates.CM1:Activated conditioned 
media and DM: Differentiated media. % CV for cell cycle analysis in response to each treatment: % (6, 
8, 5 and 9) respectively while %CV of the cell count data: % (6, 8, 12 and 5) respectively.  
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7.5.8 DETERMININGTHE AKT/mTOR SIGNALLING PATHWAY WITHIN 
C2C12CELLS TREATED WITH THE IGF-1R INHIBITOR OSI-906 
 
As shown above, pAkt and mTOR were significantly lower after treatment with Young CM1 
compared with controls. Pre-treating the C2C12 cells with OSI-906 had no effect on either the 
phosphorylated Akt or mTOR levels after treatment with CM1, since both remained lower than 
control conditions. All data are shown in Figure 7.12. 
 
 
 
Figure 7.12: The level of phosphorylated Akt and mTOR for OSI-906- pre-treated and un-treated 
cells cultured with CM1, DM and controls. The level of Akt was significantly different between OSI-
906 pre-treated and un-treated cells cultured with CM1 and DM (p>0.01). A significant difference was 
observed in mTOR level between OSI-9.6 pre-treated and un-treated cells cultured in DM (p<0.05). 
Data represent the means ± SD (n=4) in triplicates. %CV  for MFI of pAkt: CM1; 20%, 
CM1+OSI-906 ; 14%, DM+OSI-906; 24% and DM ; 9%. CV for MFI of mTOR: CM12%, 
CM1+OSI-906; 16%, DM+OSI-906; 35% and DM; 20%.  
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7.6. DISCUSSION 
It was shown in the previous chapter that C2C12 cells cultured with Young CM1 exhibited 
high levels of proliferation and lower differentiation. In contrast, C2C12 treated with Old CM1 
exhibited fusion of myoblasts to form multinucleated myotubes, similar to those observed in 
control conditions. The work presented in this chapter reveals novel signalling pathways 
through which the Young CM1, but not the Old CM1 affects intracellular signalling of C2C12 
cells, identifying possible mechanisms leading to enhanced C2C12 proliferation after treatment 
with Young CM1. These effects included MyoD and Myogenin being downregulated in C2C12 
after exposure to Young CM1; phosphorylated MEK1 and ERK1/2 were upregulated, and 
phosphorylated Akt and mTOR were downregulated in Young CM1-treated C2C12 cells. 
Blocking MAPK eliminated the enhancement C2C12 proliferation after treatment with the 
Young CM1, and reversed the observations of cellular signalling by increasing pAkt and 
mTOR while decreasing ERK1/2. Blocking the IGF-1R partially attenuated the enhancement 
of C2C12 proliferation after treatment with the Young CM1, but had little effect on 
phosphorylated Akt or mTOR. 
It is well established that MyoD is a marker of myogenic lineage, whereas Myogenin is a 
marker to drive activated myoblasts into the differentiation pathway (Knight and Kothary, 
2011). The lower levels of MyoD and Myogenin in C2C12 cells treated with Young CM1 
compared to Old CM1 was consistent with the morphological and cell cycle results, both of 
which showed supressed diffrentiation in Young CM1 compared to Old CM1-treated C2C12. 
To  determine what signalling cascades were activated or attenuated in Young and Old CM1 
in association with the induced proliferation or differentiation, respectively, multiplex studies 
were performed following 25 min incubation with CMs. This time point was determined 
following initial studies which showed the maximal activation time of these phosphorylated 
proteins (Akt/mTOR and IRS-1) was 25 min, as opposed to slightly shorter or longer periods 
in Young CM1- treated cells and CMs controls. In the current study, it was found that pAkt 
and mTOR levels increased in Old CM1-4 treated cells; while MEK1and Erk1/2 decreased. 
Furthermore, our data showed  Erk1/2 and MEK1 increased in young CM1; while a decrease 
in Erk1/2 and MEK1 in Young CM2-4 treated cells was accompained by increased in 
Akt/mTOR level.  These findings are in line with previous studies that identified higher pAkt 
and mTOR levels in differentiating myoblasts, whereas MEK1 and Erk1/2were previously 
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shown to be higherin proliferating myoblasts (Creer et al., 2005; Al-Shanti and Stewart, 2012; 
Widegren et al., 1998; Al-Shanti et al., 2014; Jones et al., 2001).  
In order to verify the role  of the MEK1 /Erk1/2 signalling pathway  for proliferation in CM1-
treated myoblast, a selective ERK  inhibitor, UO126 was used (Perkins et al., 2007; Winter et 
al., 2011). Skeletal muscle differentiation is marked by increased levels of Akt and mTOR and 
decreased in Erk1/2 (Al-Shanti et al., 2014), so the levels of these phosphorylated proteins were 
measured following incubation of CM1–treated myoblasts  with  different concentrations of 
UO126. The data showed  that adding 8µMUO126 to the Young CM1 attenuated the enhanced 
proliferation that is normally observed in this condition, and instead more myotube formation 
was evidentwhen compared to C2C12 cultured with Young CM1 alone. The concentration of 
10µM UO126 added to Young CM1also blunted proliferation and enhanced myotube 
formation, as previously described (Perkins et al., 2007). Both 8µM and 10µM UO126 
significantly increased Akt levels compared to Young CM1 alone, while levels of mTOR were 
decreased most after adding 8µM UO126 to Young CM1 compared to other concentrations of 
UO126. These concentrations of UO126 all inhibited proliferation of myoblasts treated with 
Young CM1 via inhibition of Erk1/2 activation, inducingdifferentiation and myotube 
formation.  
Our results in a previous chapter showed that the IGF -1 concentration in the young secretome 
was significantly higher compared to the old secretome. A previous study demonstrated that 
high IGF-I concentrations in vitro  favoured proliferation, whereas lower IGF-I concentrations 
promoted differentiation (Sharon A Coolican et al., 1997). Therefore, it is possible that the 
observed enhanced proliferation in young CM1 is in  part accounted for by increased IGF-1 
concentrations (Foulstone et al., 2001). To investigate this, C2C12 myoblasts were treated with 
neutralising anti-IGF-1R antibodies. The outcomes showed that blocking IGF-1R resulted in 
decreased C2C12 cell counts and %S phase of C2C12 cultured with Young CM1 compared 
with cells treated with CM1 alone. The morphological results showed thatafter blocking the 
IGF-1R of C2C12 cells cultured with Young CM1, the cells did not proliferate as much as the 
usual Young CM1-treated cells, but the myotube formation was still attenuated (as normally 
occurs after treatment with Young CM1). These findings suggest that the effects of the Young 
CM1 (increasing the rates of proliferation of C2C12 cells) do not principally work through the 
IGF-1R, and instead implicate other, as yet unknown, cytokines secreted by activated 
lymphocytes in young secretomes. For example, we showed previously that IL-6 and TNF-α 
were more highly expressed by young lymphocytes compared to old. IGF-1 in combination 
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with TNF-α and IL-6 can achieve the maximal beneficial effect on skeletal myoblasts 
proliferation via increase ERK phosphorylation (Al-Shanti et al., 2008). Interestingly, this also 
supports our cell cycle findings and elevated level of activated Erk1/2.  Furthermore, in a 
previous chapter we found elevated amphiregulin expression in the young secretome. Both of 
IGF-I and  amphiregulin  functioned synergistically  to promote cell proliferation and migration 
through activation of the MAPK/ ERK pathway (Rundhaug and Fischer, 2010). Again, this 
supports our findings which demonstrated that CM1-treated cells showed higher MAPK and 
ERK1/2 phosphorylated proteins levels compared to cells treated with Old CM1. Also blocking 
IGF-1R did not have an effect on myotube formation in cells cultured with DM compared to 
normal cells which were grown in DM. Differentiation of myoblasts is strongly regulated by 
the Akt/mTOR signalling pathway. Our results showed that the level of activated Akt in C2C12 
cells  cultured with CM1 and DM was not influenced by the IGF-1R blocker. Thus our 
findingsconflict with a previous study which reported that differentiation in C2C12 is induced 
by endogenous IGF-1 (Yoshiko et al., 2002). However, the level of mTOR in C2C12 seems to 
be influenced by IGF-1R inhibitor. 
Taken together, our data suggest that as yet unidentifiedcytokines and/or growth factors present 
in the young activated lymphocyte secretomescan induce a sustained proliferation via low 
expression of MyoD and myogenin and activation of MEK/ERK (Al-Shanti et al., 2014) 
signalling pathways, while proteins presentin the old secretomehave little effect, promoting the 
progression towards differentiaton via increased the levels of MyoD and Myogenin and 
activation of the Akt/mTOR signalling pathway (Al-Shanti et al., 2014).    
 
7.8 CONCLUSION 
In summary,  25min  was  the optimal time point to trigger Akt , mTOR and IRS-1 activation 
compared to 5, 15 and 60min in CM1, CM2 and CM4-treated cells. Old CM1-treated myoblasts 
expressed  high levels of MyoD and Myogenin compared to Young CM1- treated cells. These 
were associated withhigh levels of Akt and mTOR in differentiating cells treated with Old CM1 
and high  levels of MEK1 and ERK1/2 in proliferating cells treated with Young CM1 . The 
induced diffrentiation of Young CM1 treated myoblasts following UO126 treatment  was 
accompained by activation of Akt and mTOR.  Activation of Akt/mTOR pathway was strongly 
achieved by 8µM and 10µM UO126  resulting in increased myotube formation and decreased 
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myoblast proliferation. Using OSI-906 blocker was associted with decreased proliferation with 
no myotube formation. 
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CHAPTER 8 
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8.1 GENERAL DISCUSSION 
The aim of the work presented in this thesis was to investigate the differences between young 
and old immune cells (lymphocytes) for their impact) on skeletal muscle regeneration. To fulfil 
the aim, optimisation of lymphocyte culture conditions was undertaken. For this purpose young 
lymphocytes were isolated from fresh whole blood samples and activated using anti-CD3 for 
2, 4 and 6 days.  Our findings suggested that day 4 was the optimal culture time compared to 
days 2 and 6 with cells displaying higher proliferation, increased size of colony forming units 
and CD25 expression. Anti-CD28, a co- stimulatory molecule was added to the media to mimic 
in vivo stimulation.  Anti-CD3/CD28 -activated T lymphocytes at day 4 released higher 
concentrations of cytokines and growth factors compared to day 2. The released growth factors 
and cytokines from T- lymphocytes are important in tissue repair and regeneration (Hawke, 
2011), they contribute to the muscle cell response during proliferation and differentiation stages 
by affecting transcriptional factors (Tidball and Villalta, 2010).It is clearly important to 
optimise the volume of activated lymphocyte supernatant (secretome) to investigate the impact 
on muscle cell behaviour. To this wend it was shown that young conditioned media (i.e. the 
normal C2C12 cell media, enhanced with the lymphocyte secretome) was able to induce 
extended proliferation of C2C12 compared to non-stimulated lymphocyte secretomes and other 
control conditions (Al-Shanti et al., 2014b). These findings suggest that in our model, the 
young activated lymphocytes release key regulatory factors which are able to induce C2C12 
proliferation compared to non-activated T- lymphocytes.  
It has been well documented that immune cells undergo alterations in their intrinsic 
characteristics and marker expression during ageing. Previous studies showed that reduced 
thymic output in aged individuals negatively affects the function and phenotypes of T 
lymphocytes, including loss of T cell surface markers, TCR diversity and clonal expansion. A 
decline in the TCR diversity of T-cells was accompanied by oligoclonal expansion of naive T 
cells and memory cells. Consequently, all these changes contribute to alter the components of 
immune system declines in aged individuals (Goronzy and Weyand, 2005; Nikolich-Žugich, 
2008).These age-related changes could affect cytokines production leading to alterations in the 
local microenvironment of satellite cells and hence changes in regeneration. Therefore attempts 
were made to investigate whether the key factors and CD marker expression of T lymphocytes 
which are involved in muscle modulation, are different in older lymphocytes compared with 
young. In the current study we determined CD25 and amphiregulin expression in young and 
old lymphocytes. These were selected, as FoxP3 Tregs and amphiregulin candidates have been 
 173 
shown to contribute to muscle repair and regeneration (Burzyn et al., 2013). In addition, a 
recent study showed that muscular Treg FoxP3 cells potentially stimulate satellite cells 
proliferation, slow differentiation and enhance wound healing after CTX damage in mice 
(Castiglioni et al., 2015). The findings of this study are comparable to the present study results 
that show activated young T-lymphocytes secrete molecules (cytokines and growth factors) 
that enhance proliferation and inhibit differentiation (Al-Shanti et al., 2014). Therefore, further 
investigation of secreted Th1/Th2 cytokines from young and old lymphocytes was performed. 
Our findings strongly suggested that with ageing lymphocyte function and responses to 
challenge are altered. Our results show that old -activated lymphocytes express lower levels of 
CD25 marker and amphiregulin production and higher FoxP3 Tregs expression compared to 
young- activated lymphocytes.  Also the present study demonstrates that old lymphocytes 
release lower concentration of cytokines including: TNF-α, INF-γ, IL-6, IL-1β, IL-12, IL-2 and 
IGF-I compared to young activated lymphocytes and that these may mediate skeletal muscle 
regeneration. These changes in lymphocytes with ageing had effects on C2C12 proliferation 
and migration. The present study shows remarkable proliferation and  migration of  Young 
CM1- treated C2C12 compared to cells treated with old CM1 which undergo differentiation, 
evident as elongated and multinucleated myotube formation that is comparable to the  control 
conditions (CM2-CM4). The extended proliferation of Young CM1 treated cells was associated 
with a decrease in MyoD and Myogenin and increases in Mek1/Erk1/2 (Al-Shanti et al., 2014), 
while differentiation of myotubes treated with Old CM1 was associated with increased MyoD 
and myogenin expression and increased in Akt/ mTOR. A similar observation was recently 
made by Castiglioni and his colleagues (Castiglioni et al., 2015) who found that co-culture of 
activated T cells with murine satellite cells potentially enhanced skeletal muscle proliferation 
and wound healing compared to non-activated T-cells that did not show any myogenic effects 
on satellite cells. These findings strongly suggest that changes in lymphocyte behaviour and 
cytokine production with ageing affect skeletal muscle regeneration. It is possible that the 
competency of aged lymphocytes to respond to antigen challenge decreases and adversely 
affects downstream signalling pathways including tyrosin phosphorylation (Grossmann et al., 
1995) and NFAT and NFƘB translocation (Haynes et al., 2004; Tamir et al., 2000). 
Consequently, these changes reduce the clonal expansion and cytokines production from naive 
T- cells (Salam et al., 2013; Haynes and Maue, 2009) as a compensatory response to thymus 
dwindling in aged individuals. It was found that naive CD4 T cells that have undergone 
homeostatic cell proliferation have lower diversity in TCR repertoire and produce less IL-2 
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compared to naive CD4 cells that have not undergone homeostatic replication (Swain et al., 
2005). This was evident in our study where lower expression of the CD25 activation marker 
and IL-2 production were found which may contribute to the attenuated skeletal muscle cell 
proliferation and migration. It is possible that the decrease in cytokine and amphiregulin 
production from old T-helper cells results from an increased level of FoxP3 which was found 
to be associated with T-cell suppression (Fessler et al., 2013; Saito et al., 2010). Accordingly, 
the effect of FoxP3 Treg cells in promoting muscle repair and regeneration is excluded since 
its expression is inversely associated with amphiregulin production in young- activated 
lymphocytes. The results reported here are in contrast with a recent study that showed enhanced 
muscle repair and regeneration in young mice was generated from increased FoxP3 Treg which 
was accompanied by amphiregulin production, these differences warrant further investigation, 
however, they may be as a result of one study being performed in vitro and the other in vivo. It 
has been shown that a high concentration of IGF-I induces skeletal muscle proliferation 
(Coolican et al., 1997) and also accelerates differentiation of myoblasts, increasing the number 
of fused myonucleus in differentiated myofibres (Yin et al., 2013). Our results show that the 
proliferation of youngCM1-treated C2C12 cells was partially attenuated by the IGF-1R 
inhibitor OSI-906 and there was a delay in differentiation of myoblasts treated with OSI-
906.The latter finding is comparable to the results of a previous study which showed that the 
functional inactivation of IGF-I R on C2C12 delayed the IGF-1 -induced differentiation (Cheng 
et al., 2000). In addition, the finding  of  extended proliferation of young- treated myoblasts 
suggests that  IGF-I possibly in combination with high concentrations of TNF-α and IL-6 (Al-
Shanti et al., 2008) and amphiregulin (Sharma et al., 2006), may contribute to sustained 
proliferation of C2C12. The mitogenic effect of the latter production is enhanced in the 
presence of IL-1 and TNF-α (Woodworth et al., 1995). It is not clear which of the cytokines 
(IGF-I and amphiregulin) are directly involved. But it is clear that the altered concentrations of 
these effectors in old secretomes impacted on the ability of the secretome to enhance C2C12 
proliferation. 
Future work should up- and down-regulate candidate proteins from the lymphocyte secretomes 
in order to identify those that are able to influence skeletal muscle cell signalling, particularly 
the Akt/mTOR, MyoD and Myogenin pathways. This would lay the foundation from which it 
should be possible to intervene by producing agents that can restore the capability of older 
lymphocytes to enhance skeletal muscle regeneration. Previous studies showed that increased 
level of p38 MAPK phosphorylation and reduced proliferation rate are associated with the 
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cellular senescence of T lymphocytes. These changes are actively regulated by the inhibitory 
signalling protein called programmed cell death protein (PD1) (Henson et al., 2012) and 
cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) (Takahashi et al., 2000) which are both 
known directly to suppress the activity of T- cells. A recent study demonstrated that blocking 
these inhibitory  molecules increased the functional activity of T cells of older humans (Henson 
et al., 2015).Thus these a aforementioned studies could open  an avenue to restore the inhibitory 
effects of the aged immune system on skeletal muscle regeneration.It should be possible by 
reversing aged lymphocytes through interrupting the inhibitory signalling pathwaysthat may 
be able to enhance cytokines/growth factors–induced skeletal muscle regeneration. 
 
8.2 LIMITATIONS 
The results of the studies presented in this thesis may have been affected by a 
number of limitations which are described below. 
 
 
 Using a rodent cell line such as C2C12 could be a limitation of the present 
study because C2C12 are immortalised cells and have been maintained 
under artificial culture conditions for many years, which can cause them to 
deviate from their original biological function. However, rodent cell lines 
are still commonly used to study the molecular mechanisms of muscle 
differentiation (Cui et al., 2009) and in drug discovery research (Sultan, 
Henkel et al. 2006, Cho, Kim et al. 2009). Nevertheless, another limitation 
is that the ageing of the mouse cell lines may not necessarily reflect the 
ageing of human cell lines, and therefore the work presented in this thesis 
should be repeated in human cell lines if the aim is to find relevance to 
human ageing. 
 Another limitation could be that human cytokines were added to the murine 
skeletal muscle cells. This methodology was chosen due to the lack of 
availability of human immortalized muscle cells. Primary cell lines were 
unfeasible for the studies performed due to the need for muscle biopsies to 
be collected from human volunteers for each separate experiment. This 
model (human cytokines added to mouse cell lines) has been used by others 
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to investigate the inflammatory mediators secreted from A427 human lung 
cancer (Oraldi et al., 2013) serum creatine phosphokinase in choline- 
deficient humans in C2C12(Costa et al., 2004).Using human products with 
a murine cell line also helps to overcome some ethical and many technical 
handicaps on the in vivo study of human cells and tissues. 
 
 
 
 A proteomics study was attempted to identify the potential candidates which 
induce proliferation and migration. However, the high abundant of albumin 
human serum in RPMI-1640 lymphocytes culture media was an obstacle to 
process our samples. Therefore, X-VIVO 15 serum free media was 
recommended to use for lymphocytes culture. This experiment was 
performed. Images were taken for lymphocytes after 4 days of stimulation 
(Figure8.1) and cells were counted (Figure8.2). Cell count results showed 
no significant difference between lymphocytes cultured in RPMI-1640 and 
X-VIVO 15. However, the time constrains and the budget limit prevented 
the performance of a proteomics study. 
 
 The difficulty in recruiting healthy participants, particularly the elderly, for 
blood sample collection was another barrier that partially restricted the 
advancement of this work. This problem may be overcome in the future by 
establishing integrated clinical and academic teams with shared 
responsibilities for recruitment. It is also possible that the results presented 
in this thesis are not broadly relevant to all human ageing, since all of the 
blood donors were caucasian. 
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Figure 8.1: Young Lymphocytes growth in X-VIVO 15 (left panel) and RPMI-1640(left 
panel) at 10Mag. 
 
Figure 8.2: cell count of lymphocytes cultured with X-VIVO 15 and RPMI-1640. 
 
 
 
 
 178 
8.3 FUTURE WORK 
From the results obtained in this current study, the following future studies are 
suggested: 
 To set up larger scale studies to investigate the effect of immune system secretions (growth 
factors and cytokines) on old and young human skeletal muscle cells in vitro. 
 To reduce the methodological problems associated with identifying one or more candidate 
molecules from the hundreds secreted by lymphocytes to induce muscle proliferation and 
migration, more elaborate studies are needed. For example, we should carry out the Cignal 
Pathway reporter array which allows for the comprehensive analysis of the 45 most 
common transcriptional factors signalling pathways that are perturbed by specific genes. 
This will enable us to identify the potential proteins secreted by activated young 
lymphocytes, which induce proliferation, migration of C2C12 myoblasts and influence on 
signalling pathways and the expression of myogenic factors expression. This would allow 
the possibility to intervene by producing agents that can reverse aged T- cells function to 
enhance skeletal muscle regeneration. 
 Based on the results of the previous aim, targeted-discovery mass spectrometry proteomics 
can be applied to identify the effector proteins that are secreted by young lymphocytes 
which induce proliferation and migration. 
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8.4 CONCLUSION 
 
In summary, the findings presented in this thesis uncovered the novel regulatory role of proteins 
secreted from activated young T lymphocytes on C2C12 proliferation and migration. These 
observations provide insights into the interaction between T cells and skeletal muscle cells 
which may ultimately help us to provide therapeutic strategies to enhance wound healing and 
promote proliferation of skeletal muscle cells. Our findings also revealed that ageing is 
associated with changes in intrinsic characteristics and cytokine production of T cells, which 
in turn attenuated skeletal muscle regeneration. 
 
Our results extended the data obtained from several studies using parabiosis-models. However, 
our model is more able to examine lymphocyte-specific mediators as we are not dealing with 
the thousands of substances which exist in the blood and which need to be examined to identify 
the candidate(s) which may induce such effect. Therefore, our model could be used as 
fundamental research tool which may provide the essential knowledge needed to develop novel 
therapeutic strategies to tackle underlying mechanisms of muscle wasting. 
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An example of results generated from proteomics analysis of young secreatome. 
The sample is predominated with albumin human serum(bold) 
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Application Number…………….. (facultycoding) 
 (Sep 2007) 
Date……………………………….. 
 
MANCHESTERMETROPOLITANUNIVERSITY 
FACULTY OF SCIENCE AND ENGINEERING 
 
APPLICATION FOR ETHICAL APPROVAL 
 
 
Introduction 
All university activity must be reviewed for ethical approval. In particular, all undergraduate, 
postgraduate and staff research work, projects and taught programmes must obtain approval from their 
Faculty Academic Ethics committee (or delegated Departmental Ethics Committee).  
 
APPLICATION PROCEDURE 
 
The form should be completed legibly (preferably typed) and, so far as possible, in a way which would 
enable a layperson to understand the aims and methods of the research. Every relevant section should 
be completed. Applicants should also include a copy of any proposed advert, information sheet, consent 
form and, if relevant, any questionnaire being used. The Principal Investigator should sign the 
application form. Supporting documents, together with one copy of the full protocol should be sent to 
the Administrator of the appropriate Faculty Academic Ethics Committee.  
 
Your application will require external ethical approval by an NHS Research Ethics 
Committee if your research involves staff, patients or premises of the NHS (see guidance 
notes) 
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Work with children and vulnerable adults 
You will be required to have a Criminal Disclosure, if your work involves children or 
vulnerable adults.  
 
The Faculty Academic Ethics Committee meets every (insert period) and will respond as soon as 
possible, and where appropriate, will operate a process of expedited review. Applications that 
require approval by an NHS Research Ethics Committee or a Criminal Disclosure will take longer 
- perhaps 3 months. 
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1. DETAILS OF APPLICANT (S) 
1.1 Principal Investigator: (Member of staff or student responsible for work) 
 
1) Dr Nasser  Al-SHANTI (DoS), IRM, School of Healthcare Science, Manchester Metropolitan 
University, E226, 01612475712, n.al-shanti@mmu.ac.uk 
 
2) Sarah Al-dabbagh , Bsc. MSc, PhD Postgraduate research student, e-mail: 
sarah.aldabbagh@mmu.ac.uk 
 
 
1.2 Co-Workersand their role in the project: (e.g. students, external collaborators, etc)  
 
Supervisors and internal collaborators: 
 
 Professor Claire Stewart (C.E.Stewart@ljmu.ac.uk) 
  
 Dr. Chris Murgatroyd - 0161 2471212 (c.murgatroyd@mmu.ac.uk) 
 
Dr Jamie S. McPhee – 0161 247 5675 (j.s.mcphee@mmu.ac.uk) 
 
 
1.3 University Department/Research Institute/Other Unit: 
 
School of Healthcare Science, Manchester Metropolitan University 
School of Sport and Exercise Sciences, Liverpool John Moores University 
 
 
2. DETAILS OF THE PROJECT  
2.1 Title: Investigating the effect of immune cells on skeletal muscle cells C2C12 
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2.2 Description of Project: (please outline the background and the purpose of the research project, 
250 words max.) 
 
 
Title: Investigating the effect of immune environment on skeletal muscle stem cells proliferation 
and differentiation 
Background 
Skeletal muscle cell has a unique ability for maintenance and repair following major damage or muscle 
disease. The regenerative ability of skeletal muscle cells are highly dependent the presence of high 
population of mononucleotide and myogenic cells called satellite cells that maintain their ability to 
proliferate and differentiate to new fibers. (James  et al., 2010). The process of differentiation involves 
three major stages  which are proliferative , fusion and transition  and terminal differentiation  stages ) 
,all of which are regulated in part by the activities of  a family of muscle-specific transcription factors 
in the basic helix-loophelix family (bHLH).(Jameset al  ., 2010).  However, the regenerative ability of 
skeletal muscle cells are significantly reduced in elderly people, due to reduced systemic environment 
(Conboy et al.,2005), satellite cells numbers and hormonal imbalance but also the immune system 
efficiency decreased (Rafi et al., 2003). Myeloid cells play crucial role in muscle cells repair and 
maintenance   through release of cytokines and exogenous growth factors. The most common cytokines 
produced during inflammatory response are Interleukin -1 (IL-1 ), ( IL-6) and tumour necrosis factor –
α (TNF-α). Recent published study has shown that during inflammatory response, Monocytes 
/Macrophages shift their phenotype to participate in muscle regeneration. Strong evidence also shows 
the role of cytokines particularly IL-6 in recruitment of myeloid cells and satellite cells to the site of 
skeletal muscle injury. (Pedersen  et al., 2000).In light of such evidence, biological interactions between 
immune system and skeletal muscle cells can be proposed which may induce a detrimental effect in 
maintaining an adequate muscle mass and function in elderly people. To date, most researchers have 
focused on investigating the impact of these cytokines alone on skeletal muscle proliferation and 
differentiation. We hypothesised that combined effects of these cytokines which are present in the 
systemic environment may have detrimental effect on skeletal muscle regeneration. Therefore, our aim 
is to explore how immune cells cross-talk with skeletal muscle cells with objectives 1) to examine the 
effects of the supernatant of the culture immune cells on skeletal muscle cells proliferation, fusion and 
differentiation. Therefore, better understanding of such interactions could not only be used to study the 
skeletal muscle wasting in elderly people but also could lead research into new directions and highlight 
possible therapeutic strategies for both prevention and treatment of muscle wasting conditions with age 
and with disease 
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Describe what type of study this is (e.g. qualitative or quantitative; also indicate how the data 
will be collected and analysed).   
 
 
Both quantitative and qualitative data will be collected in the purposed study . 60 participants will be 
recruited to take part in this study .Contribution of participants involves only blood drawn which 
consumes mostly no more than 5 minutes   .During recruitment , potential participants will be provided 
with details of this study. Information of this study will be  provided in  verbal and written formats in 
order for participants  to make an informed decision on whether to participate  . Participants will be 
encouraged to understand  the information provided and make a decision away from the researchers .A 
copy of the signed consent form will be provided to the participants for their information . Participants 
have the right to withdraw from the experiment  at any time . Participants will also complete a medical 
questionnaire in which all records details are completely anonymised (free from any potential identifier 
) . This will be achieved by allocating each participant with non –identifiable Participant Number (PN) 
. The participants will be asked to give blood by phlebotomist . The needle will be inserted in to 
antecubital vein to obtain 10 ml baseline blood sample .After obtaining blood , the needle will be 
removed and guaze  applied  at the site of venepuncture . The method of blood sampling is routinely 
used in clinical and research setting . The participants then will be free to leave the laboratory . 
Blood samples will be stored at 4 C ° until analysis in strict accordance with the Human Tissue Act 
(2004) and university regulations and procedures .poly morphonuclear cells (PMNCs ) will be separated 
by density gradient centrifugation using conical tubes prior to washing with  10 ml of Phosphate Buffer 
Saline  . PMNCs will be cultured for 4 days in the presence of IL-2 .Following culture , the supernatant 
will be harvested and cultured with young C2C12 (p5)  and artificially aged C2C12  p55 . Gene 
expression of myogenic regulatory factors of C2C12 p5 & p55  will be measured . Wound healing and 
migration assays for  of C2C12  will be carried out . The level of protein expression will be determined 
using western blot. Flow cytometry  will be used to examine the proliferating and cell cycle of C2C12 
cells . creatinine kinase (CK) and protein concentration  will be assessed.  
As mentioned previously, all raw data will be stored anonymously under a participant number (PN) 
rather than name .Data storage will comply with the Data Protection Act (1998) . The data will be 
analysed to study the effect of immune cells on  young and aged skeletal muscle cells during 
proliferation and differentiation stages using *******.If a participant decided to withdraw from the 
study at any time after the experimental procedure commences , all samples and data will be destroyed 
including, paper and electronic format .  
 
 
 
 
 
2.3 Are you going to use a questionnaire? YES 
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2.4 Start Date / Duration of project: 
Start date 10/10/2012 
Duration (3 years ) 
 
 
2.5 Location of where the project and data collection will take place: 
 
School of Healthcare Science laboratories, first floor labs in John Dalton Building, Manchester 
Metropolitan University 
 
 
2.6 Nature/Source of funding 
None  
 
 
 
2.7 Are there any regulatory requirements?   NO 
If yes, please give details, e.g., from relevant professional bodies 
 
 
3. DETAILS OF PARTICIPANTS  
3.1How many?       
60 
 
3.2Age: 20-75 
 
3.3Sex: Both sexes  
 
3.4 How will they be recruited?  
 210 
 
Participants will be approached verbally, via email 
 
 
3.5 Status of participants: (e.g. students, public, colleagues, children, hospital patients, prisoners, 
including young offenders, participants with mental illness or learning difficulties.)  ? 
The majority of participants will be  healthy  staff and students at Manchester Metropolitan 
University. Some healthy  participants may be recruited from the general public. 
 
3.6 Inclusion and exclusion from the project: (indicate the criteria to be applied). 
 
Participants will be healthy individuals who are not taking medications, particularly anti- 
inflammatory drugs  
 
3.7 Payment to volunteers: (indicate any sums to be paid to volunteers). 
No payment  
 
3.8 Study information: 
Have you provided a study information sheet for the participants?   
Please attach a copy of the information sheet, where appropriate 
 
YES  
 
 
3.9 Consent: 
(A written consent form for the study participants MUST be provided in all cases, unless the 
research is a questionnaire.) 
 
Have you produced a written consent form for the participants to sign for your records?   YES  
 
 
4. RISKS AND HAZARDS 
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  Please respond to the following questions if applicable 
 
4.1 Are there any risks to the researcher and/or participants? 
(Give details of the procedures and processes to be undertaken, e.g., if the researcher is a lone-
worker.) 
 
Potential risks to participants: 
The risks involved in this study are minimal. Some minor discomfort may arise in the participant from 
collection of the blood samples. Any adverse effects will be treated by first aid and/or medical 
intervention as necessary. The method to be used is common practice in clinical settings, and in the 
literature, and members of staff supervising this project have previously used this method of blood 
collection. No major adverse effects have been recorded with this procedure provided sterile materials 
are utilised for the blood collection. Commercially-available, quality-assured, sterile materials will be 
utilised throughout this study. 
 
Potential risks to researchers: 
As this investigation would involve collection and handling of biological samples, there is some degree 
of risk to researchers which can be minimized with good laboratory practice and adherence to health 
and safety procedures. Researchers will utilise standard laboratory personal protective equipment 
(gloves, laboratory coat and safety glasses) whilst in the laboratory. Researchers will not be left alone 
with participants at any time and academic staff will supervise the participant while he/she is in the 
laboratory (with the exception of when a urine sample is provided due to need for privacy). The 
participant will not be observed during this procedure but will go to the lavatory, collect the urine 
sample and return to the laboratory before handing the sample to the researcher. 
 
 
 
 
 
 
4.2 State precautions to minimise the risks and possible adverse events: 
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Participants will be seated while the blood sample is taken in order to minimize any risk that may occur 
due to the participant suddenly feeling unwell. A small plaster will be provided to cover the puncture 
site at the end of the experimental trial once the cannula has been removed.  
 
Student researchers will be taught how to handle equipment safely.  
 
Researchers will follow good laboratory practice and adhere to laboratory health and safety procedures. 
This will include wearing gloves and safety glasses whenever handling biological samples and wearing 
a white laboratory coat at all times. 
 
 
 
4.3 What discomfort (physical or psychological) danger or interference with normal activities 
might be suffered by the researcher and/or participant(s)?  State precautions which will be 
taken to minimise them: 
 
 
As this investigation would involve collection of biological samples, there is a small risk of infection 
to both participant and researcher. This risk will be minimized by following standard aseptic techniques 
such as using an unused sterile needle for each participant and the wearing of appropriate safety apparel 
 
 
5. PLEASE DESCRIBE ANY ETHICAL ISSUES RAISED AND HOW YOU INTEND 
TO ADDRESS THESE: 
 
Ethical issues  
 
 The study involves collecting sensitive data i.e. blood samples from number of 
participants .Therefore to protect the participant’s personal data .the study will be in 
agreement with the Data Protection Act   1998 . The blood samples collected during 
this study will be kept confidential and will be identified using serial number coding so 
that the participants will remain anonymous , no hospital records will be accessed for 
this study and after analysis the sample will be disposed of. 
 
 Blood sample will be obtained from healthy young and aged people, both sexes . 
 
 As safety precaution, the researcher must wear an appropriate laboratory coat, disposal 
latex gloves and safety spectacles to reduce the risk of contamination when handling 
blood samples. Also, the participants are required to fill out medical screening 
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questionnaire to ensure they are free from infections and it is safe to take a blood 
sample. 
 
 The blood sample will be in accordance with the Human Tissue Act 2004. Each 
participants is required to formally give their consent before taking blood sample .Also 
the samples will be identified using serial number coding in order for the participants 
to remain anonymous and after analysis the blood samples will then be disposed.  
 
 
 
 
 
 
 
6. SAFEGUARDS /PROCEDURAL COMPLIANCE 
 
6.1Confidentiality: 
 
 
(a) Indicate what steps will be taken to safeguard the confidentiality of participant 
records.  If the data is to be computerised, it will be necessary to ensure compliance 
with the requirements of the Data Protection Act. 
 
All data will be kept electronically and will be stored anonymously under participant number, 
rather than participant name. Any identifiable details will not be recorded. Raw data sheets and 
records will be stored in a locked cupboard or drawer and access will be restricted to the 
involved investigators only. 
 
(b) If you are intending to make any kind of audio or visual recordings of the 
participants, please answer the following questions: 
 
 a. How long will the recordings be retained and how will they be stored? N/A 
 
 b. How will they be destroyed at the end of the project? N/A 
 
 c. What further use, if any, do you intend to make of the recordings? N/A 
 
6.2 Human Tissue Act:  
 
The Human Tissue Act came into force in November 2004, and requires appropriate 
consent for, and regulates the removal, storage and use of all human tissue. 
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a. Does your project involve taking tissue samples, e.g., blood, urine, hair, 
etc., from human subjects?  YES 
 
b. Will this be discarded when the project is terminated? YES 
 
     If NO – Explain how the samples will be placed into a tissue bank under 
the Human Tissue Act regulations: 
 
 
 
6.3 Insurance: 
 
The University holds insurance policies that will cover claims for negligence arising from the 
conduct of the University’s normal business, which includes research carried out by staff and by 
undergraduate and postgraduate students as part of their courses.  This does not extend to clinical 
negligence. There are no arrangements to provide indemnity and/or compensation in the event of 
claims for non-negligent harm. 
 
Will the proposed project result in you undertaking any activity that would not be considered as 
normal University business?  If so, please detail below: 
 
No 
 
 
 
 
 
6.4 Notification of Adverse Events (e.g., negative reaction, counsellor, etc):  
(Indicate precautions taken to avoid adverse reactions.) 
 
Please state the processes/procedures in place to respond to possible adverse reactions. 
 
In the case of clinical research, you will need to abide by specific guidance.  This may include 
notification to GP and ethics committee.  Please seek guidance for up to date advice, e.g., see 
the NRES website at http://www.nres.npsa.nhs.uk/ 
 
Although adverse reactions are highly unlikely, any incidents will be reported to the laboratory 
supervisor and necessary medical intervention will be provided immediately.  
 
 
SIGNATURE OF PRINCIPAL INVESTIGATOR        DATE: 
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.............................................................................................       ................................... 
SIGNATURE OF FACULTY ACADEMIC ETHICS       DATE: 
COMMITTEE CHAIRPERSON: 
 
..............................................................................................        .................................. 
 
 
 
 
 
 
 
School of Healthcare Science 
 
Informed Consent 
 
Project title:Investigating the effect of immune environment 
on skeletal muscle cells proliferation and differentiation 
Investigators:  
Sarah Al-Dabbagh  
 
 
To be completed by participant: 
 
The investigators have provided me with an information sheet on the above investigation which I 
have read and have had the opportunity to ask questions regarding the purpose and protocol of 
the investigation. The investigators have outlined any potential risks or discomforts associated 
with the experimental protocol. 
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The investigators have informed me of my right to withdraw from this investigation at any time 
without giving any reason for doing so. 
 
I fully and freely give my consent to participate in this investigation as it has been described to 
me and understand that participation in this investigation may not benefit me in any way. 
 
I understand that the investigators may publish the findings gathered from this investigation in 
abstracts, journals, conferences or other media formats. However, I understand that all my 
personal information will remain confidential so that nobody can identify me from such 
publications.   
 
 
 
Signature: Date: 
 
 
 
 
To be completed by researcher: 
 
I have explained the experimental protocol to the participant and have informed the participant 
of any risks or discomforts associated with the protocol. I have informed the participant of the 
purpose of the experiment and of their right to withdraw from the investigation without giving 
any reason for doing so.  
 
 
 
 
Signature: Date: 
 
 
 
Title: Investigating the effect of Immune Environment on skeletal muscle cells proliferation and 
differentiation  
 
 
Medical Screening Questionnaire 
 
It is important that the investigators are aware of any health conditions before participation in this research 
study. This is to ensure that the study protocol will not exacerbate any existing conditions of the participant. 
Please answer the following questions as accurately as possible. 
Age:  
Sex:   male       female 
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Are you currently taking any prescribed medication ie.  Corticosteroids?    
   YES/NO 
 
Are you currently attending your GP?        
 YES/NO 
 
Have you ever suffered from a cardiovascular problem?    
i.e. high blood pressure, anaemia, heart attack etc                                           
YES/NO 
Have you ever suffered from a neurological disorder?     
i.e. epilepsy, convulsions etc         
                                                                                                                                                                          
YES/NO 
Have you ever suffered from an endocrine disorder?     
i.e. diabetesetc. 
                                                                                                                             
YES/NO 
Have you ever suffered from a chronic gastrointestinal disorder?   
i.e. Crohn’s disease, irritable bowel syndrome etc     YES/NO 
Have you ever suffered from a skin disorder?      
i.e. eczema etc           YES/NO 
Do you suffer from any allergies?        
i.e. any medications, foods etc        YES/NO 
Are you aware of any other medical condition that may prevent you from participating in this investigation? i.e. 
immunological disorders, numbness in extremities, asthma etc                         YES/NO 
Are you currently taking any supplement? i.e. creatine      
      YES/NO 
If you have answered “yes” to any of these questions, please provide details below: 
 
Participant’s details  
 
Code Age Height Weight BMI 
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RM-CWI 26 1.81 75 22.89307 
JC_ CWI 31 1.73 94 31.40766 
JG_CW1 26 1.75 81 26.44898 
TW_CWI 30 1.73 75 25.05931 
AB_CWI 26 1.835 74 21.97655 
OB_CWI 23 1.835 67.7 20.10558 
KS_CWI 32 1.795 87.6 27.18787 
JO.C_CWI 30 1.835 90 26.72824 
MR-253 32 1.8 65.4 20.18519 
SR-256 27 1.76 89.3 28.82877 
FD-562 28 1.785 91.6 28.74875 
DU-596 
 20 1.705 61 20.98365 
MUH-214 20 1.74 72.9 24.07848 
FRS-824 29 1.815 69.6 21.12788 
JAM-596 23 1.8 68 20.9 
LAL-458 26 1.5 55 24.12 
SAM-895 25 1.6 85 34 
CLI-256 24 1.62 50 22.05 
MAH-895 24 1.62 50 19.05197 
HAK-568 28 1.74 75 24.7721 
ALS-595 32 1.59 75 29.66655 
MAT-591 29 1.55 52 21.64412 
STV-879 23 1.94 80 21.25624 
JAZ-353 24 1.67 64.8 23.23497 
SAR-25 26 167 70 25.09 
KM-26 31 179 70 21.84 
MAR-56 22 180 85 26.23 
SJK-85 30 169 75 26.25 
KW/CIOO 30 1.78 81 25.56495 
A5632 24 1.66 73 26.49151 
A4577 28 1.79 84 26.21641 
M5896 25 1.82 86 25.96305 
V4556 31 1.68 66 23.38435 
Hll589 28 1.75 73 23.83673 
F8965 23 1.81 85 25.94548 
Q5896 22 1.62 58 22.10029 
R8981 33 1.8 74 22.83951 
ZASIA 26 1.81 75 22.89307 
RIA-85 31 1.73 94 31.40766 
GB22 26 1.75 81 26.44898 
SAR 30 1.73 75 25.05931 
BAR 26 1.835 74 21.97655 
CL-25 23 1.835 67.7 20.10558 
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Ras3a 32 1.795 87.6 27.18787 
BA4a 30 1.835 90 26.72824 
MAQ-1 32 1.8 65.4 20.18519 
ABEE-6 27 1.76 89.3 28.82877 
ANTO-8 20 1.8 78.5 24.2284 
UND-3 28 1.785 91.6 28.74875 
Yong22 20 1.705 61 20.98365 
POR-2C 20 1.74 72.9 24.07848 
B89536 29 1.815 69.6 21.12788 
CWR-53 71 1.735 80 26.57609 
NKL-5 76 1.7 85.1 29.44637 
JWN-52 77 1.79 66.6 20.78587 
JW77 77 1.695 77.3 26.90544 
DJ-84 82 1.75 82.3 26.87347 
VPU-48 73 1.735 89 29.5659 
LNR-89 68 1.84 63.6 18.78544 
A5623 78 1.66 71 25.76571 
YS-76 76 1.695 80 27.84522 
Bo3-72 72 1.84 67.4 19.90784 
ROS-75 74 1.745 83.05 27.274 
AKM-88 75 1.8 85.6 26.41975 
FLO-89 75 1.605 59.4 23.05878 
X71-81 81 1.61 74.5 28.74118 
H1-80 82 1.75 82.3 26.87347 
GB0082A 75 1.9 120 25.95 
GB0092A 81 1.79 77 24 
GB0072A 72 1.76 106 34.3042 
MOR-58 88 1.6 86 26.56 
 
 
